Proton-binding polymers for oral administration
Crosslinked amine polymers address the challenges of managing metabolic acidosis by binding protons and chloride ions in the GI tract, effectively increasing serum bicarbonate levels and normalizing pH, thus slowing chronic kidney disease progression.
Patent Information
- Application Number
- JP2024124273
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-12-10
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for metabolic acidosis, particularly in chronic kidney disease, face challenges due to the inability to effectively manage serum bicarbonate levels and pH balance without exacerbating conditions like hypertension or hyperkalemia, especially with oral sodium bicarbonate and potassium bicarbonate.
The use of crosslinked amine polymers designed to bind and remove protons and chloride ions from the gastrointestinal tract, minimizing interference with other anions and maintaining serum bicarbonate levels, thereby normalizing blood pH.
These polymers effectively increase and maintain serum bicarbonate levels, slowing the progression of chronic kidney disease and reducing the risk of complications associated with metabolic acidosis.
Smart Images

Figure 2024164031000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates generally to orally administered proton-binding polymers that may be used to treat metabolic acidosis. [Background technology]
[0002] Metabolic acidosis is a condition in which non-volatile acids accumulate in the body in various disease states, resulting in a net addition of protons (H+) or bicarbonate (HCO3 - Metabolic acidosis is the result of metabolic and digestive processes that cause a loss of filtered bicarbonate (HCO3 -It is often accompanied by metabolic acidosis due to a decreased ability of the kidneys to excrete hydrogen ions secondary to the inability to salvage calcium (CaCl), synthesize ammonia (ammonia production), and excrete titratable acids. Clinical practice guidelines recommend initiating alkali therapy in patients with nondialysis-dependent chronic kidney disease (CKD) when serum bicarbonate is <22 mEq / L to prevent or treat the complications of metabolic acidosis. (Clinical practice guidelines for nutrition in chronic renal failure, K / DOQI, National Kidney Foundation, Am. J. Kidney Dis. 2000;35:S1-140; Raphael, KL, Zhang, Y, Wei, G, et al. 2013, Serum bicarbonate and mortality in adults in NHANES III, Nephrol. Dial. Transplant 28:1207-1213). These complications include malnutrition and growth retardation in children, exacerbation of bone disease, increased muscle breakdown, decreased albumin synthesis, and increased inflammation.(Leman,J,Litzow,JR,Lennon,EJ.1966.The effects of chronic acid loads in normal man:further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis,J.Clin.Invest.45:1608-1614;Franch HA,Mitch WE,1998,Catabolism in uremia:the impact of metabolic acidosis,J.Am.Soc.Nephrol.9:S78-81;Ballmer,PE,McNurlan,MA,Hulter,HN,et al.,1995,Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans,J.Clin.Invest.95:39-45;Farwell,WR,Taylor,EN,2010,Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey,CMAJ 182:137-141). Overt metabolic acidosis is characterized by an estimated glomerular filtration rate of 30 mL / min / 1.73 m. 2It is present in the majority of patients when the blood pressure drops below 100°C. (KDOQI bone guidelines:American Journal of Kidney Diseases(2003) 42:S1-S201.(suppl);Widmer B,Gerhardt RE,Harrington JT,Cohen JJ,Serum electrolyte and acid base composition:The influence of graded degrees of chronic renal failure,Arch Intern Med139:1099-1102,1979;Dobre M,Yang,W,Chen J,et.al.,Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD:a report from the chronic renal insufficiency cohort(CRIC) study.Am.J.Kidney Dis.62:670-678,2013;Yaqoob,MM. disease.Curr.Opin.Nephrol.Hypertens.19:489-492,2010).
[0003] Metabolic acidosis, regardless of etiology, reduces extracellular fluid bicarbonate and therefore reduces extracellular pH. The relationship between serum pH and serum bicarbonate is described by the Henderson-Hasselbalch equation: pH = pK' + log [HCO3 - ] / [(0.03×PaCO2)] where 0.03 is the physical solubility coefficient of CO2 and [HCO3 - ] and PaCO2 are the concentration of bicarbonate and the partial pressure of carbon dioxide, respectively.
[0004] There are several laboratory tests that can be used to define metabolic acidosis. The tests measure bicarbonate (HCO3- ) or proton (H + Basically, the concentration of either
[0005] The most useful measurements to determine acidosis are venous plasma bicarbonate (or total carbon dioxide [tCO2]), serum electrolytes, and Cl. - , K + , and Na + In the clinical laboratory, the measurement of venous plasma or serum electrolytes includes an estimation of tCO2. This measurement is based on the total circulating CO2 [i.e., bicarbonate (HCO3 - ), carbonic acid, (H2CO3), and dissolved CO2 (0.03 × PCO2) are reflected in the total CO2. tCO2 can also be calculated using the Henderson-Hasselbalch equation: tCO2 = HCO3 - +0.03PCO2: where PCO2 is the measured partial pressure of CO2; by using a simplified and standardized form of HCO3 - It may also be related to HCO3 - The concentration is 90% higher than tCO2, and since there is a small amount of H2CO3 present, venous tCO2 is greater than venous HCO3 in the blood. - It is often used as a reasonable approximation of the concentration of abnormal plasma HCO3, especially in chronic kidney disease. - A value <22 mEq / L generally indicates metabolic acidosis.
[0006] Serum Cl - Changes in concentration, especially serum Na + When serum Cl is disproportionate to the changes in concentration, further consideration may be given to possible acid-base disturbances. When this occurs, serum Cl - The change in concentration is typically associated with a reciprocal change in serum bicarbonate. Thus, in metabolic acidosis with a normal anion gap, when serum bicarbonate falls to <22 mEq / L, serum Cl - increases to >105 mEq / L.
[0007] Anion gap [serum Na + -(Cl - +HCO3 -Calculation of the anion gap (HCO3) is an important aspect of the diagnosis of metabolic acidosis. Metabolic acidosis may be presented with a normal or high anion gap. However, a high anion gap is associated with a high serum HCO3 - Regardless of changes in serum erythrocyte sedimentation (ESD), this generally indicates the presence of metabolic acidosis. An anion gap of >20 mEq / L (normal anion gap is 8-12 mEq / L) is a classic feature of metabolic acidosis.
[0008] Arterial blood gases are used to identify the type of acid-base disorder and to determine whether a mixed abnormality exists. In general, the results of an arterial blood gas measurement must be matched to the medical history, physical examination, and routine laboratory data listed above. Arterial blood gases are used to measure arterial carbon dioxide tension (P a CO2), acidity (pH), and oxygen pressure (P a Measure HCO3 - The concentration is calculated from pH and PaCO2. Metabolic acidosis is characterized by a pH < 7.35, P a CO2<35mmHg and HCO3 - <22 mEq / L. a O2 levels (normal 80-95 mmHg) are not used to diagnose metabolic acidosis, but can help determine the cause. Acid-base disorders are primarily classified as respiratory or metabolic. Respiratory disorders are caused by abnormal pulmonary excretion of CO2, resulting in an excess (acidosis) or deficiency (alkalosis) of CO2 (carbon dioxide) in the extracellular fluid. In respiratory acid-base disorders, serum bicarbonate (HCO3 - ) is the first direct result of changes in Pco2, and a large increase in Pco2 results in an increase in HCO3 -(Adrogue HJ, Madias NE, 2003, Respiratory acidosis, respiratory alkalosis, and mixed disorders, in Johnson RJ, Feehally J (eds): Comprehensive Clinical Nephrology. London, CV Mosby, pp. 167-182). Metabolic disorders are caused by excessive uptake or metabolic production or loss of volatile acids or bases in the extracellular fluid. These changes increase the bicarbonate anion (HCO3 - Adaptation in this case involves both buffering (immediate), respiratory (hours to days) and renal (days) mechanisms. (DuBose TD, MacDonald GA: Renal tubular acidosis, 2002, in DuBose TD, Hamm LL (eds): Acid-base and electrolyte disorders: A companion to Brenners and Rector's the Kidney, Philadelphia, WB Saunders, pp. 189-206).
[0009] The total hydrogen ion concentration in blood is determined by two quantities: serum HCO3 - It is defined as the ratio of PCO2 content (regulated by the kidney) and PCO2 content (regulated by the lungs); and is expressed as:
number
[0010] The result of an increase in total hydrogen ion concentration is a decrease in bicarbonate, the main extracellular buffer. Normal blood pH is between 7.38 and 7.42, with a hydrogen ion (H) concentration of 42–38 nmol / L. +) concentration (Goldberg M: Approach to Acid-Base Disorders. 2005. In Greenberg A, Cheung AK (eds) Primer on Kidney Diseases, National Kidney Foundation, Philadelphia, Elsevier-Saunders, pp.104-109). Bicarbonate (HCO3 - ) is an anion that acts as a buffer against pH abnormalities in the body, and normal plasma bicarbonate levels are in the range of 22-26 mEq / L (Szerlip HM: Metabolic acidosis, 2005, in Greenberg A, Cheung AK (eds) Primer on Kidney Diseases, National Kidney Foundation, Philadelphia, Elsevier-Saunders, pp.74-89). Acidosis causes a drop in blood pH (acidemia) and a loss of hydrogen ions (H + ) reflects the accumulation of bicarbonate ions (HCO3 - ) resulting in a decrease in serum bicarbonate. Metabolic acidosis can be described as:
number
[0011] To maintain the extracellular pH in the normal range, the acids produced daily must be excreted from the body. The production of acids in the body is the result of the metabolism of dietary carbohydrates, fats and amino acids. The complete oxidation of these metabolic substrates produces water and CO2. The carbon dioxide resulting from this oxidation (about 20,000 mmol / day) is efficiently exhaled by the lungs and represents the volatile acid component of the acid-base balance.
[0012] In contrast, volatile acids (approximately 50-100 mEq / day) are produced by the metabolism of sulfur- and phosphate-containing amino acids and nucleic acids. Additional non-volatile acids (lactic, butyric, acetic, other organic acids) arise from the incomplete oxidation of fats and carbohydrates, and from carbohydrate metabolism in the colon, where endemic bacteria in the intestinal tract convert substrates into small organic acids that are absorbed into the bloodstream. The effect of short-chain fatty acids on acidosis is somewhat minimized by anabolism, for example to long-chain fatty acids, or catabolism to water and CO2.
[0013] The kidneys filter HCO3 by two mechanisms: - urinary excretion of non-volatile acids; maintaining blood pH balance through the salvage of bicarbonate to prevent total bicarbonate depletion; and excretion of non-volatile acids in the urine. Both mechanisms are necessary to prevent bicarbonate depletion and acidosis.
[0014] In the first mechanism, the kidneys convert HCO3 filtered by the glomeruli into - This recovery occurs in the proximal tubules, where the recovery rate is about 4500 mEq / day of HCO3 - This mechanism is HCO3 - In the second mechanism, the kidneys produce enough H equal to the daily production of nonvolatile acids through the metabolism and oxidation of proteins, fats, and carbohydrates. + This acid load is excreted by H +This is accomplished by two distinct pathways in the kidney, including active secretion of ions and ammonia production. The end result of these two interconnected processes is the excretion of 50-100 mEq / day of non-volatile acids produced by normal metabolism.
[0015] Thus, normal renal function is required to maintain acid-base balance. In chronic kidney disease, HCO3 - The filtration and recovery of H2O is impaired, and the production and secretion of ammonia is impaired. These deficiencies rapidly lead to chronic metabolic acidosis, which is itself a strong precursor to end-stage renal disease. Decreased acid excretion with continued acid production of metabolic origin leads to H + / HCO3 - This disturbs the equilibrium, resulting in blood pH dropping below the normal value of pH=7.38-7.42.
[0016] Treatment of metabolic acidosis with alkali therapy is usually indicated to raise and maintain plasma pH above 7.20. Sodium bicarbonate (NaHCO3) is the agent most commonly used to correct metabolic acidosis. NaHCO3 is administered intravenously to reduce serum HCO3 - Levels can be appropriately elevated to increase the pH above 7.20. Further correction depends on the individual circumstances and may not be indicated when the underlying process is treatable or the patient is asymptomatic. This is especially true in certain forms of metabolic acidosis. For example, in high anion gap (AG) acidosis secondary to accumulation of organic acids, lactic acid, and ketones, the cognate anion is HCO3 - When the underlying disease is treated, serum pH is corrected; therefore, care should be taken to prevent an increase in bicarbonate above the normal range (>26 mEq / L) in these patients when alkalinity is provided to raise the pH much above 7.20.
[0017] Citrate is an appropriate alkaline therapy given orally or IV as either the potassium or sodium salt because it is metabolized by the liver, resulting in the formation of three moles of bicarbonate for every mole of citrate. Potassium citrate administered IV should be used with caution in the presence of renal impairment and should be closely monitored to avoid hyperkalemia.
[0018] Intravenous sodium bicarbonate (NaHCO3) solution may be administered when metabolic acidosis is severe or when correction is unlikely to occur without exogenous alkali administration. Oral alkali administration is the preferred method of treatment in individuals with chronic metabolic acidosis. The most common form of alkali for oral treatment is 1 g of NaHCO3, which provides 11.9 mEq of HCO3. - However, oral forms of NaHCO3 have not been approved for medical use, and the package insert for intravenous sodium bicarbonate solution contains the following contraindications, warnings, and precautions (Hospira label for NDC0409-3486-16): Contraindications: Sodium Bicarbonate Injection, USP is contraindicated in patients who are losing chloride due to vomiting or due to ongoing gastrointestinal aspiration and in patients receiving diuretics known to produce hypochloremic alkalosis. WARNING: Solutions containing sodium ions should be used with great caution, if at all, in patients with clinical conditions including congestive heart failure, severe renal insufficiency, and edema due to sodium retention. In patients with compromised renal function, administration of solutions containing sodium ions may result in sodium retention. Intravenous administration of these solutions may cause fluid and / or solute overload, resulting in alterations in serum electrolyte concentrations, hydration, congestive states, or pulmonary edema. Precautions: [...] The potentially high sodium load contributed by bicarbonate requires that sodium bicarbonate be used with caution in patients with congestive heart failure or other edematous or sodium-retaining states and in patients who are oliguric or anuric.
[0019] Acid-base disorders are common in patients with chronic kidney disease and heart failure. Chronic kidney disease (CKD) progressively impairs renal excretion of approximately 1 mmol / kg body weight of hydrogen ions, which occurs in healthy adults (Yaqoob, MM. 2010, Acidosis and progression of chronic kidney disease, Curr. Opin. Nephrol. Hyperten. 19:489-492.). The amount of acid (H + ) or base (HCO3 - The metabolic acidosis resulting from the depletion of erythrocyte secretion is particularly severe in patients with a glomerular filtration rate (GFR, an index of renal function) of 30 mL / min / 1.73 m 2It is a common complication in patients with CKD when the metabolic acidosis drops below 100%. Metabolic acidosis has significant long-term effects on protein and muscle metabolism, bone turnover, and the development of renal osteodystrophy. Metabolic acidosis also affects various paracrine and endocrine functions with further long-term outcomes, such as increased inflammatory mediators, decreased leptin, insulin resistance, and increased corticosteroid and parathyroid hormone production (Mitch WE, 1997, Influence of metabolic acidosis on nutrition, Am. J. Kidney Dis. 29:46-48.). The net effect of persistent metabolic acidosis in CKD patients is loss of bone and muscle mass, negative nitrogen balance, and accelerated chronic renal failure due to hormonal and cellular abnormalities (De Brito-Ashurst I, Varagunam M, Raftery MJ, et al, 2009, Bicarbonate supplementation slows progression of CKD and improves nutritional status, J. Am. Soc. Nephrol. 20:2075-2084). Conversely, potential concerns with alkaline therapy in CKD patients include the development or exacerbation of hypertension, accelerated vascular calcification, and expansion of extracellular fluid volume associated with sodium intake resulting in decompensation of pre-existing heart failure. Patients with moderate (GFR 20-25% of normal) CKD initially develop hyperchloremic acidosis with a normal anion gap due to the inability to salvage filtered bicarbonate and excrete protons and ammonium cations. As CKD progresses to more advanced stages, the anion gap increases, reflecting a continuing decline in the kidney's ability to excrete anions that were previously bound to non-excreted protons. Serum bicarbonate in these patients rarely falls below 15 mmol / L, with a maximum high anion gap of approximately 20 mmol / L.Non-metabolizable anions that accumulate in CKD are buffered by alkaline salts from bone (Lemann J Jr, Bushinsky DA, Hamm LL Bone buffering of acid and base in humans. Am. J. Physiol Renal Physiol. 2003 Nov, 285(5):F811-32).
[0020] Most patients with chronic kidney disease have underlying diabetes (diabetic nephropathy) and hypertension, which leads to deterioration of renal function. In almost all patients with hypertension, high sodium intake worsens hypertension. Therefore, renal, heart failure, diabetes and hypertension guidelines strictly restrict sodium intake to less than 1.5g or 65mEq / day in these patients (HFSA 2010 guidelines, Lindenfeld 2010, J Cardiac Failure V16 No6 P475). Chronic antihypertensive treatments often induce sodium excretion (diuretics) or modulate the kidney's ability to excrete sodium and water (e.g. renin angiotensin aldosterone system inhibitors "RAASi" drugs). However, as renal function deteriorates, diuretics become less effective due to the inability of the renal tubules to respond. RAASi drugs inhibit renal potassium excretion and therefore induce life-threatening hyperkalemia. Considering the additional sodium load, chronically treating patients with metabolic acidosis with sodium-containing bases that often exceed the total recommended daily sodium intake is not a reasonable treatment. As a result, oral sodium bicarbonate is not generally prescribed chronically in these patients with diabetic nephropathy. Potassium bicarbonate is also not tolerated by patients with CKD because they cannot easily excrete potassium, leading to severe hyperkalemia.
[0021] Despite these drawbacks, the role of oral sodium bicarbonate has been studied in a small subpopulation of nonhypertensive CKD patients. As part of the Kidney Research National Dialogue, alkaline therapy has been identified as having the potential to slow CKD progression and correct metabolic acidosis. The annual age-related decline in glomerular filtration rate (GFR) after age 40 is 0.75 to 1.0 mL / min / 1.73 m in normal individuals. 2 In patients with rapidly progressing CKD, >4 mL / min / 1.73 m per year 2 A steep drop in can be seen.
[0022] In one outcome study, De Brito-Ashurst et al. showed that bicarbonate supplementation preserves renal function in CKD (De Brito-Ashurst I, Varagunam M, Raftery MJ, et al, 2009, Bicarbonate supplementation slows progression of CKD and improves nutritional status, J. Am. Soc. Nephrol. 20:2075-2084). The study included 100 patients with CKD (creatinine clearance [CrCl] 15-30 mL / min / 1.73 m 2 134 adult patients with cerebrovascular disease (CED) and serum bicarbonate 16-20 mmol / L were randomly assigned to receive either oral sodium bicarbonate supplementation or standard care for 2 years. The mean bicarbonate dose in this study was 1.82 g / day, providing 22 mEq of bicarbonate / day. The primary endpoints were rate of CrCl decline, rapid CrCl decline (>3 mL / min / 1.73 mEq), and no significant difference in mean CrCl decline (>3 mL / min / 1.73 mEq). 2 / year), and end-stage renal disease ("ESRD") (CrCl < 10 mL / min). Compared with the control group, the decline in CrCl was more gradual with bicarbonate supplementation (5.93 mL / min / 1.73 m in the control group). 2 In patients receiving bicarbonate for a reduction of 1.88 mL / min / 1.73 m 2Patients receiving bicarbonate supplementation were significantly less likely to experience rapid progression (9% vs. 45%; relative risk, 0.15; 95% confidence interval, 0.06 to 0.40; P<0.0001). Similarly, fewer patients receiving bicarbonate supplementation developed ESRD (6.5% vs. 33%; relative risk, 0.13; 95% confidence interval, 0.04 to 0.40; P<0.001).
[0023] Hyperphosphatemia is a common comorbidity in patients with CKD, especially those with advanced or end-stage renal disease. Sevelamer hydrochloride is a commonly used ion exchange resin that reduces serum phosphate concentrations. However, a reported drawback of this agent is metabolic acidosis, apparently due to the net absorption of HCl in the process of binding phosphate in the small intestine. Several studies in patients with CKD and hyperphosphatemia undergoing hemodialysis or peritoneal dialysis have found a decrease in serum bicarbonate concentrations with the use of sevelamer hydrochloride (Brezina, 2004 Kidney Int. V66 S90 (2004) S39-S45; Fan, 2009 Nephrol Dial Transplant (2009) 24: 3794). Summary of the Invention
[0024] Thus, among the various aspects of the invention, compositions and methods for treating animals, including humans, as well as methods for preparing such compositions, can be described. The compositions include crosslinked amine polymers and can be used, for example, to treat diseases or other metabolic conditions in which removal of protons and / or chloride ions from the gastrointestinal tract confers physiological benefit. For example, the polymers described herein can be used to regulate acid-base related diseases in animals, including humans. In one such embodiment, the polymers described herein can be used to normalize serum bicarbonate concentrations and blood PH in animals, including humans. As a further example, the polymers described herein can be used in the treatment of acidosis. There are several different physiological conditions that explain this imbalance, each of which can be treated by polymers that bind and remove HCl.
[0025] Metabolic acidosis resulting from a net increase in acid includes processes that increase endogenous hydrogen ion production, such as ketoacidosis, L-lactic acidosis, D-lactic acidosis, and salicylic acid poisoning. Metabolism of ingested toxins, such as methanol, ethylene glycol, and paraldehyde, can also increase hydrogen ion concentration. Decreased renal excretion of hydrogen ions, such as in uremic acidosis and distal (type I) renal tubular acidosis, is another cause of a net increase in acid in the body that results in metabolic acidosis. Metabolic acidosis resulting from loss of bicarbonate is characteristic of proximal (type II) renal tubular acidosis. Gastrointestinal loss of bicarbonate in acute or chronic diarrhea also results in metabolic acidosis. Primary or secondary hypoaldosteronism is a common disorder that causes hyperkalemia and metabolic acidosis and underlies the classification of type IV renal tubular acidosis. Low-renin hypoaldosteronism is the most frequently encountered variant of this disorder.
[0026] Another way of describing metabolic acidosis is in terms of the anion gap. Causes of high anion gap acidosis include diabetic ketoacidosis, L-lactic acidosis, D-lactic acidosis, alcoholic ketoacidosis, starvation ketoacidosis, uremic acidosis associated with advanced renal failure (CKD stages 4-5), salicylate poisoning, and selected toxin exposures due to ingestion including methanol, ethylene, propylene glycol, and paraldehyde. Typical causes of anion gap acidosis include early renal failure (CKD stages 1-3), gastrointestinal losses of bicarbonate due to acute or chronic diarrhea, distal (type I) renal tubular acidosis, proximal (type II) renal tubular acidosis, type IV renal tubular acidosis, dilutional acidosis associated with large amounts of intravenous fluid administration, and treatment of diabetic ketoacidosis resulting from ketones lost in the urine.
[0027] Regarding lactic acidosis, hypoxic lactic acidosis results from an imbalance between oxygen balance and oxygen supply, and is associated with tissue ischemia, stroke, strenuous exercise, shock, cardiac arrest, low cardiac output and congestive heart failure, severe anemia, severe hypoxia and carbon monoxide poisoning, vitamin deficiency and sepsis. In other types of lactic acidosis, oxygen delivery is normal, but oxidative phosphorylation is inhibited, often as a result of cellular mitochondrial defects. This is commonly seen in inborn errors of metabolism or from the ingestion of drugs or toxins. Alternative sugars (e.g., fructose, sorbitol) used in tube feeding or as irrigation agents during surgery can also result in metabolism that induces lactic acidosis.
[0028] There are three main classifications of renal tubular acidosis, each with distinct etiologies with several subtypes. Distal (type I) renal tubular acidosis is characterized by inherited and genomic changes, particularly HCO3 - / Cl - Exchanger (AE1) or H +It may be caused by mutations in / ATPase. Examples of acquired distal (type I) renal tubular acidosis include hyperparathyroidism, Sjögren's syndrome, sponge kidney, cryoglobulinemia, systemic lupus erythematosus, renal graft rejection, chronic tubulointerstitial disease, and exposure to various drugs including amphotericin B, lithium, ifosfamide, foscarnet, toluene, and vanadium. A special classification of distal (type IV) renal tubular acidosis with hyperkalemia is found in lupus nephritis, obstructive nephropathy, sickle cell anemia, and voltage deficiency. Genetic examples include pseudohypoaldosteronism type I and pseudohypoaldosteronism type II (Gordon's disease), and exposure to certain drugs (amiloride, triamterene, trimethoprim, and pentamidine) may also result in distal (type IV) renal tubular acidosis with hyperkalemia. Proximal (type II) renal tubular acidosis may be caused by genetic or acquired causes. Genetic causes include Wilson's disease and Lowe's syndrome. Acquired causes include cystinosis, galactosemia, multiple myeloma, light chain disease, amyloidosis, vitamin D deficiency, lead and mercury ingestion, and exposure to certain drugs, including ifosfamide, cidofovir, aminoglycosides, and acetazolamide. Isolated defects in bicarbonate reabsorption may also be the cause of proximal (type II) renal tubular acidosis; examples of such defects include exposure to carbonic anhydrase inhibitors, acetazolamide, topiramate, sulfamylone, and carbonic anhydrase deficiency. Combined proximal and distal renal tubular acidosis (type III) is uncommon and results from defects in both proximal bicarbonate reabsorption and distal proton secretion. Mutations in the gene for cystolic carbonic anhydrase can cause the deficiency, as well as certain drugs, including ifosfamide. Type IV renal tubular acidosis with hyperkalemia is a cause of metabolic acidosis.The main etiology behind this type of acidosis is aldosterone deficiency; hypoaldosteronism results from primary adrenal insufficiency, the syndrome of low renin hypoaldosteronism (type IV RTA) commonly seen in older individuals, Addison's disease, and pseudohypoaldosteronism type I due to mineralocorticoid resistance. Analgesic nephropathy, chronic pyelonephritis, obstructive nephropathy, and chronic interstitial nephritis due to sickle cell disease can also produce acidosis with hyperkalemia. Finally, drugs such as amiloride, spironolactone, triamterene, trimethoprim, heparin therapy, NSAIDs, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors can induce metabolic acidosis associated with hyperkalemia.
[0029] All of the above causes and etiologies of metabolic acidosis are treatable with polymers designed to bind and remove HCl in the gastrointestinal tract.
[0030] Methods of treatment generally involve administering a therapeutically effective amount of a crosslinked amine polymer capable of removing protons and chloride ions from the gastrointestinal tract of an animal, e.g., a human. Generally, such crosslinked amine polymers may have advantageous characteristics, such as relatively low swelling, relatively high proton and chloride ion binding, and / or relatively low binding of interfering anions, e.g., phosphate, bicarbonate, citrate, short chain fatty acids, and bile acids.
[0031] In general, once the polymer is protonated, it is preferred to bind, for example, chloride as a counterion rather than other "interfering" anions listed above, since these interfering anions may be metabolically equivalent to bicarbonate in patients in need of treatment. Removing chloride from the body along with protons through binding to the amine polymers of the present disclosure has an alkalizing effect, whereas removing the interfering anions may have little or no alkalizing effect.
[0032] In certain embodiments, the polymer preferably binds and maintains the ability to bind protons and anions under physiological conditions found along the gastrointestinal (GI) lumen. These conditions can change with food intake (see, e.g., Fordtran J, Locklear T. Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Digest Dis Sci. 1966; 11(7): 503-21) and location along the GI tract (Binder, H et al. Chapters 41-45 in “Medical Physiology”, 2nd Edition, Elsevier
[2011] . Boron and Boulpaep [Ed.]). Rapid binding of protons and chloride in the stomach and small intestine is desirable. High chloride binding levels and selectivity in the posterior GI tract (lower small intestine and large intestine) is also desirable. Generally, the polymer will also have a pK such that a majority of the amines are protonated under the various pH and electrolyte conditions encountered along the GI tract, thereby allowing removal of the protons, along with a suitable counter anion (preferably chloride), from the body into the stool. a Preferably,
[0033] Because the stomach is a rich source of HCl and because it is the first potential HCl binding site (after the oral cavity), and because the retention time in the stomach is short (gastric retention half-life of approximately 90 minutes) compared to the rest of the GI tract (small intestinal transit time of approximately 4 hours; total GI transit time of 2-3 days; Read, NW et al. Gastroenterology
[1980] 79:1276), it is desirable for the polymers of the present disclosure to demonstrate rapid kinetics of proton and chloride binding in the lumen of this organ as well as in in vitro conditions designed to mimic the gastric lumen (e.g., SGF). Phosphate is a potential interfering anion for chloride binding in the stomach and small intestine, where phosphate is most absorbed (Cross, HS et al Miner Electrolyte Metab
[1990] 16:115-24). Thus, rapid and preferential binding of chloride over phosphate is desirable in the small intestine and in in vitro conditions designed to mimic the small intestinal lumen (e.g., SIB). Because colonic transit times are slow (2-3 days) compared to the small intestine, and because colonic conditions are not encountered by orally administered polymers until after stomach and small intestinal conditions have been encountered, the kinetics of chloride binding by the polymers of the present disclosure need not be rapid in the colon or in in vitro conditions designed to mimic the posterior small intestine / colon (e.g., SOB), but it is important that chloride binding and selectivity over other interfering anions is high, e.g., over 24 and / or 48 hours or more.
[0034] In one embodiment, the crosslinked amine polymer is administered as a pharmaceutical composition comprising the crosslinked amine polymer and, optionally, a pharma- ceutically acceptable carrier, diluent or excipient, or combination thereof that does not significantly interfere with the proton and / or chloride binding properties of the crosslinked amine polymer in vivo. Optionally, the pharmaceutical composition may also include an additional therapeutic agent.
[0035] A further aspect of the present disclosure is a process for the preparation of a crosslinked amine polymer that can be administered as a pharmaceutical composition, the process comprising crosslinking a preformed amine polymer in a reaction mixture containing a preformed amine polymer, a solvent for the preformed amine polymer, a crosslinking agent, and a swelling agent, the swelling agent being preferably immiscible with the solvent, the preformed amine polymer having an absorptive capacity for the swelling agent, and the amount of swelling agent in the reaction mixture being less than the absorptive capacity of the preformed amine polymer for the swelling agent.
[0036] A further aspect of the present disclosure is a process for the preparation of a crosslinked amine polymer that can be administered as a pharmaceutical composition. The process includes crosslinking a preformed amine polymer in a reaction mixture containing the preformed amine polymer, a solvent, and a crosslinking agent to form a crosslinked amine polymer. Prior to the crosslinking step, the preformed amine polymer binds a first amount of chloride and a competing anion (e.g., phosphate, citrate, and / or taurocholate), and after the crosslinking step, the crosslinked amine polymer binds a second (different) amount of chloride and a competing anion (e.g., phosphate, citrate, and / or taurocholate) in an appropriate assay (e.g., SIB or SOB). For example, in one such embodiment, the second amount of competing anion (e.g., phosphate, citrate, and / or taurocholate) bound is relatively less than the first amount of competing anion.
[0037] Amine monomers are typically polymerized in radical polymerizations via their protonated forms, because free amines induce chain rearrangement reactions, often limiting the extent of polymerization to low molecular weights. To crosslink beyond the limits of electrostatic repulsion and achieve a degree of crosslinking within crosslinked particles, two separate polymerization / crosslinking steps are carried out according to one embodiment of the present disclosure. In the first step, a preformed amine polymer is prepared. The preformed amine polymer is deprotonated and further crosslinked in the second polymerization / crosslinking step to form a polymerized crosslinked polymer. Advantageously, the main crosslinking reaction is between carbon atoms in the first step (i.e., carbon-carbon crosslinking), while in the second step, the crosslinking is primarily between amine moieties contained in the preformed amine polymer.
[0038] A further aspect of the present disclosure is a process for the preparation of crosslinked amine polymers, comprising two separate polymerization / crosslinking steps. In the first step, a preformed amine polymer is formed having a chloride binding capacity of at least 10 mmol / g in simulated gastric fluid ("SGF") and a swelling ratio in the range of 2-10. In the second step, the preformed amine polymer is crosslinked with a crosslinker containing amine reactive sites to form a polymerized crosslinked amine polymer. The resulting polymerized crosslinked amine polymer has a lower binding capacity for a competing anion (e.g., phosphate, citrate and / or taurocholate) in an appropriate assay (e.g., SIB or SOB) than the binding capacity of the preformed polymer for a competing anion (e.g., phosphate, citrate and / or taurocholate) in the same appropriate assay (e.g., SIB or SOB). In one embodiment, the preformed amine polymer has a swelling ratio in the range of 3-8. In one such embodiment, the preformed amine polymer has a swelling ratio in the range of 4-6.
[0039] A further aspect of the present disclosure is a process for the preparation of crosslinked amine polymers, comprising two distinct crosslinking steps. In the first crosslinking step, a preformed amine polymer is formed, the preformed amine polymer having a chloride binding capacity in simulated gastric fluid ("SGF") of at least 10 mmol / g, a swelling ratio in the range of 2-10, and an average particle size of at least 80 microns. The preformed amine polymer is (at least partially) deprotonated with a base, and in the second step, the deprotonated preformed amine polymer is crosslinked with a crosslinker containing amine reactive sites to form a crosslinked amine polymer after polymerization. In one embodiment, the preformed amine polymer has a swelling ratio in the range of 3-8. In one such embodiment, the preformed amine polymer has a swelling ratio in the range of 4-6.
[0040] A further aspect of the present disclosure is a process for the preparation of crosslinked amine polymers, comprising two separate polymerization / crosslinking steps. In the first step, a preformed amine polymer is formed having a chloride binding capacity in simulated gastric fluid ("SGF") of at least 10 mmol / g and a swelling ratio in the range of 2-10. The preformed amine polymer is (at least partially) deprotonated with a base and contacted with a swelling agent to swell the deprotonated preformed amine polymer. In the second step, the swollen deprotonated preformed amine polymer is crosslinked with a crosslinking agent containing amine reactive sites to form a post-polymerization crosslinked amine polymer. In one embodiment, the preformed amine polymer has a swelling ratio in the range of 3-8. In one such embodiment, the preformed amine polymer has a swelling ratio in the range of 4-6.
[0041] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer and a pharma- ceutically acceptable excipient. The crosslinked amine polymer may be prepared, for example, as described in paragraphs
[0035] ,
[0036] ,
[0037] ,
[0038] ,
[0039] , or
[0040] .
[0042] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 4 mmol / g. In one embodiment, the crosslinked amine polymer has a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 4.5, 5, 5.5, or even at least 6 mmol / g.
[0043] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a ratio of chloride binding capacity to phosphate binding capacity in simulated small intestinal buffer ("SIB") of at least 2.3: 1, respectively. In one embodiment, the crosslinked amine polymer has a ratio of chloride binding capacity to phosphate binding capacity in simulated small intestinal buffer ("SIB") of at least 2.5: 1, 3: 1, 3.5: 1, or even 4: 1, respectively.
[0044] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a simulated small intestinal buffer ("SIB") of at least 1 mmol / g, a phosphate ion binding capacity in the SIB of less than 0.4 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestinal buffer ("SIB") of at least 1.5 mmol / g, a phosphate ion binding capacity in the SIB of less than 0.6 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In another such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestinal buffer ("SIB") of at least 2.0 mmol / g, a phosphate ion binding capacity in the SIB of less than 0.8 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestine buffer solution ("SIB") of at least 2.5 mmol / g, a phosphate ion binding capacity in the SIB of less than 1.0 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestine buffer solution ("SIB") of at least 3.0 mmol / g, a phosphate ion binding capacity in the SIB of less than 1.3 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestine buffer solution ("SIB") of at least 3.5 mmol / g, a phosphate ion binding capacity in the SIB of less than 1.5 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively.In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestine buffer solution ("SIB") of at least 4.0 mmol / g, a phosphate ion binding capacity in the SIB of less than 1.7 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestine buffer solution ("SIB") of at least 4.5 mmol / g, a phosphate ion binding capacity in the SIB of less than 1.9 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a simulated small intestine buffer solution ("SIB") of at least 5.0 mmol / g, a phosphate ion binding capacity in the SIB of less than 2.1 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively. In each of the above embodiments, the crosslinked amine polymer may have a chloride ion to phosphate ion binding ratio in the SIB of at least 2.5, at least 3, at least 3.5, or even at least 4, respectively.
[0045] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a ratio of chloride ion binding capacity to phosphate ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2.3:1, respectively, and a swelling ratio of less than 5. For example, in one such embodiment, the crosslinked amine polymer may have a chloride ion to phosphate ion binding ratio in SIB of at least 2.3:1, at least 2.5, at least 3, at least 3.5, or even at least 4, respectively, and a swelling ratio of less than 5, less than 4, less than 3, less than 2, less than 1.5, or even less than 1.
[0046] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content of at least 30% of the chloride initially bound (i.e., bound during the SGF binding step) in a GI compartment transit assay ("GICTA"). In one such embodiment, the crosslinked amine polymer has a retained chloride content of at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of the chloride initially bound in a GI compartment transit assay.
[0047] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content of at least 0.5 mmol of chloride / polymer(g) in a GI Compartment Transit Assay ("GICTA"). In one such embodiment, the crosslinked amine polymer has a retained chloride content of at least 0.5, at least 1, at least 1.5, at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, or even at least 5 mmol of chloride / polymer(g) in a GI Compartment Transit Assay ("GICTA").
[0048] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content in a GI compartment transit assay ("GICTA") of at least 0.5 mmol of chloride / polymer (g) and a chloride retention at the end of the GICTA of at least 30% of the chloride initially bound in the GICTA (i.e., bound during the SGF binding step). In one such embodiment, the crosslinked amine polymer has a retained chloride content of at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of the chloride initially bound in the GI compartment transit assay and a retained chloride content of at least 0.5, at least 1, at least 1.5, at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, or even at least 5 mmol of chloride / polymer (g) in the GI compartment transit assay ("GICTA").
[0049] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity of at least 5 mmol / g in a 1 hour simulated gastric fluid ("SGF") assay and at least 8 mmol / g in a 24 hour simulated gastric fluid ("SGF") assay. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity of at least 5 mmol / g in a 1 hour simulated gastric fluid ("SGF") assay and at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, or even at least 14 mmol / g in a 24 hour simulated gastric fluid ("SGF") assay.
[0050] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay that is at least 50% of its chloride ion binding capacity in a 24 hour simulated gastric fluid ("SGF") assay. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay that is at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of its chloride ion binding capacity in a 24 hour simulated gastric fluid ("SGF") assay.
[0051] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay of at least 5 mmol / g, a chloride ion binding capacity in a 24 hour simulated gastric fluid ("SGF") assay of at least 8 mmol / g, and a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay that is at least 50% of the chloride ion binding capacity in the 24 hour simulated gastric fluid ("SGF") assay. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay of at least 5 mmol / g and a chloride ion binding capacity in a 24 hour simulated gastric fluid ("SGF") assay of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, or even at least 14 mmol / g, wherein the crosslinked amine polymer has a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay that is at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of the chloride ion binding capacity in the 24 hour simulated gastric fluid ("SGF") assay.
[0052] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 24 hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 2.5 mmol chloride / g polymer. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a 24 hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, or even at least 5 mmol chloride / g polymer.
[0053] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 2-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 0.5 mmol of chloride / g of polymer, and a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 2.5 mmol of chloride / g of polymer. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a 2-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 0.5, at least 1, at least 1.5, at least 2, at least 2.5, or even at least 3 mmol of chloride / g of polymer, and a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, or even at least 5 mmol of chloride / g of polymer.
[0054] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity of at least 2 mmol of chloride / g of polymer in 4 hours in simulated small intestinal buffer ("SIB") In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity of at least 2, at least 2.5, at least 3, at least 3.5, or even at least 4 mmol of chloride / g of polymer in 4 hours in simulated small intestinal buffer ("SIB").
[0055] A further aspect of the disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2 mmol of chloride / g of polymer at 4 hours and a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2 mmol of chloride / g of polymer at 24 hours. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2, at least 2.5, at least 3, at least 3.5, or even at least 4 mmol of chloride / g of polymer at 4 hours and the crosslinked amine polymer has a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2, at least 2.5, at least 3, at least 3.5, or even at least 4 mmol of chloride / g of polymer at 24 hours.
[0056] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 5.5 mmol chloride / g of polymer. In one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 6 mmol chloride / g of polymer.
[0057] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer as described in any of paragraphs
[0038] to
[0056] , wherein the crosslinked amine polymer has a pKa (measured in 100 mM NaCl, at equilibrium) of at least 6. In one such embodiment, the crosslinked amine polymer has a pKa of at least 6.5, at least 7, or even at least 7.5 (measured in 100 mM NaCl, at equilibrium).
[0058] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestine inorganic buffer ("SIB") of at least 4 mmol / g in 1 hour.
[0059] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestine inorganic buffer ("SIB") of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g.
[0060] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestine inorganic buffer ("SIB") of at least (i) 2 mmol / g, (ii) 2.5 mmol / g, or (iii) 3 mmol / g in 1 hour.
[0061] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride to phosphate binding ratio in simulated small intestine inorganic buffer ("SIB") of at least 2.3:1, respectively.
[0062] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having (i) a proton binding capacity and a chloride binding capacity in artificial gastric fluid of at least 5 mmol / g in 1 hour, and (ii) a proton binding capacity and a chloride binding capacity in artificial gastric fluid of at least (a) 8 mmol / g, (b) 10 mmol / g, (c) 12 mmol / g, or (d) 14 mmol / g.
[0063] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a proton binding capacity and chloride binding capacity at 1 hour in artificial gastric fluid that is at least X% of the proton binding capacity and chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in artificial gastric fluid, wherein X% is at least (i) 50%, (ii) 60%, (iii) 70%, (iv) 80%, or even (v) 90%.
[0064] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having (i) selectivity for chloride over citrate, phosphate and taurocholate in simulated small intestinal organic and inorganic buffers ("SOB"), and (ii) a chloride binding capacity in SOB of at least 4 mmol / g at 24 hours.
[0065] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having selectivity for chloride over citrate, phosphate and taurocholate in simulated small intestinal organic and inorganic buffers ("SOB") at (i) 1 hour, (ii) 4 hours, (iii) 12 hours, (iv) 18 hours, (v) 24 hours, (vi) 30 hours, (vii) 36 hours, or even (viii) 48 hours.
[0066] A further aspect of the present disclosure is a pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g in simulated small intestinal inorganic buffer ("SIB") at (i) 1 hour, (ii) 2 hours, (iii) 3 hours, (iv) 4 hours, and / or (v) greater than 4 hours.
[0067] Other aspects and features will be in part apparent and in part pointed out hereinafter. [Brief description of the drawings]
[0068] [Figure 1A]FIG. 1 is a flow chart illustrating a schematic of the mechanism of action of a polymer as it passes through the gastrointestinal tract of an individual, from ingestion / stomach (FIG. 1A), to the upper GI tract (FIG. 1B), to the lower GI tract / colon (FIG. 1C). [Figure 1B] FIG. 1 is a flow chart illustrating a schematic of the mechanism of action of a polymer as it passes through the gastrointestinal tract of an individual, from ingestion / stomach (FIG. 1A), to the upper GI tract (FIG. 1B), to the lower GI tract / colon (FIG. 1C). [Figure 1C] FIG. 1 is a flow chart illustrating a schematic of the mechanism of action of a polymer as it passes through the gastrointestinal tract of an individual, from ingestion / stomach (FIG. 1A), to the upper GI tract (FIG. 1B), to the lower GI tract / colon (FIG. 1C). [Diagram 2] 1 is a plot of equilibrium chloride binding by (Example 019067-A2) at different pH levels, as described more fully in the Examples. [Diagram 3] FIG. 1 is a series of photographs of particulate amine polymers demonstrating the lack of agglomeration in the solvent-dispersed Step 2 reaction compared to agglomeration in the non-dispersed Step 2 reaction, which is more fully described in the Examples. [Figure 4] 1 is a plot of swelling of a preformed amine polymer versus the amount of crosslinker used in the first polymerization / crosslinking step according to one embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0069] Abbreviations and definitions The following definitions and methods are provided to better define the present invention and to guide those of ordinary skill in the art in the practice of the present invention. Unless otherwise noted, terms should be understood according to conventional usage by those of ordinary skill in the art.
[0070] The term "absorbency," as used herein in conjunction with a polymer and a swelling agent (or a mixture of swelling agents, in the case of a mixture of swelling agents), is the amount of swelling agent (or such mixture) that is absorbed by a given amount of dry polymer (e.g., in the form of dry beads) that is immersed in an excess amount of swelling agent (or such mixture) over a period of at least 16 hours at room temperature.
[0071] The term "acrylamide" has the structural formula H2C=CH-C(O)NR- * A moiety having the formula: * represents the point of attachment of the moiety to the remainder of the molecule, and R is hydrogen, hydrocarbyl, or substituted hydrocarbyl;
[0072] The term "acrylic acid" has the structural formula H2C=CH-C(O)O- * A moiety having the formula: * represents the point of attachment of the moiety to the remainder of the molecule;
[0073] The terms "alicyclic," "alicyclo," or "alicyclyl" refer to saturated monocyclic groups of 3 to 8 carbon atoms and include cyclopentyl, cyclohexyl, cycloheptyl, and the like.
[0074] The term "aliphatic" refers to saturated and non-aromatic unsaturated hydrocarbyl moieties having, for example, 1 to about 20 carbon atoms, or, in specific embodiments, 1 to about 12 carbon atoms, 1 to about 10 carbon atoms, 1 to about 8 carbon atoms, or even 1 to about 4 carbon atoms. Aliphatic groups include, for example, alkyl moieties such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, and the like, and alkenyl moieties of comparable chain length.
[0075] The term "alkanol" refers to an alkyl moiety substituted with at least one hydroxyl group. In some embodiments, an alkanol group is a "lower alkanol" containing 1 to 6 carbon atoms, each bonded to an oxygen atom. In other embodiments, a lower alkanol group contains 1 to 3 carbon atoms.
[0076] The term "alkenyl group" includes linear or branched carbon radicals having at least one carbon-carbon double bond. The term "alkenyl group" can include conjugated and non-conjugated carbon-carbon double bonds, or combinations thereof. Alkenyl groups can include, for example, without limitation, from 2 to about 20 carbon atoms, or in certain embodiments, from 2 to about 12 carbon atoms. In certain embodiments, alkenyl groups are "lower alkenyl" groups having from 2 to about 4 carbon atoms. Examples of alkenyl groups include, but are not limited to, ethynyl, propenyl, allyl, vinyl, butenyl, and 4-methylbutenyl. The terms "alkenyl group" and "lower alkenyl group" include groups having "cis" or "trans" orientations, or alternatively, "E" or "Z" orientations.
[0077] The term "alkyl group", whether used alone or within other terms, such as "haloalkyl groups", "aminoalkyl groups", and "alkylamino groups", encompasses saturated straight or branched carbon radicals having, for example, from 1 to about 20 carbon atoms, or, in specific embodiments, from 1 to about 12 carbon atoms. In other embodiments, an alkyl group is a "lower alkyl" group having from 1 to about 6 carbon atoms. Examples of such groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, and the like. In more specific embodiments, a lower alkyl group has from 1 to 4 carbon atoms.
[0078] The term "alkylamino group" refers to an amino group that is directly attached to the remainder of the molecule through the nitrogen atom of the amino group, where the nitrogen atom of the alkylamino group is substituted by one or two alkyl groups. In some embodiments, an alkylamino group is a "lower alkylamino" group having one or two alkyl groups of one to six carbon atoms attached to the nitrogen atom. In other embodiments, a lower alkylamino group has one to three carbon atoms. Suitable "alkylamino" groups can be mono- or dialkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino, pentamethyleneamine, and the like.
[0079] The term "allyl" refers to a compound of the structure H2C=CH-CH2- * A moiety having the formula: * represents the point of attachment of the moiety to the remainder of the molecule, the point of attachment being to a heteroatom or an aromatic moiety;
[0080] The term "allylamine" refers to a moiety having the structural formula HC=CH-CHN(X)(X): where X and X are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl, or X and X together form a substituted or unsubstituted alicyclic, aryl, or heterocyclic moiety, each typically having from 3 to 8 atoms in the ring, as defined in association with such terms.
[0081] The terms "amine" or "amino", when used alone or as part of another group, refer to a group of formula -N(X8)(X9): where X8 and X9 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl, heteroaryl, or heterocyclic, or X8 and X9 together form a substituted or unsubstituted alicyclic, aryl, or heterocyclic moiety, each typically having from 3 to 8 atoms in the ring, as defined in connection with such terms.
[0082] The term "aminoalkyl group" encompasses straight or branched alkyl groups having from 1 to about 10 carbon atoms, any one of which may be substituted with one or more amino groups attached directly to the remainder of the molecule through an atom other than the nitrogen atom of the amine group(s). In some embodiments, aminoalkyl groups are "lower aminoalkyl" groups having from 1 to 6 carbon atoms and one or more amino groups. Examples of such groups include aminomethyl, aminoethyl, aminopropyl, aminobutyl, and aminohexyl.
[0083] The term "aromatic group" or "aryl group" refers to an aromatic group having one or more rings, which may be pendantly attached together or fused. In certain embodiments, the aromatic group has 1, 2 or 3 rings. Monocyclic aromatic groups may contain 5 to 10 carbon atoms, typically 5 to 7 carbon atoms, more typically 5 to 6 carbon atoms in the ring. Typical polycyclic aromatic groups have 2 or 3 rings. Polycyclic aromatic groups having 2 rings typically have 8 to 12 carbon atoms, preferably 8 to 10 carbon atoms in the ring. Examples of aromatic groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl, or acenaphthyl.
[0084] The term "bead" is used to describe crosslinked polymers that are substantially spherical in shape.
[0085] The term "bonded" as used herein in connection with a polymer and one or more ions, i.e., cations (e.g., "proton-bonded" polymers) and anions, refers to an "ionically bonded" polymer, and / or when it is associated with the ions, generally not necessarily in a non-covalent manner, but with sufficient association strength that at least a portion of the ions remain bound under the in vitro or in vivo conditions under which the polymer is used for a period of time sufficient to effect removal of the ions from the solution or body.
[0086] The term "crosslinker", when used alone or within other terms, encompasses hydrocarbyl or substituted hydrocarbyl, linear or branched molecules capable of reacting more than once with any of the above monomers or the infinite polymer network described in Formula 1. The reactive groups in the crosslinker can include, but are not limited to, alkyl halides, epoxides, phosgene, anhydrides, carbamates, carbonates, isocyanates, thioisocyanates, esters, activated esters, carboxylic acids and derivatives, sulfonates and derivatives, acyl halides, aziridines, alpha, beta-unsaturated carbonyls, ketones, aldehydes, pentafluoroaryl groups, vinyls, allyls, acrylates, methacrylates, acrylamides, methacrylamides, styrenes, acrylonitriles, and combinations thereof. In one exemplary embodiment, the reactive groups in the crosslinker include alkyl halides, epoxides, anhydrides, isocyanates, allyls, vinyls, acrylamides, and combinations thereof. In one such embodiment, the reactive group of the crosslinker is an alkyl halide, epoxide, or allyl.
[0087] The term "diallylamine" refers to an amino moiety bearing two allyl groups.
[0088] The terms "dry beads" and "dry polymer" refer to beads or polymers that contain 5% by weight or less of a non-polymeric swelling agent or solvent. Often the swelling agent / solvent is water remaining at the end of purification. This is generally removed by freeze-drying or oven-drying prior to storage or further crosslinking of the preformed amine polymer. The amount of swelling agent / solvent can be measured by heating (e.g., heating to 100-200°C) and the resulting weight change. This is referred to as "loss on drying" or "LOD".
[0089] The term "ether" refers to a compound of the formula * -H x CO-CH x - * ;In the formula, *represents the point of attachment to the remainder of the moiety, and x is independently equal to 0, 1, 2, or 3; represents a moiety having oxygen bonded to two separate carbon atoms designated as .
[0090] The term "gel" is used to describe a cross-linked polymer having an irregular shape.
[0091] The term "GI Compartment Transit Assay" or "GICTA" refers to an assay in which free amine test polymers, including free amine sevelamer and bixalomer controls, are sequentially exposed to different buffers that simulate different conditions to which the polymers are exposed while passing through the human GI tract. The incubation times in these different conditions are selected to represent the approximate transit time of the polymer through a particular section of the GI tract. The first step in the "GICTA" is to perform a "Simulated Gastric Fluid (SGF)" assay in which the polymer is incubated in SGF buffer at a polymer concentration of 2.5 mg / mL. The composition of the SGF reflects typical ion concentrations in the fasted stomach (as described elsewhere). The polymer is incubated for 1 hour at 37°C in a solid phase extraction (SPE) tube equipped with a 20 micrometer pore size frit. A blank SPE tube containing SGF buffer without polymer is included throughout the "GICTA" screening and is treated in an identical manner. 400 microliters of sample is removed, filtered, diluted as necessary, and assayed for chloride content using ion chromatography. For each polymer tested, chloride binding is calculated using the following formula: (Cl start-Cl equilibrium)×4 / 2.5 The binding capacity is expressed as chloride (mmol) / polymer (g), where Cl start corresponds to the starting chloride concentration (mM) in the SGF buffer, Cl equilibrium corresponds to the chloride equilibrium value (mM) in the diluted measurement filtrate after 1 h exposure to the test polymer, 4 is the dilution factor, and 2.5 is the polymer concentration in mg / mL. The SPE tube is rinsed two more times with DI water and excess liquid is removed by applying negative pressure at the bottom. Artificial small intestine organic and inorganic buffer (SOB) buffer is then added to the tube to achieve a polymer concentration of 2.5 mg / mL (supernatants for ion chromatography analysis are sampled in the SGF binding step, but no polymer loss is assumed). The concentrations of possible competing anions in the SOB buffer reflect the typical concentrations of fluids present in the small intestine (listed elsewhere). The polymer is incubated in this buffer for 2 h at 37°C. A 400 microliter sample is removed, filtered, diluted as necessary, and assayed for bound or desorbed ions in this buffer using ion chromatography. For each polymer tested and for each anion present in the SOB buffer, binding is calculated as mmol of bound anion per gram of polymer. Bound ions / desorbed ions (mmol / g) = ([ions] 開始 -[ion] 最終 ) x [dilution factor] / 2.5 In the formula, [ion] 開始 corresponds to the starting concentration of the ion in the SOB buffer (mM), and [ion] 最終corresponds to the final value (mM) of that particular ion in the measured filtrate after exposure to the test polymer, and 2.5 is the polymer concentration in mg / mL. Excess SOB buffer is then removed by applying negative pressure at the bottom of the tube, the tube is rinsed two more times with DI water, and excess liquid is removed by applying negative pressure at the bottom. Then "holding buffer" is added to the tube to achieve a polymer concentration of 2.5 mg / mL (supernatants are sampled for ion chromatography analysis in the SGF and SOB binding steps, but no polymer is lost). The holding buffer contains 50 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 100 mM sodium acetate, 2 mM sodium phosphate, 3 mM sodium sulfate, 17 mM sodium chloride, and 30 mM sodium bicarbonate, adjusted to pH 7. The anion composition in the retention buffer represents typical posterior gut concentrations (Wrong, O et al.
[1965] Clinical Science 28, 357-375). The SPE tubes are capped, sealed, and incubated at 37°C for approximately 40 hours, which is a typical transit time through the human colon (Metcalf, AM et al. Gastroenterology
[1987] 92:40-47). A 400 microliter sample is removed, filtered, diluted as necessary, and assayed for the anion content listed above for SOB. For each polymer tested, the ions bound to or desorbed from the polymer in the retention matrix are calculated using the following calculation: Bound ions / desorbed ions (mmol / g) = ([ions] 開始 -[ion] 最終 ) x [dilution factor] / 2.5 In the formula, [ion] 開始 corresponds to the starting concentration of the ion in the holding buffer (mM), [ion] 最終where 1 corresponds to the final value (mM) of that particular ion in the measured filtrate after 40 hours exposure to the test polymer (mM), and 2.5 is the polymer concentration in mg / mL. Excess retention matrix is removed by applying negative pressure at the bottom of the SPE tube. The tube is rinsed two more times with DI water and excess liquid is removed by applying negative pressure at the bottom. Ions that remain bound to the polymer are eluted by adding 0.2 M NaOH to the SPE tube to achieve a final polymer concentration of 2.5 mg / mL (assuming no polymer is lost in the previous three binding steps) and incubated at 37° C. for 16-20 hours. 600 microliters of sample is removed, filtered, diluted as necessary, and assayed for the anion content listed above for SOB. For each polymer tested, the ions desorbed from the polymer in the retention matrix are calculated using the following calculation: Desorbed ions (mmol / g) = ([ions] 開始 -[ion] 最終 ) x [dilution factor] / 2.5 In the formula, [ion] 開始 corresponds to the starting concentration (mM) of ions in the elution solution (0.2 M NaOH), and [ions] 最終 corresponds to the final value (in mM) of that particular ion in the measured filtrate after exposure of the test polymer to 0.2 M NaOH for 16-20 h, and 2.5 is the polymer concentration in mg / mL.
[0092] The term "halo" means a halogen atom, for example, a fluorine, chlorine, bromine, or iodine atom.
[0093] The term "haloalkyl group" includes groups in which any one or more of the alkyl carbon atoms are replaced by halo as defined above. Specifically included are monohaloalkyl, dihaloalkyl, and polyhaloalkyl groups, including perhaloalkyl. Monohaloalkyl groups can have, for example, either iodo, bromo, chloro, or fluoro atoms in the group. Dihalo and polyhaloalkyl groups can have two or more of the same halo atoms, or a combination of different halo atoms. "Lower haloalkyl group" includes groups having 1 to 6 carbon atoms. In some embodiments, lower haloalkyl groups have 1 to 3 carbon atoms. Examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl.
[0094] The term "heteroaliphatic" describes a chain of 1 to 25 carbon atoms, typically 1 to 12 carbon atoms, more typically 1 to 10 carbon atoms, and most typically 1 to 8 carbon atoms, and in some embodiments 1 to 4 carbon atoms that can be saturated or unsaturated (but not aromatic) containing one or more heteroatoms, such as halogens, oxygen, nitrogen, sulfur, phosphorus, or boron. The heteroatom can be part of a pendant (or side) group attached to the chain of atoms (e.g., -CH(OH)--CH(NH2)- where the carbon atom is a member of a chain of atoms) or can be one of the chain atoms (e.g., -ROR- or -RNHR- where each R is aliphatic). Heteroaliphatic encompasses heteroalkyls and heterocycles, but does not include heteroaryls.
[0095] The term "heteroalkyl" describes a fully saturated heteroaliphatic moiety.
[0096] The term "heteroaryl", unless otherwise stated, refers to a monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms, where one or more (in one embodiment, 1, 2, or 3) ring atoms are heteroatoms selected from N, O, or S, and the remaining ring atoms are carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like. As defined herein, the terms "heteroaryl" and "aryl" are mutually exclusive. "Heteroarylene" refers to a divalent heteroaryl radical.
[0097] The term "heteroatom" refers to an atom other than carbon and hydrogen. Typically, but not exclusively, heteroatoms are selected from the group consisting of halogen, sulfur, phosphorus, nitrogen, boron and oxygen atoms. Groups containing more than one heteroatom may contain different heteroatoms.
[0098] The terms "heterocyclic", "heterocyclic", or "heterocyclyl" refer to a saturated or unsaturated group of 4 to 8 ring atoms, where one or two ring atoms are heteroatoms, such as N, O, B, P, and S(O). n n is an integer from 0 to 2; and the remaining ring atoms are carbon. In addition, one or two ring carbon atoms in the heterocyclyl ring may be optionally replaced by a -C(O)- group. More specifically, the term heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydro-pyranyl, thiomorpholino, and the like. When the heterocyclyl ring is unsaturated, it may contain one or two ring double bonds, provided that the ring is not aromatic. When the heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocyclic amino, and is a subset of the heterocyclyl group.
[0099] The term "hydrocarbon group" or "hydrocarbyl group" refers to a chain of 1 to 25 carbon atoms, typically 1 to 12 carbon atoms, more typically 1 to 10 carbon atoms, and most typically 1 to 8 carbon atoms. The hydrocarbon group may have a straight or branched chain structure. Typical hydrocarbon groups have one or two branches, typically one branch. Typically, the hydrocarbon group is saturated. The unsaturated hydrocarbon group may have one or more double bonds, one or more triple bonds, or a combination thereof. Typical unsaturated hydrocarbon groups have one or two double bonds or one triple bond; more typically, the unsaturated hydrocarbon group has one double bond.
[0100] "Initiator" is a term used to describe an agent that starts a polymerization.
[0101] The term "molecular weight per nitrogen" or "MW / N" refers to the calculated molecular weight of a polymer per nitrogen atom. The term represents the average molecular weight to represent one amine functional group in the crosslinked polymer. The term is calculated by dividing the mass of a polymer sample by the number of moles of nitrogen present in the sample. "MW / N" is the inverse of the theoretical capacity, and the calculation is based on the feed ratio, assuming complete reaction of the crosslinker and monomer. The lower the molecular weight per nitrogen, the higher the theoretical capacity of the crosslinked polymer.
[0102] "Optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances when the event or circumstance occurs and instances when the event or circumstance does not occur. For example, "a heterocyclyl group optionally substituted with an alkyl group" means that the alkyl may, but need not, be present, and that the description includes embodiments in which the heterocyclyl group is substituted with an alkyl group and embodiments in which the heterocyclyl group is not substituted with an alkyl group.
[0103] "Pharmaceutically acceptable" means a carrier, diluent, or excipient that, when used in conjunction with the carrier, diluent, or excipient, respectively, is generally safe, non-toxic, and biologically or otherwise useful in preparing pharmaceutical compositions desirable for veterinary and / or human pharmaceutical use.
[0104] The "Simulated Gastric Fluid" or "SGF" assay describes a test to determine total chloride binding capacity for a test polymer using a defined buffer that mimics the contents of gastric fluid as follows: Simulated Gastric Fluid (SGF) consists of 35 mM NaCl, 63 mM HCl, pH 1.2. To perform the assay, the free amine polymer to be tested is prepared at a concentration of 2.5 mg / mL (25 mg dry weight) in 10 mL of SGF buffer. The mixture is incubated overnight at 37°C for approximately 12-16 hours with agitation on a rotary mixer. Unless another period is otherwise stated, the SGF binding data or binding capacity listed herein is determined for a period of this duration. After incubation and mixing, the tube containing the polymer is centrifuged at 500-1000Xg for 2 minutes to pellet the test sample. Approximately 750 microliters of supernatant is removed and filtered using a suitable filter, such as a 0.45 micrometer pore size syringe filter fitted onto a 96-well 2 mL collection plate, or an 800 microliter, 1 micrometer pore size, 96-well glass filter plate. In the latter configuration, multiple samples tested in SGF buffer can be prepared for analysis, including control tubes containing free amine sevelamer, free amine bixalomer standard controls, and blank buffer that are run through all of the assay steps. With samples arrayed on the filter plate and a collection plate fitted to the bottom, the unit is centrifuged at 1000Xg for 1 minute and the samples are filtered. For small sample sets, a syringe filter may be used in place of the filter plate to collect approximately 2-4 mL of filtrate in a 15 mL container. After filtration, each filtrate is diluted 4X with water and the chloride content of the filtrate is measured by ion chromatography (IC). The IC method (e.g., Dionex ICS-2100, Thermo Scientific) consists of an AS11 column and a 15 mM KOH mobile phase, an injection volume of 5 microliters, a run time of 3 minutes, a wash / rinse volume of 1000 microliters, and a flow rate of 1.25 mL / min. To determine the chloride bound to the polymer, the following calculation is completed: (Cl start-Cl equilibrium)×4 / 2.5 The binding capacity is expressed as chloride (mmol) / polymer (g): where ClStart corresponds to the starting chloride concentration (mM) in the SGF buffer, ClEquilibrium corresponds to the equilibrium value of chloride in the diluted measurement filtrate after exposure to the test polymer, 4 is the dilution factor and 2.5 is the polymer concentration in mg / mL.
[0105] "Simulated Small Intestine Inorganic Buffer" or "SIB" is a test to determine the chloride and phosphate binding capacity of free amine test polymers in a selective specific interference buffer assay (SIB). The chloride and phosphate binding capacity of free amine test polymers, along with the chloride and phosphate binding capacities of free amine sevelamer and bixalomer control polymers, were determined using a selective specific interference buffer assay (SIB) as follows: The buffer used for the SIB assay contains 36 mM NaCl, 20 mM NaH2PO4, 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), buffered to pH 5.5. SIB buffer contains concentrations of chloride, phosphate, and pH present in the human duodenum and upper gastrointestinal tract (Stevens T, Conwell DL, Zuccaro G, Van Lente F, Khandwala F, Purich E, et al. Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects. Gastrointestinal endoscopy. 2004;60(3):351-5, Fordtran J, Locklear T. Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Digest Dis Sci. 1966;11(7):503-21) and is a useful indicator of selectivity of chloride binding compared to phosphate binding by the polymer. To perform the assay, the free amine polymer to be tested is prepared at a concentration of 2.5 mg / mL (25 mg dry weight) in 10 mL of SIB buffer. The mixture is incubated at 37° C. for 1 hour with agitation on a rotary mixer. Unless another period is otherwise stated, the SIB binding data or binding capacity listed herein is determined for this duration. After incubation and mixing, the tubes containing the polymer are centrifuged at 1000×g for 2 minutes to pellet the test samples.750 microliters of the supernatant is removed and filtered using a 96-well glass filter plate with 800 microliters of 1 micrometer pore size fitted onto a 96-well 2 mL collection plate; in this arrangement, multiple samples tested in SIB buffer can be prepared for analysis, including a control tube containing free amine sevelamer, a standard control of free amine bixalomer, and blank buffer that is run through all of the assay steps. With samples arrayed on the filter plate and a collection plate fitted to the bottom, the unit is centrifuged at 1000Xg for 1 minute and the samples are filtered. For small sample sets, a syringe filter (0.45 micrometer) may be used in place of the filter plate to collect approximately 2-4 mL of filtrate in a 15 mL vial. After filtration into the collection plate, each filtrate is diluted before being measured for chloride or phosphate content. For chloride and phosphate measurements, the filtrate under analysis is diluted 4X with water. The chloride and phosphate content of the filtrate is measured by ion chromatography (IC). The IC method (e.g., Dionex ICS-2100, Thermo Scientific) consists of an AS24A column, 45 mM KOH mobile phase, 5 microliter injection volume, approximately 10 minute run time, 1000 microliter wash / rinse volume, and a flow rate of 0.3 mL / min. To determine polymer bound chloride, complete the following calculation: Binding capacity in mmol of chloride / polymer (g) = (Cl 開始 -Cl 最終 )×4 / 2.5 In the formula, Cl 開始 corresponds to the starting concentration of chloride in the SIB buffer, Cl 最終 where x represents the final chloride value measured in the diluted filtrate after exposure to the test polymer, 4 is the dilution factor, and 2.5 is the polymer concentration in mg / mL. To determine the phosphate bound to the polymer, complete the following calculation: Binding capacity in mmol of phosphate / polymer (g) = (P 開始 -P 最終 )×4 / 2.5 In the formula, P 開始corresponds to the starting concentration of phosphate in the SIB buffer, P 最終 corresponds to the final value of phosphate in the diluted filtrate measured after exposure to the test polymer, 4 is the dilution factor, and 2.5 is the polymer concentration in mg / mL.
[0106] "Simulated Small Intestine Organic and Inorganic Buffer" or "SOB" is a test to determine chloride binding capacity measured in the presence of specific organic and inorganic interferences commonly found in the gastrointestinal tract. The chloride binding capacity, as well as the binding capacity of other anions, of free amine test polymers and free amine sevelamer and bixalomer control polymers were measured in the presence of specific organic interferences commonly found in the gastrointestinal tract as follows: To mimic the conditions of the GI cavity, the SOB screen is used to determine the chloride binding capacity of the free amine polymers when exposed to chloride in the presence of other potentially competing anions such as bile acids, fatty acids, phosphate, acetate and citrate. The test buffer used for the SOB assay contains 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), 50 mM sodium acetate, 36 mM sodium chloride, 7 mM sodium phosphate, 1.5 mM sodium citrate, 30 mM oleic acid and 5 mM sodium taurocholate buffered to pH 6.2. The concentrations of potential competing anions reflect the typical gastrointestinal concentrations present at various points in the GI tract, and the pH is an average value representing the pH values encountered in both the duodenum and large intestine. The chloride concentration used is the same as that used in the SIB screening. To perform the assay, the free amine polymer to be tested is accurately weighed into a 16×100 mm glass tube with a liquid-tight screw cap. An appropriate amount of SOB buffer is added to the tube to achieve a final polymer concentration of 2.5 mg / mL. The mixture is incubated at 37° C. for 2 hours (unless a different time is stated) with agitation on a rotary mixer. SOB binding data or binding capacity determined for this duration is determined for this duration unless another time period is stated otherwise. After incubation and mixing, 600 microliters of supernatant is removed and filtered using a 96-well glass filter plate. With samples arrayed in the filter plate and a collection plate fitted to the bottom, the unit is centrifuged at 1000×g for 1 minute and the samples are filtered.For small sample sets, a syringe filter may be used in place of the filter plate, and approximately 2-4 mL of filtrate may be collected in a 15 mL vial. After filtration into the collection plate, each filtrate is diluted appropriately before being measured for anion content. The IC method (e.g., Dionex ICS-2100, Thermo Scientific) consists of an AS24A column, a 20 mM to 100 mM KOH gradient, a 5 microliter injection volume, approximately 30 minutes runtime, a 1000 microliter wash / rinse volume, and a 0.3 mL / min flow rate. This method is suitable for quantifying chloride, phosphate, and taurocholate. Other suitable methods may be substituted. To determine the ions bound to the polymer, complete the following calculation: Binding capacity in mmol of ions / polymer (g) = ([ions] 開始 -[ion] 最終 ) x [dilution factor] / 2.5 In the formula, [ion] 開始 corresponds to the starting concentration of ions in the SOB buffer, [ions] 最終 corresponds to the final value of that particular ion in the measured filtrate after exposure to the test polymer, dilution factor is the dilution factor, and 2.5 is the polymer concentration in mg / mL.
[0107] The terms "substituted hydrocarbyl", "substituted alkyl", "substituted alkenyl", "substituted aryl", "substituted heterocyclic" or "substituted heteroaryl" as used herein refer to hydrocarbyl, alkyl, alkenyl, aryl, heterocyclic, or heteroaryl moieties in which a carbon chain atom is replaced by at least one atom other than carbon and hydrogen, including moieties in which a carbon chain atom is replaced by a heteroatom, such as nitrogen, oxygen, silicon, phosphorus, boron, sulfur, or halogen atom. These substituents include halogen, heterocyclic, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketal, acetal, ester, and ether.
[0108] "Swelling ratio" or simply "swelling" describes the amount of water absorbed by a given amount of polymer divided by the weight of the polymer aliquot. Swelling ratio is expressed as swell = (swollen polymer (g) - dry polymer (g)) / dry polymer (g). Methods used to determine the swell ratio of any given polymer include: a. Place 50-100 mg of dry (<5 wt.% moisture content) polymer into an 11 mL sealable test tube (with screw cap) of known weight (weight of tube = weight A). b. Add deionized water (10 mL) to the test tube containing the polymer. Seal the tube and tumble at room temperature for 16 h (overnight). After incubation, centrifuge the tube at 3000 x g for 3 min and carefully remove the supernatant by vacuum aspiration. For polymers that form a very loose precipitate, perform another centrifugation step. c. After step (b), record the weight of the swollen polymer plus test tube (Weight B). d. Freeze at -40° C. for 30 minutes. Freeze dry for 48 hours. Weigh the dried polymer and test tube (record as Weight C). e. Calculate the absorbed water (g) per gram of polymer, defined as [(Weight B - Weight A) - (Weight C - Weight A)] / (Weight C - Weight A).
[0109] "Target ion" is the ion to which the polymer binds, typically referring to the primary ion bound by the polymer or the ion whose binding to the polymer is believed to result in the therapeutic effect of the polymer (e.g., proton and chloride binding leading to the net removal of HCl).
[0110] The term "theoretical capacity" refers to the calculated predicted binding of hydrochloric acid in the "SGF" assay, expressed in mmol / g. Theoretical capacity is based on the assumption that 100% of the amines from the monomer(s) and crosslinker(s) are incorporated into the crosslinked polymer based on the respective feed ratios. Theoretical capacity is therefore equal to the concentration of amine functional groups in the polymer (mmol / g). Theoretical capacity assumes that each amine is available to bind its respective anion and cation and is not adjusted for the type of amine formed (e.g., do not subtract the capacity of quaternary amines that are not available to bind protons).
[0111] "Therapeutically effective amount" means the amount of proton-linked crosslinked amine polymer that, when administered to a patient for treating a disease, is sufficient to effect such treatment of the disease. What constitutes a "therapeutically effective amount" will vary depending on the polymer, the severity of the disease, and the age, weight, etc., of the mammal being treated.
[0112] "Treating" or "treatment" of a disease includes (i) inhibiting the disease, i.e., arresting or reducing the occurrence of the disease or its clinical symptoms; or (ii) ameliorating the disease, i.e., causing the regression of the disease or its clinical symptoms. Inhibiting a disease includes, for example, prevention.
[0113] The term "triarylamine" refers to an amino moiety bearing three allyl groups.
[0114] The term "vinyl" refers to a compound of the structure R x H y C=CH- * ;In the formula, * represents the point of attachment of the moiety to the remainder of the molecule, where the point of attachment is a heteroatom or aryl, X and Y are independently 0, 1 or 2, such that X+Y=2, and R is hydrocarbyl or substituted hydrocarbyl.
[0115] The term "crosslinker weight percent" refers to the percentage calculated by the mass of the polymer sample that is derived from the crosslinker. The crosslinker weight percent is calculated using the feed ratio of the polymerization and assumes complete conversion of the monomer and crosslinker(s). The mass attributed to the crosslinker is equal to the expected increase in molecular weight in an infinite polymer network after the reaction (e.g., 1,3-dichloropropane is 113 amu, but only 42 amu are added to the polymer network after crosslinking with DCP, because the chlorine atom as a leaving group is not incorporated into the polymer network).
[0116] When introducing elements of the present invention or preferred embodiment(s) thereof, the articles "a," "an," "the," and "said" are intended to mean that there are one or more elements. The terms "comprising," "including," and "having" are intended to be inclusive and not exclusive (i.e., other elements may be present in addition to the elements listed).
[0117] Embodiment As previously described, among various aspects of the present disclosure, methods of treatment can be described that use compositions comprising non-absorbed crosslinked polymers containing free amine moieties. In one embodiment, the crosslinked amine polymers have the potential to remove clinically significant amounts of protons and chloride ions from the gastrointestinal tract of animals, including humans, upon administration of a therapeutically effective amount (i.e., an effective dose) of the crosslinked amine polymer to achieve a therapeutic or prophylactic benefit.
[0118] The therapeutically effective dose of the crosslinked amine polymer disclosed herein depends at least in part on the disease being treated, the potency of the crosslinked free amine polymer, and the intended effect. In one embodiment, the daily dose of the crosslinked free amine polymer is sufficient to slow the rate of decrease in serum bicarbonate levels over an extended period of time. In another embodiment, the daily dose of the crosslinked free amine polymer is sufficient to maintain serum bicarbonate levels over an extended period of time. In another embodiment, the daily dose of the crosslinked free amine polymer is sufficient to increase serum bicarbonate levels over an extended period of time. For example, in one embodiment, the daily dose is sufficient to achieve or maintain a serum bicarbonate level of at least about 20 mEq / L over an extended period of time. By way of further example, in one such embodiment, the daily dose is sufficient to achieve or maintain a serum bicarbonate level of at least about 21 mEq / L over an extended period of time. By way of further example, in one such embodiment, the daily dose is sufficient to maintain a serum bicarbonate level of at least about 22 mEq / L over an extended period of time. In yet another embodiment, the daily dose is sufficient to maintain a serum bicarbonate level of at least about 24 mEq / L over an extended period of time, in each of the above embodiments, which is at least one month; for example, at least two months, at least three months, or even at least several months.
[0119] In general, dosage levels of the crosslinked amine polymers for therapeutic and / or prophylactic use may range from about 0.5 g / day to about 20 g / day. A range of about 1 g / day to about 10 g / day is generally preferred to promote patient compliance. For example, in one such embodiment, the dose is about 2 g / day to about 7 g / day. As a further example, in one such embodiment, the dose is about 3 g / day to about 6 g / day. As a further example, in one such embodiment, the dose is about 4 g / day to about 5 g / day. Optionally, the daily dose may be administered as a single dose (i.e., once per day) or divided into multiple doses (e.g., two, three or more doses) over the course of a day. In general, the crosslinked amine polymers for therapeutic and / or prophylactic use may be administered as a fixed daily dose or titrated based on the serum bicarbonate level or other indicator of acidosis of the patient in need of treatment. Titration may be performed as needed at the initiation or throughout treatment, with initiation and maintenance dosage levels varying from patient to patient based on the severity of the underlying disease.
[0120] As shown diagrammatically in Figures 1A-1C, according to one embodiment, the non-absorbed free amine polymers of the present disclosure are taken orally and used to treat metabolic acidosis in mammals (including by increasing serum bicarbonate and normalizing blood pH) by binding HCl in the gastrointestinal ("GI") tract and removing HCl through the stool. The free amine polymers are taken orally at compliance enhancing doses targeted to chronically bind sufficient HCl to allow a clinically significant increase in serum bicarbonate of 3 mEq / L (Figure 1A). In the stomach (Figure 1B), the free amines are transported to the stomach via the H + The positive charges in the polymer are then protonated by Cl by controlling the access of the binding sites through crosslinking and hydrophilic / hydrophobic properties. - available to bind to other larger organic anions (e.g., X - and Y -In the lower GI tract / colon (Figure 1C), the Cl-2+ complex is bound to a lesser extent, if at all. - is not completely released and HCl is removed from the body through regular bowel movements and fecal excretion, resulting in a net alkalinization in the serum. - is Cl - / HCO3 - Not available for exchange via the antiporter system.
[0121] In one embodiment, the polymer is designed to simultaneously maximize efficacy (net HCl binding and excretion) and minimize GI side effects (through low swelling particle design and particle size distribution). Optimized HCl binding is achieved by optimizing capacity (number of amine binding sites), selectivity (preferred chloride binding in the colon versus other anions, especially organic anions), and retention (retention of Cl in the colon and intestine). - / HCO3 - This can be achieved through careful balancing of the chloride ion exchanger (which does not release significant amounts of chloride in the lower GI tract to avoid the activity of the antiporter); - / HCO3 - The exchanger may mediate the uptake of chloride ions from the intestinal lumen and the reciprocal exchange for bicarbonate from the serum, thereby effectively reducing serum bicarbonate.
[0122] Competing anions that replace chloride lead to a net reduction in bicarbonate through the following mechanisms. First, replacement of chloride from the polymer in the GI lumen, especially in the intestinal tract, provides for easy exchange with bicarbonate in serum. The colon has an anion exchanger (chloride / bicarbonate antiporter) that removes chloride from the luminal side in exchange for secreted bicarbonate. When free chloride is released from the polymer in the GI tract, it is exchanged for bicarbonate, which is then lost in the excreta, causing a reduction in total extracellular bicarbonate (Davis, 1983; D'Agostino, 1953). Binding of short chain fatty acids (SCFAs) in exchange for bound chloride in the polymer reduces extracellular HCO 3- This results in the depletion of reserves. Short-chain fatty acids are products of bacterial metabolism of complex carbohydrates that are not catabolized by normal digestive processes (Chemlarova, 2007). Short-chain fatty acids that reach the colon are absorbed and distributed to various tissues, with a common metabolic fate being the generation of H2O and CO2 and conversion to bicarbonate equivalents. Thus, binding of SCFAs to polymers to neutralize proton charges is detrimental to overall bicarbonate reserves and buffering capacity, necessitating the design of chemical and physical features in the polymer that limit SCFA exchange. Finally, phosphate binding to polymers should be similarly limited, since phosphate represents an additional source of buffering capacity in situations where ammonia production and / or hydrogen ion secretion are impaired in chronic kidney disease.
[0123] For each binding of a proton, an anion is preferably bound as the positive charge is about to leave the human body as a neutral polymer. The "binding" of ions is more than the minimum binding, i.e., at least about 0.2 mmol of ions / polymer (g), in some embodiments at least about 1 mmol of ions / polymer (g), in some embodiments at least about 1.5 mmol of ions / polymer (g), in some embodiments at least about 3 mmol of ions / polymer (g), in some embodiments at least about 5 mmol of ions / polymer (g), in some embodiments at least about 10 mmol of ions / polymer (g), in some embodiments at least about 12 mmol of ions / polymer (g), in some embodiments at least about 13 mmol of ions / polymer (g), in some embodiments, or even at least about 14 mmol of ions / polymer (g). In one embodiment, the polymers are characterized by high proton binding capacity while at the same time imparting selectivity for anions; selectivity for chloride is achieved by reducing the binding of interfering anions, including but not limited to phosphate, citrate, acetate, bile acids, and fatty acids. For example, in some embodiments, the polymers of the present disclosure bind phosphate with a binding capacity of less than about 5 mmol / g, less than about 4 mmol / g, less than about 3 mmol / g, less than about 2 mmol / g, or even less than about 1 mmol / g. In some embodiments, the polymers of the present disclosure bind bile and fatty acids with a binding capacity of less than about 5 mmol / g, less than about 4 mmol / g, less than about 3 mmol / g, less than about 2 mmol / g, in some embodiments, less than about 1 mmol / g, in some embodiments, less than about 0.5 mmol / g, in some embodiments, less than about 0.3 mmol / g, and in some embodiments, less than about 0.1 mmol / g.
[0124] The efficacy of the polymer may be determined in animal models or in human volunteers and patients. In vitro, ex vivo and in vivo approaches are also useful for determining HCl binding. In vitro binding solutions can be used to measure the binding capacity for protons, chloride and other ions at different pH. Ex vivo extracts, such as gastrointestinal cavity contents from human volunteers or from model animals, can be used for similar purposes. Selectivity to preferentially bind and / or retain certain ions over others can also be demonstrated in such in vitro and ex vivo solutions. In vivo models of metabolic acidosis can be used to test the efficacy of the polymers in normalizing acid / base balance - for example, 5 / 6 nephrectomized rats fed a casein-containing chow diet (described in Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE. Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney international. 2008;73(2):192-9), or adenine-fed rats (Terai K, K Mizukami and M Okada. 2008. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphatemia model. Nephrol. 13:139-146).
[0125] In one embodiment, the polymers described in this disclosure are given to animals, including humans, in one, two or three doses per day (most preferably not exceeding a daily dose of 5 g or less per day) to treat metabolic acidosis, and these daily doses achieve a clinically significant and sustained increase in serum bicarbonate of approximately 3 mEq / L. The amount of HCl binding achieved by oral administration of the polymer is determined by the polymer binding capacity, which is generally in the range of 5-25 mEq HCl per gram of polymer. In addition, the polymer is preferably selective about the anion that is bound to balance the proton binding, with chloride being the preferred anion. Anions other than chloride that are bound to neutralize the proton positive charge include phosphate, short chain fatty acids, long chain fatty acids, bile acids or other organic or inorganic anions. The binding of these anions other than chloride affects the overall bicarbonate pool in the intracellular and extracellular compartments.
[0126] In one embodiment, the mechanism of action for the HCl polymer binder includes the following: In the stomach or elsewhere in the GI tract, the free amine polymers release protons (H +) binding. The positive charge formed as a result of this binding is then available for chloride anion binding. After leaving the stomach, the polymer sequentially encounters different GI tract environments: duodenum, jejunum, ileum, and colon, each of which complements different organic and inorganic anions. The physical and chemical properties of the polymer are designed to control the access of the protonated binding sites to the collected anions. Physical barriers include crosslinks (size exclusion to prevent anion binding) and chemical sites (to keep out larger organic ions, such as acetate, propionate, butyrate, or other short chain fatty acids, commonly present in the colon), as well as combinations of the two properties, to limit phosphate, bile acid, and fatty acid binding. By tuning the chemistry of the bead crosslinks and amine binding sites, chloride can be tightly bound so that exchange with other anions and release in the lower GI tract is reduced or eliminated. Without being bound by theory, anions with ions and / or hydration radii larger than chloride can be eliminated or reduced from binding by incorporating these properties into the HCl-binding polymer. For example, the ionic radius of chloride is smaller than the corresponding values for phosphate and other anions commonly encountered in the GI lumen, either in hydrated or non-hydrated form (Supramolecular Chemistry, Steed, JW (2009) John Wiley and Sons, page 226; Kielland, J (1937), J. Am. Chem. Soc. 59: 1675-1678). To selectively bind smaller ions, polymers typically exhibit high crosslink density to create preferential access to polymer binding sites. High crosslink density materials, however, are typically characterized by low swelling ratios. The swelling ratio can be achieved by the following compositional and process variables: 1) the molar ratio of the amine monomer (or polymer) and crosslinker, 2) the monomer+crosslinker to solvent ratio in the crosslinking reaction, 3) the net charge of the polymer (at the physiological pH and tonicity of the environment in which it will be used), 4) the hydrophilic / hydrophobic balance of the backbone polymer, and / or 5) post-crosslinking of existing materials.
[0127] In some embodiments, the theoretical chloride binding capacity of the polymers of the present disclosure may range from about 1 mmol / g to about 25 mmol / g. In one embodiment, the theoretical chloride binding capacity of the polymer is from about 3 mmol / g to about 25 mmol / g. In another embodiment, the theoretical chloride binding capacity of the polymer is from about 6 mmol / g to about 20 mmol / g. In another embodiment, the theoretical chloride binding capacity of the polymer is from about 9 mmol / g to about 17 mmol / g.
[0128] In one embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 2 mmol / g at 1 hour in a simulated small intestine inorganic buffer ("SIB"). For example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 2.5 mmol / g at 1 hour in a SIB. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 3 mmol / g at 1 hour in a SIB. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 3.5 mmol / g at 1 hour in a SIB. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 4 mmol / g at 1 hour in a SIB. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 4.5 mmol / g at 1 hour in a SIB. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 5 mmol / g in SIB at 1 hour. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 5.5 mmol / g in SIB at 1 hour. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a chloride ion binding capacity of at least 6 mmol / g in SIB at 1 hour. In one exemplary embodiment of each of the above embodiments in this paragraph, the crosslinked amine polymer may have a swelling ratio not greater than about 1.5.
[0129] In one embodiment, the crosslinked polymers of the present disclosure are characterized by a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g in simulated small intestine inorganic buffer ("SIB"). For example, in one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g after 1 hour in the SIB. By way of further example, in one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g after 2 hours in the SIB. By way of further example, in one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g after 3 hours in the SIB. By way of further example, in one such embodiment, the crosslinked amine polymer has a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g after 4 hours in the SIB. By way of further example, in one such embodiment, the crosslinked amine polymer has a chloride to phosphate ion binding ratio in the SIB of at least 2.5:1, respectively. In one exemplary embodiment of each of the above embodiments in this paragraph, the crosslinked amine polymer may have a swelling ratio not exceeding about 1.5.
[0130] In one embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and a chloride binding capacity in simulated gastric fluid ("SGF") of at least 8 mmol / g. For example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 10 mmol / g in SGF. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and a chloride binding capacity in SGF of at least 12 mmol / g. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and a chloride binding capacity in SGF of at least 14 mmol / g. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and a chloride binding capacity after 1 hour in SGF that is at least 50% of the proton binding capacity and the chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in SGF. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and chloride binding capacity after 1 hour in SGF that is at least 60% of the proton binding capacity and chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in SGF. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and chloride binding capacity after 1 hour in SGF that is at least 70% of the proton binding capacity and chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in SGF. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and chloride binding capacity after 1 hour in SGF that is at least 80% of the proton binding capacity and chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in SGF. By way of further example, in one such embodiment, the crosslinked polymer of the present disclosure is characterized by a proton binding capacity and chloride binding capacity after 1 hour in SGF that is at least 90% of the proton binding capacity and chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in SGF.
[0131] In one embodiment, the crosslinked polymers of the present disclosure are characterized by a selectivity for chloride over citrate, phosphate, and taurocholate in simulated small intestinal organic and inorganic buffers ("SOB"), or a chloride binding capacity in SOB at 24 hours of at least 4 mmol / g.
[0132] In one embodiment, the crosslinked polymers of the present disclosure are characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 1 hour in simulated small intestinal organic and inorganic buffers ("SOB"). For example, in one such embodiment, the crosslinked polymers are characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 4 hours in SOB. As a further example, in one such embodiment, the crosslinked polymers are characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 12 hours in SOB. As a further example, in one such embodiment, the crosslinked polymers are characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 18 hours in SOB. As a further example, in one such embodiment, the crosslinked polymers are characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 24 hours in SOB. As a further example, in one such embodiment, the crosslinked polymer is characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 30 hours in SOB. As a further example, in one such embodiment, the crosslinked polymer is characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 36 hours in SOB. As a further example, in one such embodiment, the crosslinked polymer is characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 42 hours in SOB. As a further example, in one such embodiment, the crosslinked polymer is characterized by selectivity for chloride over citrate, phosphate, and taurocholate after 48 hours in SOB.
[0133] Generally, crosslinked polymers having the characteristics described above and elsewhere herein have a pK of at least 6, at least 6.5, at least 7, at least 7.5. a or at least physiological ionic conditions that are at the upper end of the pH values encountered along the GI tract (Fallingborg, J Aliment. Pharmacol. Therap
[1989] 3:05-613).
[0134] In some embodiments, the molecular weight per nitrogen of the polymers of the present disclosure may range from about 40 to about 1000 daltons. In one embodiment, the molecular weight per nitrogen of the polymer is from about 40 to about 500 daltons. In another embodiment, the molecular weight per nitrogen of the polymer is from about 50 to about 170 daltons. In another embodiment, the molecular weight per nitrogen of the polymer is from about 60 to about 110 daltons.
[0135] In some embodiments, the crosslinker weight % range is about 10-90% by weight of the crosslinked amine polymer, for example, in some embodiments, the crosslinker weight % range is about 15-90% by weight of the crosslinked amine polymer, or even about 25-90% by weight of the crosslinked amine polymer.
[0136] As described above, crosslinked amine polymers with high chloride binding capacity and high selectivity for chloride over other competing anions, such as phosphate, may be prepared in a two-step process according to one embodiment of the present disclosure. In general, the selectivity of the polymer is a function of the crosslink density, and the capacity of the polymer is a function of the free amine density of the crosslinked amine polymer. Advantageously, the two-step process disclosed herein provides both high chloride binding capacity and high selectivity for chloride over other competing ions by relying primarily on carbon-carbon bridges in the first step and nitrogen-nitrogen bridges in the second step.
[0137] In the first step, the crosslinking is preferably a carbon-to-carbon crosslinking that is under-capacity, i.e., under-free amine. In the second step, the crosslinking is amine-consumable and is targeted for tuning for selectivity. Based on the desired high capacity, the C-N ratio is preferably optimized to maximize amine functionality for HCl binding, while still maintaining spherical polymer particles of controlled particle size to ensure non-absorbent and acceptable mouthfeel that are stable under GI conditions. The preferred degree of carbon-carbon crosslinking achieved after the first step is sufficient to allow the resulting beads to swell between 4X and 6X in water (i.e., swelling ratio of 4-6).
[0138] In general, the crosslinked amine polymer may be a crosslinked homopolymer or crosslinked copolymer that contains free amine sites. The free amine sites may be separated, for example, by repeating linker (or intervening) units of the same or varying length. In some embodiments, the polymer includes repeat units that contain amine sites and intervening linker units. In other embodiments, multiple amine-containing repeat units are separated by one or more linker units. In addition, the multifunctional crosslinker may include HCl-binding functional groups, e.g., amines, ("active crosslinkers") or may lack HCl-binding functional groups, e.g., amines ("active crosslinkers").
[0139] In a preferred embodiment, the first polymerization (crosslinking) step results in preformed amine polymer beads having a target size and chloride binding capacity. For example, in one such embodiment, the beads have a chloride binding capacity of at least 10 mmol / g in simulated gastric fluid ("SGF") and a swelling ratio in the range of 4-6. The resulting preformed amine polymer is then preferably deprotonated (at least partially) with a base and combined with a non-protonated swelling agent to swell the free amine polymer without protonating the amine functional groups. Furthermore, the amount of non-protonated swelling agent is selected to adjust the degree of subsequent crosslinking that effectively forms the template, which is then induced via an amine-consuming crosslinking step. In a second crosslinking step, the swollen deprotonated preformed amine polymer is crosslinked with a crosslinker containing amine reactive sites to form the crosslinked amine polymer after polymerization.
[0140] In general, selectivity for chloride over other competing ions is achieved by highly crosslinked amine polymers. For example, a relatively high chloride binding capacity can be obtained by reacting preformed amine polymer beads with a pure crosslinker in the presence of a swelling agent (water). This "non-dispersed" reaction gives access to high selectivity for chloride over competing ions in SIB and SOB assays, but also results in macroscopically (and microscopically) aggregated polymer beads. It is therefore advantageous to include a solvent (e.g., heptane) in the second crosslinking step to disperse the preformed crosslinked polymer beads so as to avoid bead-to-bead reactions and the resulting aggregation. However, the use of too much solvent (dispersant) can dilute the reaction solution to the point that the resulting beads are not sufficiently crosslinked to have the desired selectivity for chloride over other competing anions (see Table 12). However, by using a crosslinker that also functions as a solvent (dispersant), sufficient solvent (dispersant) can be included in the reaction mixture to avoid bead-to-bead reactions and aggregation without diluting the mixture to the point that the degree of amine-consuming crosslinking is insufficient. For example, in an attempt to take advantage of the dispersive properties of the solvent (to avoid agglomeration during the reaction) while maintaining reactivity, pure DCE and DCP were used, serving a dual purpose as both a solvent (dispersant) and a crosslinker. Interestingly, DCE was found to have superior dispersive properties as a solvent when compared to similar reactions with DCP and / or heptane. In addition, less agglomeration was observed when first dispersed in DCE and then subjected to a second operation where water was added to swell the beads. Agglomeration may occur if water is added to the preformed amine polymer before the beads are dispersed in DCE.
[0141] The use of 1,2-dichloroethane ("DCE") as a cross-linking solvent also generates HCl molecules during the second step. These HCl molecules protonate some of the free amine sites, limiting the number of binding sites available for cross-linking by blocking reactive sites for the cross-linking reaction. As a result, the use of DCE creates a self-limiting effect on the secondary cross-linking.
[0142] In each of the above embodiments, the reaction mixture may contain a wide range of amounts of crosslinking agent. For example, in one embodiment, the crosslinking agent may be used in large excess relative to the amount of preformed amine polymer in the reaction mixture. Stated differently, in such embodiments, the crosslinking agent is the crosslinking solvent, i.e., both the solvent for the reaction mixture and the crosslinking agent for the preformed amine polymer. In such embodiments, other solvents may optionally be included in the reaction mixture, but are not required. Alternatively, the preformed amine polymer, swelling agent, and crosslinking agent may be dispersed in a solvent that is miscible with the crosslinking agent and immiscible with the swelling agent. For example, in some embodiments, the swelling agent may be a polar solvent; in some such embodiments, for example, the swelling agent may include water, methanol, ethanol, n-propanol, isopropanol, formic acid, acetic acid, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, nitromethane, or combinations thereof. As a further example, when the swelling agent comprises a polar solvent, the solvent system for the reaction mixture typically comprises a non-polar solvent, such as pentane, cyclopentane, hexane, cyclohexane, benzene, toluene, 1,4-dioxane, chloroform, diethyl ether, dichloromethane, dichloroethane, dichloropropane, dichlorobutane, or a combination thereof. In certain embodiments, the crosslinker and the solvent may be the same; that is, the solvent is a crosslinking solvent, such as 1,2-dichloroethane, 1,3-dichloropropane, 1,4-dichlorobutane, or a combination thereof.
[0143] In one embodiment, the preformed amine polymer is dispersed in a reaction mixture comprising a crosslinker, a swelling agent for the preformed amine polymer, and a (dispersing) solvent. In one such embodiment, for example, the ratio of (dispersing) solvent to preformed amine polymer in the reaction mixture is at least 2:1 (milliliters of solvent:grams of preformed amine polymer). As a further example, in one such embodiment, the ratio of (dispersing) solvent to preformed amine polymer in the reaction mixture is at least 3:1 (milliliters of solvent:grams of preformed amine polymer). As a further example, in one such embodiment, the ratio of (dispersing) solvent to preformed amine polymer in the reaction mixture is at least 4:1 (milliliters of solvent:grams of preformed amine polymer). As a further example, in one such embodiment, the ratio of (dispersing) solvent to preformed amine polymer in the reaction mixture is at least 5:1 (milliliters of solvent:grams of preformed amine polymer). By way of further example, in one such embodiment, the ratio of (dispersing) solvent to preformed amine polymer in the reaction mixture is at least 7.5:1 (milliliters of solvent:grams of preformed amine polymer). By way of further example, in one such embodiment, the ratio of (dispersing) solvent to preformed amine polymer in the reaction mixture is at least 10:1 (milliliters of solvent:grams of preformed amine polymer). In each of the above embodiments, the (dispersing) solvent may comprise a combination of an inert solvent (with respect to the preformed amine polymer), such as one of the non-polar solvents identified above, and a cross-linking solvent, or the (dispersing) solvent may comprise exclusively a cross-linking solvent (e.g., DCE or DCP).
[0144] Note that in the crosslinking solvent (e.g., DCE-dispersed reactions), there is a large excess of crosslinker regardless of the amount of crosslinking solvent (e.g., DCE) used to disperse the beads (e.g., 1 g:3 mL::beads:DCE and 1 g:10 mL::beads:DCE both have a large excess of crosslinker that is largely not consumed during the reaction). Despite this, the relative degree of crosslinking, as well as the performance in the SIB and SOB assays, is not affected by changes in the ratio of reactive crosslinker to polymer beads (see Table 6). This is possible because the reaction is limited by the acid neutralizing capacity of the polymer beads rather than the amount of crosslinker (e.g., DCE).
[0145] In order to react more efficiently with DCE or other crosslinking agents, the amines of the preformed polymer beads preferably have a free electron pair (neutral, deprotonated). As the free amines of the preformed polymer beads react with a crosslinking agent (e.g., DCE), HCl is generated to protonate the amines, thereby limiting the reaction. For this reason, the preformed amine polymer beads preferably start as free amines in the second crosslinking step. If the preformed amine polymer beads are protonated after the first step of carbon-carbon crosslinking, the amine-consumable crosslinking in the second step will be limited, thereby reducing the desired selectivity for chloride over other competing ions. This is demonstrated by adding a known amount of HCl to the preformed amine polymer beads just before the second step crosslinking with DCE (Table 7). When less than 3 mol % HCl (relative to the amines in the preformed polymer amine beads) is added before the second step crosslinking, the total chloride capacity (SGF) and chloride selectivity in the SIB and SOB are similar to beads not treated with HCl in the second step. When more than 5 mol % HCl (relative to the amine in the preformed polymeric amine beads) is added prior to the second step crosslinking, the total chloride capacity (SGF) increases and the chloride selectivity decreases in the SIB and SOB, indicating less crosslinker contamination.
[0146] The benefit of the deprotonated preformed polymer beads in the second step crosslinking highlights the benefit of using two steps to obtain the final product. In the first step to form the amine polymer beads, all monomers (e.g., allylamine and DAPDA) are protonated and remain in the aqueous phase, avoiding radical rearrangement reactions that severely limit the polymerization of unprotonated allylamine (and derivatives). Once the beads are formed through carbon-carbon crosslinking, they can then be deprotonated and further crosslinked with an amine-reactive crosslinker in the second step.
[0147] Given a large excess of dual crosslinker / solvent, mono-incorporation of this reagent can occur, resulting in alkyl chloride functional groups in the crosslinked polymer beads that are hydrophobic in nature and can increase non-specific interactions with undesired solutes other than HCl, which is more hydrophobic in nature. Washing with ammonium hydroxide solution converts the alkyl chlorides to alkyl-amine functional groups that are hydrophilic and minimize non-specific interactions with undesired solutes. Other modifications that result in more hydrophilic groups other than alkyl chlorides, such as -OH, are suitable for quenching mono-contaminated crosslinker / solvent.
[0148] Any range of polymerization chemistries may be used in the first reaction step, provided that the crosslinking mechanism is primarily carbon-carbon crosslinking. Thus, in one exemplary embodiment, the first reaction step comprises radical polymerization. In such reactions, the amine monomers are typically monofunctional vinyl, allyl, or acrylamide (e.g., allylamine), and the crosslinker has two or more vinyl, allyl, or acrylamide functional groups (e.g., diallylamine). Simultaneous polymerization and crosslinking occurs through radical initiated polymerization of a mixture of mono- and polyfunctional allylamines. The resulting polymer network is thus crosslinked through the carbon backbone. Each crosslinking reaction forms a carbon-carbon bond (as opposed to a substitution reaction in which a carbon-heteroatom bond is formed during crosslinking). During simultaneous polymerization and crosslinking, the amine functional groups of the monomers do not undergo crosslinking reactions and are preserved in the final polymer (i.e., primary amines remain primary, secondary amines remain secondary, and tertiary amines remain tertiary).
[0149] In those embodiments in which the first reaction step involves radical polymerization, a wide range of initiators may be used, including cationic and radical initiators. Some examples of suitable initiators that may be used include: free radical peroxy and azo type compounds, such as azodiisobutyronitrile, azodiisovaleronitrile, dimethyl azodiisobutyrate, 2,2' azobis(isobutyronitrile), 2,2'-azobis(N,N'-dimethyleneisobutylamidine) dihydrochloride, 2,2'-azobis(2-amidinopropane) dihydrochloride, 2,2'-azobis(N,N'-dimethyleneisobutylamidine), 1,1'-azobis(l-cyclohexanecarbonyl)nitrile, 1,1'-azobis(1,1' ... ), 4,4'-azobis(4-cyanopentanoic acid), 2,2'-azobis(isobutyramide) dihydrate, 2,2'-azobis(2-methylpropane), 2,2'-azobis(2-methylbutyronitrile), VAZO67, cyanopentanoic acid, peroxypivalate, dodecylbenzene peroxide, benzoyl peroxide, di-t-butyl hydroperoxide, t-butyl peracetate, acetyl peroxide, dicumyl peroxide, cumyl hydroperoxide, dimethylbis(butylperoxy)hexane.
[0150] In some embodiments, the preformed amine polymer comprises a residue of an amine corresponding to Formula 1: [ka] wherein R1, R2 and R3 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, provided that at least one of R1, R2 and R3 is other than hydrogen. In other words, at least one of R1, R2 and R3 is hydrocarbyl or substituted hydrocarbyl, and the others of R1, R2 and R3 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl. In one embodiment, for example, R1, R2 and R3 are independently hydrogen, aryl, aliphatic, heteroaryl, or heteroaliphatic, provided that each of R1, R2 and R3 is not hydrogen. As a further example, in one such embodiment, R1, R2 and R3 are independently hydrogen, saturated hydrocarbon, unsaturated aliphatic, unsaturated heteroaliphatic, heteroalkyl, heterocyclic, aryl, or heteroaryl, provided that each of R1, R2 and R3 is not hydrogen. As a further example, in one such embodiment, R1, R2, and R3 are independently hydrogen, alkyl, alkenyl, allyl, vinyl, aryl, aminoalkyl, alkanol, haloalkyl, hydroxyalkyl, ether, heteroaryl, or heterocycle, provided that each of R1, R2, and R3 is not hydrogen. As a further example, in one such embodiment, R1, R2, and R3 are independently hydrogen, alkyl, aminoalkyl, alkanol, aryl, haloalkyl, hydroxyalkyl, ether, heteroaryl, or heterocycle, provided that each of R1, R2, and R3 is not hydrogen. As a further example, in one such embodiment, R1 and R2 (combined with the nitrogen atom to which they are attached) together form part of a ring structure, such that the monomer described by formula 1 is a nitrogen-containing heterocycle (e.g., piperidine), and R3 is hydrogen, or heteroaliphatic. By way of further example, in one embodiment, R1, R2, and R3 are independently hydrogen, aliphatic, or heteroaliphatic, provided that at least one of R1, R2, and R3 is other than hydrogen. By way of further example, in one embodiment, R1, R2, and R3 are independently hydrogen, allyl, or aminoalkyl.
[0151] In one embodiment, the preformed amine polymer comprises a residue of an amine corresponding to formula 1, where R1, R2, and R3 are independently hydrogen, heteroaryl, aryl, aliphatic, or heteroaliphatic, provided that at least one of R1, R2, and R3 is aryl or heteroaryl. For example, in this embodiment, R1 and R2 may be combined with the nitrogen atom to which they are attached to form a saturated or unsaturated nitrogen-containing heterocyclic ring. As a further example, R1 and R2 may be combined with the nitrogen atom to which they are attached to form part of a pyrrolidino, pyrrole, pyrazolidine, pyrazole, imidazolidine, imidazole, piperidine, pyridine, piperazine, diazine, or triazine ring structure. As a further example, R1 and R2 may be combined with the nitrogen atom to which they are attached to form part of a piperidine ring structure.
[0152] In one embodiment, the preformed amine polymer comprises the residue of an amine corresponding to Formula 1, where R1, R2, and R3 are independently hydrogen, aliphatic, or heteroaliphatic, provided that at least one of R1, R2, and R3 is other than hydrogen. For example, in this embodiment, R1, R2, and R3 may independently be hydrogen, alkyl, alkenyl, allyl, vinyl, aminoalkyl, alkanol, haloalkyl, hydroxyalkyl, ether, or heterocycle, provided that at least one of R1, R2, and R3 is other than hydrogen. As a further example, in one such embodiment, R1 and R2 may combine with the nitrogen atom to which they are attached to form a saturated or unsaturated nitrogen-containing heterocyclic ring. As a further example, in one such embodiment, R1 and R2, in combination with the nitrogen atom to which they are attached, may form part of a pyrrolidino, pyrrole, pyrazolidine, pyrazole, imidazolidine, imidazole, piperidine, piperazine, or diazine ring structure. As a further example, in one such embodiment, R1 and R2, in combination with the nitrogen atom to which they are attached, may form part of a piperidine ring structure. As a further example, in one such embodiment, the amine corresponding to formula 1 is cycloaliphatic, and at least one of R1, R2, and R3 is aliphatic or heteroaliphatic. As a further example, in one such embodiment, R1, R2, and R3 are independently hydrogen, alkyl, aryl, vinyl, cycloaliphatic, aminoalkyl, alkanol, or heterocyclic, with the proviso that at least one of R1, R2, and R3 is other than hydrogen.
[0153] In some embodiments, the amine-containing monomer is polymerized and the polymer is crosslinked simultaneously in a displacement polymerization reaction in a first reaction step. The amine reactants (monomers) in the simultaneous polymerization and crosslinking reaction can react more than once for displacement polymerization. In one such embodiment, the amine monomer is a linear amine that possesses at least two reactive amine sites that participate in the displacement polymerization reaction. In another embodiment, the amine monomer is a branched amine that possesses at least two reactive amine sites that participate in the displacement polymerization reaction. The crosslinker for simultaneous displacement polymerization and crosslinking typically has at least two amine reactive sites, such as alkyl-chlorides and alkyl-epoxides. To be incorporated into the polymer, the primary amine reacts with the crosslinker at least once and potentially up to three times, the secondary amine can react with the crosslinker up to two times, and the tertiary amine can react with the crosslinker only once. In general, however, the formation of a significant number of quaternary nitrogens / amines is generally not favored because the quaternary amine cannot bind to a proton.
[0154] Exemplary amines that may be used in the substitution polymerization reactions described herein include 1,3-bis[bis(2-aminoethyl)amino]propane, 3-amino-1-{[2-(bis{2-[bis(3-aminopropyl)amino]ethyl}amino)ethyl](3-aminopropyl)amino}propane, 2-[bis(2-aminoethyl)amino]ethanamine, tris(3-aminopropyl)amine, 1,4-bis[bis(3-aminopropyl)amino]butane, 1,2-ethanediamine, 2-amino-1-(2-aminoethylamino)ethane, 1,2-bis(2-aminoethylamino)ethane, 1,3-propanediamine, 3,3'-diaminodipropylamine, 2,2-dimethyl-1,3-propanediamine, 2-methyl-1,3-propanediamine, N,N'-dimethyl-1,3-propanediamine, N-methyl-1,3-diaminopropane, 3,3'-diamino-N-methyldipropylamine, 1,3-diaminopentane, 1,2-diamino-2-methylpropane, 2-methyl-1,5-diaminopentane, 1,2-diaminopropane, 1,10-diaminodecane, 1,8-diamino Nooctane, 1,9-diaminooctane, 1,7-diaminoheptane, 1,6-diaminohexane, 1,5-diaminopentane, 3-bromopropylamine hydrobromide, N,2-dimethyl-1,3-propanediamine, N-isopropyl-1,3-diaminopropane, N,N'-bis(2-aminoethyl)-1,3-propanediamine, N,N'-bis(3-aminopropyl)ethylenediamine, N,N'-bis(3-aminopropyl)-1,4-butanediamine tetrahydrochloride, 1,3-diamino-2-propanol, N-ethylethylenediamine Amines, 2,2'-diamino-N-methyldiethylamine, N,N'-diethylethylenediamine, N-isopropylethylenediamine, N-methylethylenediamine, N,N'-di-tert-butylethylenediamine, N,N'-diisopropylethylenediamine, N,N'-dimethylethylenediamine, N-butylethylenediamine, 2-(2-aminoethylamino)ethanol, 1,4,7,10,13,16-hexaazacyclooctadecane, 1,4,7,10-tetraazacyclododecane, 1,4,7-triazacyclononane, N,Examples of the amines include N'-bis(2-hydroxyethyl)ethylenediamine, piperazine, bis(hexamethylene)triamine, N-(3-hydroxypropyl)ethylenediamine, N-(2-aminoethyl)piperazine, 2-methylpiperazine, homopiperazine, 1,4,8,11-tetraazacyclotetradecane, 1,4,8,12-tetraazacyclopentadecane, 2-(aminomethyl)piperidine, and 3-(methylamino)pyrrolidine.
[0155] Exemplary crosslinking agents that may be used in the substitution polymerization reaction and the post-polymerization crosslinking reaction include, but are not limited to, one or more multifunctional crosslinking agents, such as: dihaloalkanes, haloalkyloxiranes, alkyloxirane sulfonates, di(haloalkyl)amines, tri(haloalkyl)amines, diepoxides, triepoxides, tetraepoxides, bis(halomethyl)benzenes, tri(halomethyl)benzenes, tetra(halomethyl)benzenes, epihalohydrins such as epichlorohydrin and epibromohydrin, poly(epichlorohydrin), (iodine), arylalkyl(aryl) ... methyl)oxirane, glycidyl tosylate, glycidyl 3-nitrobenzenesulfonate, 4-tosyloxy-1,2-epoxybutane, bromo-1,2-epoxybutane, 1,2-dibromoethane, 1,3-dichloropropane, 1,2-dichloroethane, l-bromo-2-chloroethane, 1,3-dibromopropane, bis(2-chloroethyl)amine, tris(2-chloroethyl)amine, and bis(2-chloroethyl)methylamine, 1,3-butadiene diepoxide, 1,5-hexadiene diepoxide, diglycidyl ether, 1 ,2,7,8-diepoxyoctane, 1,2,9,10-diepoxydecane, ethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, 1,4-butanediol diglycidyl ether, 1,2-ethanediol diglycidyl ether, glycerol diglycidyl ether, 1,3-diglycidyl glyceryl ether, N,N-diglycidylaniline, neopentyl glycol diglycidyl ether, diethylene glycol diglycidyl ether, 1,4-bis(glycidyloxy)benzene, resorcinol diglycidyl ether, 1,6-hexanediol diglycidyl ether, trimethylolpropane diglycidyl ether, 1,4-cyclohexanedimethanol diglycidyl ether, 1,3-bis-(2,3-epoxypropyloxy)-2-(2,3-dihydroxypropyloxy)propane, 1,2-cyclohexanedicarboxylic acid diglycidyl ester, 2,2'-bis(glycidyloxy)diphenylmethane, bisphenol F diglycidyl ether, 1,4-bis(2',3'epoxypropyl)perfluoro-n-butane, 2,6-di(oxiran-2-ylmethyl(methy1))-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]isoindole-1,3,5,7-tetraone, bisphenol A diglycidyl ether, ethyl 5-hydroxy-6,8-di(oxiran-2-ylmethyl)-4-oxo-4-h-chromene-2-carboxylate, bis[4-(2,3-epoxy-propylthio)phenyl]-sulfide, 1,3-bis(3-glycidoxypropyl)tetrahydrofuran Methyldisiloxane, 9,9-bis[4-(glycidyloxy)phenyl]fluorine, triepoxyisocyanurate, glycerol triglycidyl ether, N,N-diglycidyl-4-glycidyloxyaniline, isocyanuric acid (S,S,S)-triglycidyl ester, isocyanuric acid (R,R,R)-triglycidyl ester, triglycidyl isocyanurate, trimethylolpropane triglycidyl ether, glycerol propoxylate triglycidyl ether ether, triphenylolmethane triglycidyl ether, 3,7,14-tris[[3-(epoxypropoxy)propyl]dimethylsilyloxy]-1,3,5,7,9,11,14-heptacyclopentyltricyclo[7,3,3,15,11]heptasiloxane, 4,4'methylenebis(N,N-diglycidylaniline), bis(halomethyl)benzene, bis(halomethyl)biphenyl and bis(halomethyl)naphthalene, toluene diisocyanate, acrylonitrile, Examples of suitable amines include trichlorosilyl, methyl acrylate, ethylene bisacrylamide, pyromellitic dianhydride, succinyl dichloride, dimethyl succinate, 3-chloro-1-(3-chloropropylamino-2-propanol, 1,2-bis(3-chloropropylamino)ethane, bis(3-chloropropyl)amine, 1,3-dichloro-2-propanol, 1,3-dichloropropane, 1-chloro-2,3-epoxypropane, and tris[(2-oxiranyl)methyl]amine.
[0156] In some embodiments, the preformed amine polymer is a crosslinked amine polymer comprising a residue of an amine corresponding to Formula 1a, the crosslinked amine polymer being prepared by radical polymerization of an amine corresponding to Formula 1a: [ka] wherein R4 and R5 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl. In one embodiment, for example, R4 and R5 are independently hydrogen, saturated hydrocarbon, unsaturated aliphatic, aryl, heteroaryl, unsaturated heteroaliphatic, heterocyclic, or heteroalkyl. As a further example, in one such embodiment, R4 and R5 are independently hydrogen, aliphatic, heteroaliphatic, aryl, or heteroaryl. As a further example, in one such embodiment, R4 and R5 are independently hydrogen, alkyl, alkenyl, aryl, vinyl, aryl, aminoalkyl, alkanol, haloalkyl, hydroxyalkyl, ether, heteroaryl, or heterocyclic. As a further example, in one such embodiment, R4 and R5 are independently hydrogen, alkyl, aryl, aminoalkyl, alkanol, aryl, haloalkyl, hydroxyalkyl, ether, or heterocyclic. By way of further example, in one such embodiment, R4 and R5 (combined with the nitrogen atom to which they are attached) together form part of a ring structure, such that the monomer described by formula 1a is a nitrogen-containing heterocycle (e.g., piperidine). By way of further example, in one embodiment, R4 and R5 are independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one embodiment, R4 and R5 are independently hydrogen, allyl, or aminoalkyl.
[0157] In some embodiments, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to formula 1b, the crosslinked amine polymer being prepared by substitutional polymerization of an amine corresponding to formula 1b with a multifunctional crosslinker (optionally also containing an amine moiety): [ka] wherein R4 and R5 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; R6 is aliphatic; and R 61 and R62 is independently hydrogen, aliphatic, or heteroaliphatic. In one embodiment, for example, R4 and R5 are independently hydrogen, saturated hydrocarbon, unsaturated aliphatic, aryl, heteroaryl, heteroalkyl, or unsaturated heteroaliphatic. By way of further example, in one such embodiment, R4 and R5 are independently hydrogen, aliphatic, heteroaliphatic, aryl, or heteroaryl. By way of further example, in one such embodiment, R4 and R5 are independently hydrogen, alkyl, alkenyl, aryl, vinyl, aryl, aminoalkyl, alkanol, haloalkyl, hydroxyalkyl, ether, heteroaryl, or heterocycle. By way of further example, in one such embodiment, R4 and R5 are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkanol, aryl, haloalkyl, hydroxyalkyl, ether, heteroaryl, or heterocycle. By way of further example, in one such embodiment, R4 and R5 (combined with the nitrogen atom to which they are attached) together form part of a ring structure such that the monomer described by formula 1a is a nitrogen-containing heterocycle (e.g., piperidine). By way of further example, in one embodiment, R4 and R5 are independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one embodiment, R4 and R5 are independently hydrogen, allyl, or aminoalkyl. By way of further example, in each of the embodiments recited in this paragraph, R6 can be methylene, ethylene, or propylene, and R 61 and R 62 may be independently hydrogen, allyl, or aminoalkyl.
[0158] In some embodiments, the preformed amine polymer is a crosslinked amine polymer that includes a residue of an amine corresponding to formula 1c: [ka] wherein R7 is hydrogen, aliphatic or heteroaliphatic, and R8 is aliphatic or heteroaliphatic. For example, in one such embodiment, R7 is hydrogen and R8 is aliphatic or heteroaliphatic. As a further example, in one such embodiment, R7 and R8 are independently aliphatic or heteroaliphatic. As a further example, in one such embodiment, at least one of R7 and R8 includes an allyl moiety. As a further example, in one such embodiment, at least one of R7 and R8 includes an aminoalkyl moiety. As a further example, in one such embodiment, R7 and R8 each include an allyl moiety. As a further example, in one such embodiment, R7 and R8 each include an aminoalkyl moiety. As a further example, in one such embodiment, R7 includes an allyl moiety and R8 includes an aminoalkyl moiety.
[0159] In some embodiments, the preformed amine polymer is a crosslinked amine polymer that includes residues of an amine corresponding to Formula 2: [ka] During the ceremony, m and n are independently non-negative integers; R 10 , R 20 , R 30 , and R 40 is independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; X1 is, [ka] and; X2 is hydrocarbyl or substituted hydrocarbyl; each X 11 is independently hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxyl, amino, boronic acid, or halo; z is a non-negative integer.
[0160] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to Formula 2, the crosslinked amine polymer being prepared by (i) substitutional polymerization of an amine corresponding to Formula 2 with a multifunctional crosslinker (optionally containing an amine moiety) or (2) radical polymerization of an amine corresponding to Formula 2, wherein m and n are independently 0, 1, 2 or 3, and n is 0 or 1.
[0161] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to Formula 2, the crosslinked amine polymer being prepared by (i) substitution polymerization of an amine corresponding to Formula 2 with a multifunctional crosslinker (optionally containing an amine moiety) or (2) radical polymerization of an amine corresponding to Formula 2, R 10 , R 20 , R 30 , and R 40 is independently hydrogen, aliphatic, aryl, heteroaliphatic, or heteroaryl. By way of further example, in one such embodiment, R 10 , R 20 , R 30 , and R 40 is independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, R 10 , R 20 , R 30 , and R 40 is independently hydrogen, alkyl, allyl, vinyl, or aminoalkyl. By way of further example, in one such embodiment, R 10 , R 20 , R 30 , and R 40 are independently hydrogen, alkyl, aryl, vinyl, -(CH2) d NH2, -(CH2) d N[(CH2) e NH2)]2, where d and e are independently 2 to 4. In each of the above exemplary embodiments in this paragraph, m and z can be independently 0, 1, 2, or 3, and n is 0 or 1.
[0162] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2, the crosslinked amine polymer being prepared by (i) substitutional polymerization of an amine corresponding to Formula 2 with a multifunctional crosslinker (optionally including an amine moiety) or (2) radical polymerization of an amine corresponding to Formula 2, where X2 is aliphatic or heteroaliphatic. For example, in one such embodiment, X2 is aliphatic or heteroaliphatic and R 10 , R 20 , R 30 , and R 40 is independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, X2 is alkyl or aminoalkyl and R 10 , R 20 , R 30 , and R 40 is independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, X2 is alkyl or aminoalkyl and R 10 , R 20 , R 30 , and R 40 is independently hydrogen, alkyl, allyl, vinyl, or aminoalkyl. In each of the above exemplary embodiments in this paragraph, m and z can independently be 0, 1, 2, or 3; and n is 0 or 1.
[0163] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to Formula 2, the crosslinked amine polymer being prepared by (i) substitutional polymerization of an amine corresponding to Formula 2 with a multifunctional crosslinker (optionally including an amine moiety) or (2) radical polymerization of an amine corresponding to Formula 2, where m is a positive integer. For example, in one such embodiment, m is a positive integer, z is zero, and R 20 is hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, m is a positive integer (e.g., 1 to 3), z is a positive integer (e.g., 1 to 2), and X 11 is hydrogen, aliphatic or heteroaliphatic, R 20is hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, m is a positive integer, z is zero, 1, or 2, and X 11 is hydrogen, alkyl, alkenyl, or aminoalkyl; R 20 is hydrogen, alkyl, alkenyl, or aminoalkyl.
[0164] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to Formula 2, the crosslinked amine polymer being prepared by (i) substitutional polymerization of an amine corresponding to Formula 2 with a multifunctional crosslinker (optionally including an amine moiety) or (2) radical polymerization of an amine corresponding to Formula 2, where n is a positive integer and R 30 is hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, n is 0 or 1 and R 30 is hydrogen, alkyl, alkenyl, or aminoalkyl.
[0165] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2, the crosslinked amine polymer being prepared by (i) substitution polymerization of an amine corresponding to Formula 2 with a multifunctional crosslinker (optionally including an amine moiety) or (2) radical polymerization of an amine corresponding to Formula 2, wherein m and n are independently non-negative integers, and X2 is aliphatic or heteroaliphatic. For example, in one such embodiment, m is 0-2, n is 0 or 1, X2 is aliphatic or heteroaliphatic, and R 10 , R 20 , R 30 , and R 40 is independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, m is 0 to 2, n is 0 or 1, X2 is alkyl or aminoalkyl, and R 10 , R 20 , R 30 , and R 40is independently hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, m is 0 to 2, n is 0 or 1, X2 is alkyl or aminoalkyl, and R 10 , R 20 , R 30 , and R 40 is independently hydrogen, alkyl, alkenyl, or aminoalkyl.
[0166] In some embodiments, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to formula 2a, the crosslinked amine polymer being prepared by substitutional polymerization of an amine corresponding to formula 2a with a multifunctional crosslinker (optionally also containing an amine moiety): [ka] During the ceremony, m and n are independently non-negative integers; Each R 11 is independently hydrogen, hydrocarbyl, heteroaliphatic, or heteroaryl; R 21 and R 31 is independently hydrogen or heteroaliphatic; R 41 is hydrogen, substituted hydrocarbyl, or hydrocarbyl; X1 is, [ka] and; X2 is alkyl or substituted hydrocarbyl; each X 12 is independently hydrogen, hydroxy, amino, aminoalkyl, boronic acid, or halo; z is a non-negative integer.
[0167] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to formula 2a, the crosslinked amine polymer being prepared by substitutional polymerization of an amine corresponding to formula 1 with a multifunctional crosslinker (optionally containing an amine moiety). For example, in one such embodiment, m and z are independently 0, 1, 2 or 3, and n is 0 or 1.
[0168] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to formula 2a, the crosslinked amine polymer being prepared by substitutional polymerization of an amine corresponding to formula 2a with a multifunctional crosslinker (optionally including an amine moiety), where each R 11 are independently hydrogen, aliphatic, aminoalkyl, haloalkyl, or heteroaryl; R 21 and R 31 are independently hydrogen or heteroaliphatic; R 41 is hydrogen, aliphatic, aryl, heteroaliphatic, or heteroaryl. For example, in one such embodiment, each R 11 is hydrogen, aliphatic, aminoalkyl, or haloalkyl; R 21 and R 31 are independently hydrogen or heteroaliphatic; R 41 is hydrogen, alkylamino, aminoalkyl, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, each R 11 is hydrogen, aliphatic, aminoalkyl, or haloalkyl; R 21 and R 31 is hydrogen or aminoalkyl, R 41 is hydrogen, aliphatic, or heteroaliphatic. By way of further example, in one such embodiment, each R 11 and R 41 are independently hydrogen, alkyl, or aminoalkyl; R 21 and R 31 is independently hydrogen or heteroaliphatic. By way of further example, in one such embodiment, each R 11 and R 41are independently hydrogen, alkyl, -CH2) d NH2, -(CH2) d N[(CH2) e NH)]2: where d and e are independently 2 to 4; R 21 and R 31 In each of the above exemplary embodiments in this paragraph, m and z can independently be 0, 1, 2, or 3; and n is 0 or 1.
[0169] Exemplary amines for the synthesis of polymers containing repeat units corresponding to Formula 2a include, but are not limited to, those found in Table A.
[0170] [Table 1] [Table 2]
[0171] Exemplary crosslinkers for the synthesis of polymers containing amine residues corresponding to Formula 2a include, but are not limited to, those found in Table B. [Table 3]
[0172] In some embodiments, the preformed amine polymer is a crosslinked amine polymer comprising a residue of an amine corresponding to Formula 2b, the crosslinked amine polymer being prepared by radical polymerization of an amine corresponding to Formula 2b: [ka] During the ceremony, m and n are independently non-negative integers; Each R 12 is independently hydrogen, substituted hydrocarbyl, or hydrocarbyl; R 22 and R 32is independently hydrogen substituted hydrocarbyl, or hydrocarbyl; R 42 is hydrogen, hydrocarbyl or substituted hydrocarbyl; X1 is, [ka] and; X2 is alkyl, aminoalkyl, or alkanol; each X 13 is independently hydrogen, hydroxy, alicyclic, amino, aminoalkyl, halogen, alkyl, heteroaryl, boronic acid, or aryl; z is a non-negative integer, The amine corresponding to formula 2b contains at least one allyl group.
[0173] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2b, the crosslinked amine polymer being prepared by radical polymerization of an amine corresponding to Formula 2b, wherein m and z are independently 0, 1, 2 or 3, and n is 0 or 1.
[0174] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising a residue of an amine corresponding to Formula 2b, the crosslinked amine polymer being prepared by radical polymerization of an amine corresponding to Formula 1, (i) R 12 Or R 42 independently contains at least one allyl or vinyl moiety; (ii) m is a positive integer; R 22 contains at least one allyl or vinyl moiety, and / or (iii) n is a positive integer and R 32 contains at least one allyl moiety. For example, in one such embodiment, m and z are independently 0, 1, 2 or 3, and n is 0 or 1. For example, in one such embodiment, R 12 or R 42are combined to contain at least two allyl or vinyl moieties. By way of further example, in one such embodiment, m is a positive integer and R 12 , R 22 and R 42 are combined to contain at least two allyl or vinyl moieties. By way of further example, in one such embodiment, n is a positive integer and R 12 , R 32 and R 42 are combined to contain at least two allyl or vinyl moieties. By way of further example, in one such embodiment, m is a positive integer, n is a positive integer, and R 12 , R 22 , R 32 and R 42 are combined to contain at least two allyl or vinyl moieties.
[0175] In one embodiment, the preformed amine polymer is a crosslinked amine polymer comprising residues of an amine corresponding to Formula 2b, the crosslinked amine polymer being prepared by radical polymerization of an amine corresponding to Formula 2b, 12 are independently hydrogen, aminoalkyl, allyl, or vinyl; R 22 and R 32 are independently hydrogen, alkyl, aminoalkyl, haloalkyl, alkenyl, alkanol, heteroaryl, alicyclic heterocycle, or aryl; R 42 is hydrogen or substituted hydrocarbyl. For example, in one such embodiment, each R 12 is aminoalkyl, allyl or vinyl; R 22 and R 32 are independently hydrogen, alkyl, aminoalkyl, haloalkyl, alkenyl, or alkanol; R 42 is hydrogen or substituted hydrocarbyl. By way of further example, in one such embodiment, each R 12 and R 42 are independently hydrogen, alkyl, aryl, vinyl, -(CH2) d NH2 or -(CH2) dN[(CH2) e NH2]2: where d and e are independently 2 to 4; R 22 and R 32 is independently hydrogen or heteroaliphatic.
[0176] Exemplary amines and crosslinkers (or salts thereof, such as the hydrochloride, phosphoric acid, sulfuric acid, or hydrobromide salts thereof) for the synthesis of polymers described by formula 2b include, but are not limited to, those in Table C.
[0177] [Table 4]
[0178] In some embodiments, the preformed amine polymer is a preformed polymer obtained by utilizing a monomer described in any of Formulas 1, 1a, 1b, 1c, 2, 2a, and 2b, or a crosslinked amine polymer resulting from the reaction of a linear polymer composed of repeat units described in Formula 3 with an external crosslinker or a preexisting polymer functional group that can function as a crosslinking site. Formula 3 can be a repeat unit of a preformed copolymer or terpolymer, where X 15 is either a random, alternating, or block copolymer. The repeat unit in formula 3 can also represent the repeat unit of a preformed polymer that is branched or hyperbranched, and the primary branch point can be from any atom in the backbone of the polymer: [ka] During the ceremony, R 15 , R 16 and R 17 is independently hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxyl, amino, boronic acid, or halo; X 15 teeth, [ka] and X5 is hydrocarbyl, substituted hydrocarbyl, oxo (-O-), or amino; z is a non-negative integer.
[0179] In one embodiment, R 15 , R 16 and R 17 are independently hydrogen, aryl, or heteroaryl, X5 is hydrocarbyl, substituted hydrocarbyl, oxo, or amino, and m and z are non-negative integers. 15 , R 16 and R 17 is independently aliphatic or heteroaliphatic, X5 is hydrocarbyl, substituted hydrocarbyl, oxo (-O-), or amino, and m and z are non-negative integers. 15 , R 16 and R 17 is independently unsaturated aliphatic or unsaturated heteroaliphatic, X5 is hydrocarbyl, substituted hydrocarbyl, oxo, or amino, and z is a non-negative integer. 15 , R 16 and R 17 is independently alkyl or heteroalkyl, X5 is hydrocarbyl, substituted hydrocarbyl, oxo, or amino, and z is a non-negative integer. 15 , R 16 and R 17 is independently alkylamino, aminoalkyl, hydroxyl, amino, boronic acid, halo, haloalkyl, alkanol, or ether; X5 is hydrocarbyl, substituted hydrocarbyl, oxo, or amino; and z is a non-negative integer. 15 , R 16 and R 17 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxyl, amino, boronic acid, or halo; X5 is oxo, amino, alkylamino, ether, alkanol, or haloalkyl; and z is a non-negative integer.
[0180] Exemplary crosslinkers that may be used in the radical polymerization reaction include, but are not limited to, one or more multifunctional crosslinkers, such as: 1,4-bis(allylamino)butane, 1,2-bis(allylamino)ethane, 2-(allylamino)-1-[2-(allylamino)ethylamino]ethane, 1,3-bis(allylamino)propane, 1,3-bis(allylamino)-2-propanol, triallylamine, diallylamine, divinylbenzene, 1,7-octadiene, 1,6-heptadiene, 1,7-diphenylmethane, 1,6-diphenylmethane ...6-diphenylmethane, 1,7-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-diphenylmethane, 1,6-di Examples of suitable vinyl ethers include vinyl ether, 1,8-nonadiene, 1,9-decadiene, 1,4-divinyloxybutane, 1,6-hexamethylenebisacrylamide, ethylenebisacrylamide, N,N'-bis(vinylsulfonylacetyl)ethylenediamine, 1,3-bis(vinylsulfonyl)2-propanol, vinyl sulfone, N,N'-methylenebisacrylamide polyvinyl ether, polyallyl ether, divinylbenzene, 1,4-divinyloxybutane, and combinations thereof.
[0181] Crosslinked polymers derived from the monomers and polymers in Formulas 1-3 may be synthesized either in solution or bulk, or in a dispersed medium. Examples of solvents suitable for the synthesis of the polymers of the present disclosure include, but are not limited to, water, low boiling alcohols (methanol, ethanol, propanol, butanol), dimethylformamide, dimethylsulfoxide, heptane, chlorobenzene, toluene.
[0182] As described above, the product of the first polymerization step is preferably in the form of beads with diameters controlled in the range of 5-1000 microns, preferably 10-500 microns, and most preferably 40-180 microns.
[0183] The product of the first polymerization step is preferably in the form of beads having a swelling ratio in water between 2 and 10, more preferably from about 3 to about 8, and most preferably from about 4 to about 6.
[0184] In addition, the crosslinked polymer beads obtained from the first polymerization step, when protonated, may reduce the amount of nitrogen-nitrogen crosslinking in the second crosslinking step. Thus, in certain embodiments, the preformed amine polymer is at least partially deprotonated by treatment with a base, preferably a strong base, such as a hydroxide base. For example, in one embodiment, the base may be NaOH, KOH, NH4OH, NaHCO3, Na2CO3, K2CO3, LiOH, Li2CO3, CsOH or other metal hydroxides. When the charge is removed from the preformed crosslinked amine polymer beads by deprotonation, the beads tend to collapse, and the crosslinker used in the second step may not be able to access the binding sites on the polymer unless the beads are prevented from collapsing. One means of preventing the crosslinked polymer beads from collapsing is to swell the beads with a swelling agent, such as water, to allow the crosslinker of the second step to access the binding sites.
[0185] The preformed polymer may be crosslinked to form a post-polymerization crosslinked polymer using any of a range of crosslinking compounds containing at least two amine-reactive functional groups. In one such embodiment, the crosslinking agent is a compound containing at least two amine-reactive groups selected from the group consisting of halides, epoxides, phosgene, anhydrides, carbamates, carbonates, isocyanates, thioisocyanates, esters, activated esters, carboxylic acids and their derivatives, sulfonates and their derivatives, acyl halides, aziridines, α,β-unsaturated carbonyls, ketones, aldehydes, and pentafluoroaryl groups. The crosslinking agent may be any of the crosslinking agents disclosed herein, including, for example, crosslinkers selected from Table B. By way of further example, in one such embodiment, the crosslinking agent is a dihalide, such as a dichloroalkane.
[0186] As described above, in certain embodiments, a swelling agent for the preformed amine polymer may be included in the reaction mixture for the second polymerization step together with the crosslinking agent. In general, the swelling agent and the crosslinking agent may be miscible or immiscible, and the swelling agent may be any composition or combination of compositions capable of swelling the preformed amine polymer. Exemplary swelling agents include polar solvents such as water, methanol, ethanol, n-propanol, isopropanol, n-butanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, propylene carbonate, or combinations thereof. In addition, the amount of swelling agent included in the reaction mixture is typically less than the absorption capacity of the preformed amine polymer for the swelling agent. For example, it is generally preferred that the weight ratio of swelling agent to preformed polymer in the reaction mixture is less than 4:1. As a further example, in some embodiments, the weight ratio of swelling agent to preformed polymer in the reaction mixture is less than 3:1. By way of further example, in some embodiments, the weight ratio of swelling agent in the reaction mixture to preformed polymer is less than 2:1. By way of further example, in some embodiments, the weight ratio of swelling agent in the reaction mixture to preformed polymer is less than 1:1. By way of further example, in some embodiments, the weight ratio of swelling agent in the reaction mixture to preformed polymer is less than 0.5:1. By way of further example, in some embodiments, the weight ratio of swelling agent in the reaction mixture to preformed polymer is less than 0.4:1. By way of further example, in some embodiments, the weight ratio of swelling agent in the reaction mixture to preformed polymer is less than 0.3:1. Generally, however, the weight ratio of swelling agent in the reaction mixture to preformed polymer is typically at least 0.05:1, respectively.
[0187] When the swelling agent comprises water, the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 4:1 (water to polymer). For example, in one such embodiment, the reaction mixture comprises water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 3.5:1. By way of further example, in one such embodiment, the reaction mixture comprises water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 3:1. By way of further example, in one such embodiment, the reaction mixture comprises water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 2.5:1. By way of further example, in one such embodiment, the reaction mixture comprises water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 2:1. By way of further example, in one such embodiment, the reaction mixture includes water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 1.5:1. By way of further example, in one such embodiment, the reaction mixture includes water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 1:1. By way of further example, in one such embodiment, the reaction mixture includes water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 0.75:1. By way of further example, in one such embodiment, the reaction mixture includes water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 0.5:1. By way of further example, in one such embodiment, the reaction mixture includes water as a swelling agent and the weight ratio of water to preformed amine polymer in the reaction mixture is typically less than about 0.25:1. Generally, however, when water is used as the swelling agent, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 0.15:1 (water to polymer), but less than the water absorption capacity of the preformed amine polymer.As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 0.2:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 0.25:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 0.5:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 0.75:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 1:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 1.5:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 2:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 2.5:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 3:1, but less than the water absorption capacity of the preformed amine polymer. As a further example, in one embodiment, the weight ratio of water to preformed amine polymer in the reaction mixture is typically at least about 3.5:1, but less than the water absorption capacity of the preformed amine polymer.Thus, in certain embodiments, the weight ratio of water to preformed amine polymer ranges from about 0.15:1 to about 4:1. By way of further example, in certain embodiments, the weight ratio of water to preformed amine polymer ranges from about 0.2:1 to about 3.5:1. By way of further example, in certain embodiments, the weight ratio of water to preformed amine polymer ranges from about 0.2:1 to about 3:1.
[0188] In each of the above embodiments, the reaction mixture may contain a wide range of amounts of crosslinking agent. For example, in one embodiment, the crosslinking agent may be used in large excess relative to the amount of preformed amine polymer in the reaction mixture. Stated differently, in such embodiments, the crosslinking agent is a crosslinking solvent, i.e., both a solvent for the reaction mixture and a crosslinking agent for the preformed amine polymer. In such embodiments, other solvents may optionally be included in the reaction mixture, but are not required. Alternatively, the preformed amine polymer, swelling agent, and crosslinking agent may be dispersed in a solvent that is miscible with the crosslinking agent and immiscible with the swelling agent. For example, in some embodiments, the swelling agent may be a polar solvent; in some such embodiments, for example, the swelling agent may include water, methanol, ethanol, n-propanol, isopropanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, or combinations thereof. As a further example, when the swelling agent comprises a polar solvent, the solvent system for the reaction mixture typically comprises a non-polar solvent, such as pentane, cyclopentane, hexane, cyclohexane, benzene, toluene, 1,4-dioxane, chloroform, diethyl ether, dichloromethane, dichloroethane, dichloropropane, dichlorobutane, or a combination thereof. In certain embodiments, the crosslinker and the solvent may be the same; that is, the solvent is a crosslinking solvent, such as 1,2-dichloroethane, 1,3-dichloropropane, 1,4-dichlorobutane, or a combination thereof.
[0189] In those embodiments in which the reaction mixture includes a swelling agent, it may be preferred to combine the preformed amine polymer with a solvent (alternatively, may be referred to as a dispersant) before the preformed amine polymer is combined with the swelling agent in the reaction mixture. In certain embodiments, the resulting crosslinked polymer is less prone to agglomeration when the preformed amine polymer is combined with a solvent (dispersant) that is immiscible with the swelling agent before the preformed amine polymer is combined with the swelling agent. Thus, in certain embodiments, less than 25% of the particles in a representative sample of the population of crosslinked amine particles after polymerization are aggregated into aggregates. For example, in some embodiments, less than 20% of the particles in a representative sample of the population of crosslinked amine particles after polymerization are aggregated into aggregates. As a further example, in some embodiments, less than 15% of the particles in a representative sample of the population of crosslinked amine particles after polymerization are aggregated into aggregates. As a further example, in some embodiments, less than 10% of the particles in a representative sample of the population of crosslinked amine particles after polymerization are aggregated into aggregates. By way of further example, in some embodiments, less than 5% of the particles in a representative sample of the population of crosslinked amine particles after polymerization are aggregated into aggregates. By way of further example, in some embodiments, less than 1% of the particles in a representative sample of the population of crosslinked amine particles after polymerization are aggregated into aggregates. Aggregation may be assessed using a microscope or other particle size distribution measurement means. Lack of agglomeration may be defined as generally separated free-flowing beads lacking macroscopic and / or microscopic clumps. Particle size distribution (as defined elsewhere) may indicate that aggregation has occurred, for example, when the average size (d(50)) and / or d(90) of the crosslinked amine polymer after polymerization increases after the crosslinking step compared to the preformed amine polymer particles described above.
[0190] In one embodiment, a preformed amine polymer is formed in a first step, and the preformed amine polymer is crosslinked in a second step to form a post-polymerization crosslinked polymer without isolating the preformed amine polymer between the first and second steps (sometimes referred to as a "one-pot synthesis"). For example, in one such embodiment, a preformed amine polymer is formed in a first reaction mixture (as described previously herein), and then the preformed amine polymer is crosslinked using any of the crosslinkers disclosed herein (including, for example, a crosslinker selected from Table B) without isolating the preformed amine polymer in the first reaction mixture. By way of further example, in one such embodiment, the preformed polymer may be dispersed in any of the non-polar solvents disclosed herein (including, for example, a crosslinking solvent) to form a reaction mixture, and a swelling agent is added to the reaction mixture. In one such exemplary embodiment, the crosslinker is selected from Table B, the solvent is a crosslinkable water-immiscible solvent, such as 1,2-dichloroethane ("DCE") or 1,3-dichloropropane ("DCP"), and the swelling agent comprises water. In each of the above embodiments, the preformed polymer may be an amine-containing polymer containing residues of monomers set forth in any of Formulas 1, 1a, 1b, 1c, 2, 2a, and 2b, or a linear polymer composed of repeat units set forth in Formula 3; for example, in each of the above embodiments, the preformed polymer may contain residues of two or more small molecule amines and a crosslinker disclosed in Table C.
[0191] In one exemplary embodiment, the preformed polyamine polymer can be crosslinked, for example, under suspension conditions, to produce particles of a targeted particle size and morphology. The crosslinker can be either water-miscible or water-insoluble. When a water-immiscible crosslinker (e.g., DCE or DCP) is used as a dispersant, high chloride binding selectivity is achieved, as demonstrated, for example, in SIB and / or SOB.
[0192] In one embodiment, the amine polymer can be formed in one reaction sequence in the same reaction flask and then further crosslinked. The crosslinked amine polymer can be prepared, for example, in suspension condition to produce particles of targeted particle size and morphology. In the same reaction flask, without isolation, the water content in the beads can be reduced by Dean-Stark method or other similar evaporation techniques. The water is adjusted to the targeted amount so that a second crosslinking reaction can be carried out to produce the final polymer with desired properties and characteristics.
[0193] In one embodiment, the crosslinked amine polymer is treated to reduce the concentration of any remaining amine reactive groups (e.g., amine reactive functional groups) introduced into the crosslinked polymer by the crosslinking agent. For example, in one such embodiment, the crosslinked polymer (e.g., post-polymerization crosslinked polymer as described above) is treated with a quenching agent, such as a base, washed, heated, or otherwise treated to remove or quench the amine reactive groups. For example, in one embodiment, the crosslinked polymer is treated with ammonium hydroxide. The ammonium hydroxide treatment can be performed immediately after the reaction, during the washing steps, or after the polymer has been washed and heated, in which case the polymer can be treated through another series of washing steps. In another embodiment, the crosslinked polymer is heated in a conventional or vacuum oven at a temperature above room temperature for a period of time, such as greater than 36 hours at 60°C. The oven incubation may be performed under an inert atmosphere (e.g., nitrogen or argon) to reduce the possibility of oxidation.
[0194] In one embodiment, the preformed amine polymer characterized by a selectivity for a first chloride compared to citrate, phosphate and / or taurocholate in the SGF, SIB and / or SOB is crosslinked in a post-polymerization crosslinking reaction to give a crosslinked polymer (i.e., post-polymerization crosslinked polymer) having a selectivity for a second (different) chloride compared to citrate, phosphate and / or taurocholate in the SGF, SIB and / or SOB. In one such embodiment, the preformed amine polymer is the reaction product of a substitution polymerization of a multifunctional reagent, at least one of which contains an amine moiety. In another such embodiment, the preformed polymer is the reaction product of a radical polymerization of a monomer containing at least one amine moiety or nitrogen-containing moiety. In a second crosslinking step (which may be optionally performed after the preformed polymer is isolated or as the second step in a one-pot reaction), the preformed amine polymer is crosslinked by a multifunctional crosslinker, optionally containing an amine moiety.
[0195] In one exemplary embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for phosphate in the SIB compared to the preformed amine polymer. For example, in one such embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for phosphate in the SIB compared to the preformed polymer. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 10% greater than the binding capacity of the preformed polymer for chloride in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 25% greater than the binding capacity of the preformed polymer for chloride in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 50% greater than the binding capacity of the preformed polymer for chloride in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 75% greater than the binding capacity of the preformed polymer for chloride in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 100% greater than the binding capacity of the preformed polymer for chloride in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 125% greater than the binding capacity of the preformed polymer for chloride in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 150% greater than the binding capacity of the preformed polymer for chloride in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in the SIB that is at least 200% greater than the binding capacity of the preformed polymer for chloride in the SIB.As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 10% less than the binding capacity of the preformed polymer for phosphate in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 20% less than the binding capacity of the preformed polymer for phosphate in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 30% less than the binding capacity of the preformed polymer for phosphate in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 40% less than the binding capacity of the preformed polymer for phosphate in the SIB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 50% less than the binding capacity of the preformed polymer for phosphate in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 60% less than the binding capacity of the preformed polymer for phosphate in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 70% less than the binding capacity of the preformed polymer for phosphate in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 80% less than the binding capacity of the preformed polymer for phosphate in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 90% less than the binding capacity of the preformed polymer for phosphate in the SIB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate in the SIB that is at least 95% less than the binding capacity of the preformed polymer for phosphate in the SIB.As a further example, in one such embodiment, the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride in SIB (a percentage increase of at least 10%, 25%, 50%, 75%, 100%, 125%, 150%, 175%, or even at least 200%) and a decreased binding capacity for phosphate (a percentage decrease of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even at least 95%) compared to the preformed amine polymer, and (ii) a decreased binding capacity for chloride in SGF compared to the preformed amine polymer.
[0196] In one exemplary embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for phosphate, citrate or taurocholate in the SOB compared to the preformed amine polymer. For example, in one such embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for phosphate in the SOB compared to the preformed polymer. As a further example, in one such embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for citrate in the SOB compared to the preformed amine polymer. As a further example, in one such embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in the SOB compared to the preformed amine polymer. As a further example, in one such embodiment, the crosslinked polymer after polymerization has an increased binding capacity for chloride and a decreased binding capacity for the combined phosphate, citrate and taurocholate in the SOB compared to the preformed amine polymer.
[0197] By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 10% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 25% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 50% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 75% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 100% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 125% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 150% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for chloride in SOB that is at least 200% greater than the binding capacity of the preformed polymer for chloride in SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a capacity for phosphate, citrate, and taurocholate that is at least 10% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in SOB.By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 20% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 30% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 40% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 50% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 60% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 70% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. As a further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 80% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB.By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 90% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has a binding capacity for phosphate, citrate, and taurocholate in the SOB that is at least 95% less than the binding capacity of the preformed polymer for phosphate, citrate, and taurocholate in the SOB. By way of further example, in one such embodiment, the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride in SOB (a percentage increase of at least 10%, 25%, 50%, 75%, 100%, 125%, 150%, 175%, or even at least 200%), and a decreased binding capacity for phosphate, citrate, and taurocholate (a percentage decrease of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even at least 95%), compared to the preformed amine polymer; and (ii) a decreased binding capacity in SGF compared to the preformed amine polymer.
[0198] The starting molecules described in formulas 1-3 may be copolymerized with one or more other monomers, oligomers or other polymerizable groups of the present invention. Such copolymer structures can include, but are not limited to, block or block-like polymers, graft copolymers, and random copolymers. The incorporation of the monomers described in formulas 1-3 can range from 1% to 99%. In some embodiments, the incorporation of the comonomer is between 20% and 80%.
[0199] Non-limiting examples of comonomers that may be used alone or in combination include: styrene, allylamine hydrochloride, substituted allylamine hydrochloride, substituted styrene, alkyl acrylate, substituted alkyl acrylate, alkyl methacrylate, substituted alkyl methacrylate, acrylonitrile, methacrylonitrile, acrylamide, methacrylamide, N-alkyl acrylamide, N-alkyl methacrylamide, N,N-dialkyl acrylamide, N,N-dialkyl methacrylamide, isoprene, butadiene, ethylene, vinyl acetate, N-vinyl amide, maleic acid derivatives, vinyl ether, allyle, methallyl monomers, and combinations thereof. Functionalized versions of these monomers may also be used. Additional specific monomers or comonomers that may be used in this invention include, but are not limited to, 2-propen-1-ylamine, 1-(allylamino)-2-aminoethane, 1-[N-allyl(2-aminoethyl)amino]-2-aminoethane, methyl methacrylate, ethyl methacrylate, propyl methacrylate (all isomers), butyl methacrylate (all isomers), 2-ethylhexyl methacrylate, isobornyl methacrylate, methacrylic acid, benzyl methacrylate, phenyl methacrylate, methacrylonitrile, a-methylstyrene, methyl acrylate, ethyl acrylate, propyl acrylate (all isomers), butyl ... Sil acrylate, isobornyl acrylate, acrylic acid, benzyl acrylate, phenyl acrylate, acrylonitrile, styrene, glycidyl methacrylate, 2-hydroxyethyl methacrylate, hydroxypropyl methacrylate (all isomers), hydroxybutyl methacrylate (all isomers), N,N-dimethylaminoethyl methacrylate, N,N-diethylaminoethyl methacrylate, triethylene glycol methacrylate, itaconic anhydride, itaconic acid, glycidyl acrylate, 2-hydroxyethyl acrylate, hydroxypropyl acrylate (all isomers), hydroxybutyl acrylate (all isomers), N,N-dimethylaminoethyl acrylate, N,N-Diethylaminoethyl acrylate, triethylene glycol acrylate, methacrylamide, N-methylacrylamide, N,N-dimethylacrylamide, N-tert-butyl methacrylamide, N-N-butyl methacrylamide, N-methylol methacrylamide, N-ethylol methacrylamide, N-tert-butyl acrylamide, N-N-butyl acrylamide, N-methylol acrylamide, N-ethylol acrylamide, 4-acryloylmorpholine, vinyl benzoic acid (all isomers), diethylaminostyrene ( all isomers), a-methylvinylbenzoic acid (all isomers), diethylamino a-methylstyrene (all isomers), p-vinylbenzenesulfonic acid, p-vinylbenzenesulfonic acid sodium salt, trimethoxysilylpropyl methacrylate, triethoxysilylpropyl methacrylate, tributoxysilylpropyl methacrylate, dimethoxymethylsilylpropyl methacrylate, diethoxymethylsilylpropyl methacrylate, dibutoxymethylsilylpropyl methacrylate, diisopropoxymethylsilylpropyl methacrylate, di Methoxysilylpropyl methacrylate, diethoxysilylpropyl methacrylate, dibutoxysilylpropyl methacrylate, diisopropoxysilylpropyl methacrylate, trimethoxysilylpropyl acrylate, triethoxysilylpropyl acrylate, tributoxysilylpropyl acrylate, dimethoxymethylsilylpropyl acrylate, diethoxymethylsilylpropyl acrylate, dibutoxymethylsilylpropyl acrylate, diisopropoxymethylsilylpropyl acrylate, dimethoxysilylpropyl Examples of the silyl acrylate include propyl acrylate, diethoxysilylpropyl acrylate, dibutoxysilylpropyl acrylate, diisopropoxysilylpropyl acrylate, maleic anhydride, N-phenylmaleimide, N-butylmaleimide, N-vinylformamide, N-vinylacetamide, allylamine, methallylamine, allyl alcohol, methyl vinyl ether, ethyl vinyl ether, butyl vinylt ether, butadiene, isoprene, chloroprene, ethylene, vinyl acetate, and combinations thereof.
[0200] Further modifications to the preformed crosslinked polymer can be made through the addition of modifying agents, including but not limited to amine monomers, additional crosslinking agents, and polymers. Modifications can be achieved through covalent or non-covalent methods. These modifications can be distributed evenly or unevenly throughout the preformed polymer material, including modifications that are biased to the surface of the preformed crosslinked polymer. Additionally, modifications can be made to alter the physical properties of the preformed crosslinked polymer, including but not limited to reactions occurring between remaining reactive groups, such as haloalkyl and allyl groups, on the preformed polymer. Reactions and modifications to the preformed crosslinked polymer can include but are not limited to acid-base reactions, nucleophilic substitution reactions, Michael reactions, non-covalent electrostatic interactions, hydrophobic interactions, physical interactions (crosslinking), and radical reactions.
[0201] In one embodiment, the crosslinked amine polymer after polymerization is a crosslinked amine polymer comprising a structure corresponding to Formula 4: [ka] wherein each R is independently hydrogen or an ethylene bridge between two nitrogen atoms of the crosslinked amine polymer. [ka] and a, b, c, and m are integers. Typically, m is a large integer indicating an expanded polymer network. In one such embodiment, the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1:1 to 5:1. For example, in one such embodiment, the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1.5:1 to 4:1. As a further example, in one such embodiment, the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1.75:1 to 3:1. For example, in one such embodiment, the ratio of the sum of a and b is 57, c is 24, and m is a large integer indicating an expanded polymer network. In each of the above embodiments, the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 2:1 to 2.5:1. As described in each of the above embodiments, each R may independently be hydrogen or an ethylene bridge between the two nitrogen atoms. Typically, however, 50-95% of the R substituents are hydrogen and 5-50% are ethylene bridges. [ka] For example, in one such embodiment, 55-90% of the R substituents are hydrogen and 10-45% are ethylene bridges. [ka] By way of further example, in one such embodiment, 60-90% of the R substituents are hydrogen and 10-40% are ethylene bridges. By way of further example, in one such embodiment, 65-90% of the R substituents are hydrogen and 10-35% are ethylene bridges. [ka] By way of further example, in one such embodiment, 70-90% of the R substituents are hydrogen and 10-30% are ethylene bridges. By way of further example, in one such embodiment, 75-85% of the R substituents are hydrogen and 15-25% are ethylene bridges. By way of further example, in one such embodiment, 80-85% of the R substituents are hydrogen and 15-20% are ethylene bridges. By way of further example, in one such embodiment, about 81% of the R substituents are hydrogen and about 19% are ethylene bridges.
[0202] As described in more detail in the examples, polymers with increased crosslinking and / or entanglement were found to swell less than those with less crosslinking and / or entanglement, and also had binding capacity for target ions (e.g., chloride) equal to or greater than polymers with less crosslinking and / or entanglement, while binding of interfering ions, e.g., phosphate, was significantly reduced. The selectivity effect was introduced in two different ways: 1) the overall capacity was sacrificed for chloride specificity. Crosslinkers that do not contain chloride binding sites (e.g., epichlorohydrin) allow for increased crosslinking, but the overall capacity is reduced in proportion to the amount of crosslinker incorporated into the polymer. 2) the overall capacity is preserved for chloride specificity: crosslinkers that contain chloride binding sites (e.g., diallylamine) allow for increased crosslinking, but the overall capacity remains the same or is reduced by a small amount.
[0203] The polymers described herein exhibit ion-binding properties, generally proton binding, for the formation of positive charges followed by anion binding. In a preferred embodiment, the polymer exhibits chloride-binding properties. Ion (e.g. chloride) binding capacity is a measure of the amount of a particular ion that an ion-binding agent can bind in a given solution. For example, the binding capacity of an ion-binding polymer can be measured in vitro, e.g. in water or in saline solution, or in a solution / matrix containing cations and anions representative of gastrointestinal cavity conditions, or in vivo, e.g., from urinary excretion of ions (e.g., bicarbonate or citrate), or ex vivo, e.g., using aspirates, e.g., chime / gastrointestinal cavity contents obtained from laboratory animals, patients or volunteers. Measurements can be made in solutions that contain only the target ion or at least do not contain other competing solutes that compete with the target ion for binding to the polymer. In these cases, a non-interfering buffer is used (e.g., a solution of hydrochloric acid, with or without additional sodium chloride). Alternatively, measurements can be made in an interference buffer containing other competing solutes, for example other ions or metabolites that compete with the target ions for binding to the resin.
[0204] In some embodiments, the polymer binds hydrochloric acid. For in vivo applications, for example, in the treatment of metabolic acidosis, it is desirable for the polymer to have high proton and chloride binding capacity. In vitro measurements of binding capacity do not necessarily translate to in vivo binding capacity. Therefore, it is useful to define binding capacity in terms of both in vitro binding capacity and in vivo binding capacity.
[0205] The in vitro chloride binding capacity of the polymers of the invention in HCl can be greater than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 mmol / g. In some embodiments, the in vitro chloride binding capacity of the polymers of the invention with respect to the target ion is greater than about 5.0 mmol / g, preferably greater than about 7.0 mmol / g, even more preferably greater than about 9.0 mmol / g, even more preferably greater than about 10.0 mmol / g. In some embodiments, the chloride binding capacity can range from about 5.0 mmol / g to about 25 mmol / g, preferably from about 7.5 mmol / g to about 20 mmol / g, even more preferably from about 10 mmol / g to about 15 mmol / g. Several techniques for determining chloride binding capacity are known in the art.
[0206] The maximum binding capacity in vivo (i.e., the maximum amount of [protons and] chloride bound under conditions likely to be encountered in the human GI tract) can be assessed by chloride binding in a simulated gastric fluid assay ("SGF") for 12-16 hours and is a structural indicator of how well the monomers and crosslinkers are incorporated. The SGF value represents an experimental confirmation of the theoretical maximum binding capacity of the polymer and is in the same range as the calculated capacity based on the stoichiometry of the starting materials.
[0207] To balance the proton binding, chloride is the anion of choice to bind because its removal does not negatively affect serum bicarbonate. Anions other than chloride that can be bound to neutralize the proton positive charge include phosphate, short chain fatty acids, long chain fatty acids, bile acids, or other organic or inorganic anions. Binding of these anions other than chloride affects the overall bicarbonate pool in the intracellular and extracellular compartments.
[0208] The selectivity of the polymers for chloride binding can be evaluated in vitro using conditions that mimic the various conditions, anions, and anion concentrations encountered in the GI cavity. Chloride binding can be compared to phosphate alone (e.g., SIB [artificial intestinal buffer]; or the range of anions found in the GI tract (e.g., SOB).
[0209] In some embodiments, chloride binding in the SIB assay after exposure of the polymer to test buffer for 1 hour at 37° C. is greater than about 2.0 mmol / g polymer, preferably greater than about 2.5 mmol / g polymer, more preferably greater than about 3.0 mmol / g polymer, even more preferably greater than about 3.5 mmol / g polymer, and most preferably greater than about 4.0 mmol / g polymer.
[0210] In some embodiments, chloride binding in the SOB assay after exposure of the polymer to test buffer for 2 hours at 37° C. is greater than about 1.0 mmol / g polymer, preferably greater than about 2.0 mmol / g polymer, more preferably greater than about 3.0 mmol / g polymer, even more preferably greater than about 3.5 mmol / g polymer, and most preferably greater than about 4.0 mmol / g polymer.
[0211] In some embodiments, chloride binding in the SOB assay after 24 hours exposure of the polymer to test buffer at 37° C. is greater than about 0.5 mmol / g polymer, preferably greater than about 1 mmol / g polymer, more preferably greater than about 1.5 mmol / g polymer, even more preferably greater than about 2.0 mmol / g polymer, even more preferably greater than about 2.5 mmol / g polymer, and most preferably greater than about 3.0 mmol / g polymer. Chloride binding in the SOB after 24 hours exposure at 37° C. is an indication of the ability of the polymer to retain chloride as it passes through the GI tract.
[0212] Another method for measuring (proton and) chloride retention is to first expose the polymer to SGF, isolate the polymer, then expose the polymer to SOB, isolate the polymer again, and then expose the polymer to conditions that are representative of the intestinal tract, for example using a "GI Compartment Transit Assay" (GICTA) buffer. In some embodiments, the amount of chloride remaining bound to the polymer after exposure to SGF for 1 hour, then SOB at 37° C. for 2 hours, then GICTA at 37° C. for 48 hours is greater than about 0.5 mmol / g polymer, preferably greater than about 0.5 mmol / g polymer, more preferably greater than about 1.0 mmol / g polymer, even more preferably greater than about 2.0 mmol / g polymer, and most preferably greater than about 3.0 mmol / g polymer. In one embodiment, the polymer has a retained chloride content of at least 30% of the chloride initially bound (i.e., bound during the SGF binding step) in the GI Compartment Transit Assay ("GICTA"). In one such embodiment, the crosslinked amine polymer has a retained chloride content of at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of the chloride initially bound in a GI compartment transit assay. In one embodiment, the polymer has a retained chloride content of at least 0.5, at least 1, at least 1.5, at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, or even at least 5 mmol of chloride / polymer (g) in a GI compartment transit assay ("GICTA").In one embodiment, the crosslinked amine polymer has a retained chloride content of at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of the chloride initially bound in a GI compartment transit assay and a retained chloride content of at least 0.5, at least 1, at least 1.5, at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, or even at least 5 mmol of chloride / polymer (g) in a GI compartment transit assay ("GICTA").
[0213] In some embodiments, the in vivo binding performance of the polymers of the present disclosure can be evaluated by measuring the change in uric acid levels after administration to animals, including humans, with normal renal function. The removal of additional HCl (or HCl equivalents) from the body by the action of the administered polymer is reflected in changes in urinary bicarbonate, titratable acid, citrate, or other indicators of uric acid excretion, given sufficient time to reach metabolic equilibrium.
[0214] To bind protons, the amine components of the polymer can be primary, secondary or tertiary amines, but not quaternary amines. Quaternary amines remain substantially charged under all physiological conditions and therefore do not bind protons before anions are bound. The percentage of quaternary amines can be measured in a number of ways, including titration and back-titration approaches. Another simple but accurate method is to compare anion (e.g., chloride) binding at low and high pH. Chloride binding at low pH (e.g., SGF buffer conditions; pH 1.2) does not distinguish quaternary amines from other amines, but chloride binding assays at high pH (e.g., QAA buffer conditions; pH 11.5) do. At this high pH, primary, secondary and tertiary amines are not substantially protonated and do not contribute to chloride binding. Therefore, any binding observed under these conditions can be attributed to the presence of permanently charged quaternary amines. A comparison of chloride binding at low pH (e.g., SGF conditions) versus high pH (e.g., QAA conditions) is an indication of the degree of quaternization, and by extension, the amount of bound protons along with chloride. The polymers of the present disclosure contain 40%, 30%, 20%, 10%, and most preferably 5% or less of quaternary amines.
[0215] The swelling ratio of the polymers of the present disclosure represents an experimental confirmation of the degree of crosslinking, and by extension, the relative pore size of the polymer and the accessibility of anions greater than (or having a greater hydration ratio than) chloride. In some embodiments, swelling is measured in deionized water and expressed as grams of water per gram of dry polymer. The polymers of the present disclosure have a swelling ratio in deionized water of ≦5 g / g, ≦4 g / g, ≦3 g / g, ≦2 g / g, or ≦1 g / g.
[0216] The ability of a polymer to retain chloride (and not release it, allowing it to be exchanged with other anions) as it passes through the different conditions tested in the GI cavity is an important feature that is likely to be a predictor of relative in vivo efficacy. The GI compartment translocation assay (GICTA) can be used to evaluate chloride retention. Screening of SGF and then SOB (artificial intestinal organic / inorganic buffer) is first performed to allow chloride and other anions to bind to the polymer, the polymer is isolated and exposed to conditions that mimic the intestine (e.g., GICTA retention assay matrix) for 40 hours. The polymer is again isolated and the remaining anions bound to the polymer are eluted in sodium hydroxide and measured. The polymers of the present disclosure retain more than 30%, 40%, 50%, 60%, 70%, 80% or most preferably more than 90% of the chloride bound in SGF after undergoing the chloride retention assay as described.
[0217] Using a heterogeneous polymerization process, the polymer particles are obtained as spherical beads, the diameter of which is controlled in the range of 5-1000 microns, preferably 10-500 microns, and most preferably 40-180 microns.
[0218] In general, the pharmaceutical composition of the present disclosure comprises the proton-binding crosslinked amine polymer described herein. Preferably, the pharmaceutical composition comprising the crosslinked amine polymer is formulated for oral administration. The pharmaceutical form in which the polymer is administered includes powder, tablet, pill, lozenge, sachet, cachet, elixir, suspension, syrup, soft or hard gelatin capsule, and the like. In one embodiment, the pharmaceutical composition comprises only the crosslinked amine polymer. Alternatively, the pharmaceutical composition may comprise a carrier, diluent, or excipient in addition to the crosslinked amine polymer. Examples of carriers, excipients, and diluents that may be used in these formulations as well as others include food, beverage, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, propylhydroxybenzoate, and talc. Pharmaceutical excipients useful in the pharmaceutical composition include binders such as microcrystalline cellulose, colloidal silica and combinations thereof (Prosolv90), carbopol, povidone and xanthan gum; flavorings such as sucrose, mannitol, xylitol, maltodextrin, fructose or sorbitol; lubricants such as magnesium stearate, stearic acid, sodium stearyl fumarate and vegetable-based fatty acids; and, optionally, disintegrants such as croscarmellose sodium, gellan gum, low-substituted hydroxypropyl ethers of cellulose, sodium starch glycolate. Other additives may include plasticizers, pigments, talc, and the like. Such additives and other suitable ingredients are well known in the art; see, for example, Gennaro AR (ed), Remington's Pharmaceutical Sciences, 20th Edition.
[0219] In one embodiment, the pharmaceutical composition comprising the crosslinked amine polymer of the present disclosure contains a relatively low amount of sodium. For example, in one such embodiment, the pharmaceutical composition contains less than 1 g of sodium per dose. By way of further example, in one such embodiment, the pharmaceutical composition contains less than 0.5 g of sodium per dose. By way of further example, in one such embodiment, the pharmaceutical composition contains less than 0.1 g of sodium per dose. By way of further example, in one such embodiment, the pharmaceutical composition is sodium-free.
[0220] In one embodiment, the daily dose of the novel chronic metabolic acidosis treatment is compliant (approximately 5 g or less per day) and achieves a clinically significant and sustained increase in serum bicarbonate of approximately 3 mEq / L at these daily doses. The non-absorbable nature of the polymer and the lack of sodium load and / or the introduction of other ions that are harmful to such oral drugs allow for the first time chronic treatment of metabolic acidosis without worsening blood pressure / hypertension and / or causing increased fluid retention and fluid overload. Another benefit is the further delay in the progression of kidney disease and the initiation of lifelong renal replacement therapy (end stage renal disease "ESRD" including dialysis three times a week) or the need for kidney transplantation. Both are associated with high mortality, poor quality of life, and a significant burden on health care systems worldwide. In the United States alone, approximately 20% of the 400,000 ESRD patients die and 100,000 new patients start dialysis each year.
[0221] In one embodiment, the pharmaceutical composition comprises a sodium-free, non-absorbed crosslinked amine polymer for the treatment of metabolic acidosis, which increases serum bicarbonate and normalizes blood pH in mammals through bound HCl. One preferred embodiment is directed to the prevention of metabolic acidosis by the administration of polymer-bound HCl in the stomach / upper GI tract. + followed by administration of bound Cl in an amount sufficient to cause a clinically significant increase in serum bicarbonate of at least 1.6 mEq / L, more preferably at least 2 mEq / L, and most preferably 3 mEq / L or greater. -The amount of HCl binding is determined by the capacity of the polymer (the target range for HCl binding capacity is 5-20 mEq HCl / g polymer) and selectivity. In the stomach, free amines are converted to bound H + The positive charges formed in situ on the polymer are then protonated by Cl by controlling the access of binding sites through crosslinking (size exclusion, mesh size) and chemical sites (tailored hydrophilicity / hydrophobicity to keep away larger organic ions (e.g. acetate, propionate and butyrate or other short chain fatty acids commonly present in the colon), phosphate, bile and fatty acids). - anions other than chloride are bound to a lesser extent, if at all. By tailoring the chemistry of the bead cross-linking and amine binding sites, one can ensure that chloride is tightly bound and not released in the lower GI tract. HCl is removed from the body with regular bowel movements / feces, resulting in net HCl binding. In another embodiment, the polymer will be preformed with some quaternized / protonated amine groups, and chloride binding is achieved through ion exchange with citrate or carbonate, such that up to 90% of the cation binding sites on the polymer will be preloaded with citrate and / or carbonate as counterions.
[0222] In one embodiment, an important feature of the sodium-free, non-absorbable crosslinked amine polymers for the treatment of metabolic acidosis that increase serum bicarbonate and normalize blood pH in mammals is that they do not increase blood pressure or exacerbate hypertension, which is of particular concern in diabetic kidney disease patients. An additional benefit of not introducing sodium is the absence of associated increased fluid retention that causes fluid overload, which is of particular concern in heart failure patients. The ability of the polymers to safely and effectively treat metabolic acidosis without introducing harmful counterions allows for a delay in the progression of kidney disease, which is of particular concern in chronic kidney disease patients who have not yet reached dialysis. The initiation of dialysis could be delayed for at least 3, 6, 9 or 12 months.
[0223] In yet another embodiment of the sodium-free non-absorbable amine polymer for the treatment of metabolic acidosis, the polymer is a crosslinked bead having a preferred particle size range that is (i) large enough to avoid active or active absorption through the GI tract and (ii) small enough so as not to cause a gritty or unpleasant mouthfeel when ingested as a powder, sachet and / or chewable tablet / dosage form having an average particle size of 40-180 microns. Preferably, the desired particle size morphology is achieved through a heterogeneous polymerization reaction, e.g., suspension or emulsion polymerization. To minimize GI side effects in patients that are often associated with the movement of high volumes of polymer gel through the GI tract, it is preferred that the polymer has a low swelling ratio (0.5-5 times its own weight in water). In yet another embodiment, the polymer is a crosslinked bead having a preferred particle size range that is large enough to avoid active or active absorption through the GI tract and (ii) small enough so as not to cause a gritty or unpleasant mouthfeel when ingested as a powder, sachet and / or chewable tablet / dosage form having an average particle size of 40-180 microns. Preferably, the polymer has a low swelling ratio (0.5-5 times its own weight in water) to minimize GI side effects in patients that are often associated with the movement of high volumes of polymer gel through the GI tract. In yet another embodiment, the polymer is a crosslinked bead having a preferred particle size range that is large enough to prevent Cl- absorption in the colon and intestine. - / HCO3 - The net effect of blocking the antiporter is to block Cl from the intestinal lumen. - The aim of this invention is to effectively increase serum bicarbonate by reducing the intake of arginine and the associated exchange of bicarbonate from the serum.
[0224] In one embodiment, the crosslinked amine polymer may be administered together with other effective pharmaceutical agents depending on the condition being treated. This co-administration may include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. For example, for the treatment of metabolic acidosis, the crosslinked amine polymer may be administered together with the general treatments required to treat the underlying co-morbid diseases, including but not limited to hypertension, diabetes, obesity, heart failure, and complications of chronic kidney disease. These drugs and the crosslinked amine polymer may be formulated together in the same dosage form or administered simultaneously, as long as they do not show any clinically significant drug-drug-interactions. Alternatively, these treatments and the crosslinked amine polymer may be administered separately, sequentially, with one administered followed by the other.
[0225] The present disclosure further includes the embodiments listed below.
[0226] Embodiment 1. A process for the preparation of a crosslinked amine polymer, comprising crosslinking a preformed amine polymer in a reaction mixture to form a crosslinked amine polymer, the reaction mixture comprising a preformed amine polymer, a solvent, a crosslinking agent, and a swelling agent for the preformed amine polymer, the preformed amine polymer having an absorption capacity for the swelling agent, and the amount of swelling agent in the reaction mixture is less than the absorption capacity of the preformed amine polymer for the swelling agent.
[0227] Embodiment 2. A process for the preparation of a particulate crosslinked amine polymer comprising: (i) polymerizing an amine-containing monomer to form a particulate preformed amine polymer; (ii) deprotonating the preformed amine polymer with a base; (iii) swelling the deprotonated preformed amine polymer with a swelling agent; and (iv) crosslinking the preformed amine polymer in a reaction mixture with a crosslinker comprising amine reactive sites, wherein carbon-carbon bridges are formed predominantly in the polymerization step and nitrogen-nitrogen bridges are formed predominantly in the crosslinking step.
[0228] Embodiment 3. A process for the preparation of a particulate crosslinked amine polymer, comprising forming the particulate crosslinked amine polymer in at least two steps of polymerization / crosslinking, the first step comprising polymerizing an amine-containing monomer to form a preformed amine polymer having a chloride binding capacity of at least 10 mmol / g in simulated gastric fluid ("SGF") and a swelling ratio in the range of 2-10, and the second step comprising crosslinking the preformed amine polymer with a crosslinking agent in a reaction mixture to produce nitrogen-nitrogen crosslinks within the preformed amine polymer.
[0229] Embodiment 4. A process for the preparation of a particulate crosslinked amine polymer comprising at least two separate steps of polymerization / crosslinking, a first step comprising forming a preformed amine polymer having a chloride binding capacity of at least 10 mmol / g in simulated gastric fluid ("SGF") and a swelling ratio in the range of 2-10, and a second step comprising crosslinking the preformed amine polymer with a crosslinker containing amine reactive sites to form a post-polymerized crosslinked amine polymer in a reaction mixture, wherein the resulting post-polymerized crosslinked amine polymer has a binding capacity for phosphate, citrate and / or taurocholate in SIB or SOB that is less than the binding capacity of the preformed amine polymer for phosphate, citrate and / or taurocholate in the same assay.
[0230] Embodiment 5. A process for the preparation of a particulate crosslinked amine polymer comprising: (i) forming a preformed amine polymer having a chloride binding capacity of at least 10 mmol / g in simulated gastric fluid ("SGF"), a swelling ratio in the range of 2 to 10, and an average particle size of at least 80 microns; (ii) at least partially deprotonating the preformed amine polymer with a base; and (iii) crosslinking the deprotonated preformed amine polymer in a reaction mixture with a crosslinker containing amine reactive sites to form a post-polymerization crosslinked amine polymer.
[0231] Embodiment 6. A process for the preparation of a particulate crosslinked amine polymer comprising: (i) forming a preformed amine polymer in simulated gastric fluid ("SGF") having a chloride binding capacity of at least 10 mmol / g and a swelling ratio in the range of 2 to 10; (ii) at least partially deprotonating the preformed amine polymer with a base; (iii) contacting the preformed amine polymer with a swelling agent to swell the deprotonated preformed amine polymer; and (iv) crosslinking the swollen deprotonated preformed amine polymer in a reaction mixture with a crosslinker containing amine reactive sites to form a polymerized crosslinked amine polymer.
[0232] Embodiment 7. The process of any of the above-recited embodiments, wherein the swelling agent is a polar solvent.
[0233] Embodiment 8. The process of any of the above-enumerated embodiments, wherein the swelling agent is water, methanol, ethanol, n-propanol, isopropanol, n-butanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, propylene carbonate, or a combination thereof.
[0234] Embodiment 9. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 4:1.
[0235] Embodiment 10. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 3:1.
[0236] Embodiment 11. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 2:1.
[0237] Embodiment 12. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 1:1.
[0238] Embodiment 13. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.5:1.
[0239] Embodiment 14. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.4:1.
[0240] Embodiment 15. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.3:1.
[0241] Embodiment 16. The process of any above-recited embodiment, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is at least 0.15:1.
[0242] Embodiment 17. The process of any of the above-recited embodiments, wherein the crosslinker contains at least two amine-reactive functional groups.
[0243] Embodiment 18. The process of any of the above-enumerated embodiments, wherein the crosslinker is a compound containing at least two amine-reactive groups selected from the group consisting of alkyl halides, epoxides, phosgene, anhydrides, carbamates, carbonates, isocyanates, thioisocyanates, esters, activated esters, carboxylic acids and their derivatives, sulfonates and their derivatives, acyl halides, aziridines, α,β-unsaturated carbonyls, ketones, aldehydes, and pentafluoroaryl groups.
[0244] Embodiment 19. The process of any of the above-recited embodiments, wherein the crosslinker is a crosslinker selected from Table B.
[0245] Embodiment 20 The process of any of the above-recited embodiments, wherein the crosslinker is a dichloroalkane.
[0246] Embodiment 21 The process of any of the above-recited embodiments, wherein the crosslinker is dichloroethane or dichloropropane.
[0247] Embodiment 22. The process of any of the above-recited embodiments, wherein the reaction mixture comprises a non-polar solvent.
[0248] Embodiment 23. The process of any of the above-recited embodiments, wherein the reaction mixture comprises a crosslinking solvent.
[0249] Embodiment 24. The process of any of the above-recited embodiments, wherein the swelling agent and the solvent are immiscible.
[0250] Embodiment 25. The process of any of the above-recited embodiments, wherein the swelling agent and the crosslinking agent are immiscible.
[0251] Embodiment 26. The process of any of the above-enumerated embodiments, wherein the preformed polymer is combined with the crosslinker and solvent before the polymer is combined with the swelling agent.
[0252] Embodiment 27. The process of any above-enumerated embodiment, further comprising forming a preformed amine polymer in a solvent system, wherein the crosslinked amine polymer is formed without isolating the preformed amine polymer from the solvent system.
[0253] Embodiment 28. The process of any above-recited embodiment, wherein the preformed amine polymer comprises a residue of an amine selected from Table C.
[0254] Embodiment 29. A preformed amine polymer comprises a residue of an amine corresponding to Formula 1: [ka] wherein R1, R2, and R3 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, provided that at least one of R1, R2, and R3 is other than hydrogen; the process described in any of the above-listed embodiments.
[0255] Embodiment 30. The preformed amine polymer is characterized by a first selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIB and / or SOB, and the crosslinked polymer is characterized by a second selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIB and / or SOB: (i) the crosslinked polymer has increased chloride binding capacity and decreased phosphate binding capacity in SIB compared to the preformed amine polymer; (ii) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in SOB compared to the preformed amine polymer; (iii) the crosslinked polymer has an increased chloride binding capacity and a decreased citrate binding capacity in SOB compared to the preformed amine polymer; or (iv) The process of any of the above-enumerated embodiments, wherein the crosslinked polymer has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in SOB compared to the preformed amine polymer.
[0256] Embodiment 31 The process of embodiment 30, wherein the crosslinked polymer has a reduced binding capacity for chloride in SGF compared to the preformed amine polymer.
[0257] Embodiment 32. The process of embodiment 30, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride and a decreased binding capacity for phosphate in SIB, and (ii) a decreased binding capacity in SGF, compared to the preformed amine polymer.
[0258] Embodiment 33. The process of embodiment 30, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride in SOB and a decreased binding capacity for phosphate, citrate and / or taurocholate in combination, compared to the preformed amine polymer, and (ii) a decreased binding capacity in SGF.
[0259] Embodiment 34. A process for the preparation of a crosslinked amine polymer, comprising crosslinking a preformed amine polymer in a reaction mixture to form a crosslinked amine polymer, the reaction mixture comprising a preformed amine polymer, a solvent, and a crosslinker, the preformed amine polymer characterized by a first selectivity for chloride relative to citrate, phosphate, and / or taurocholate in the SIB and / or SOB, and the crosslinked polymer characterized by a second selectivity for chloride relative to citrate, phosphate, and / or taurocholate in the SIB and / or SOB: (i) the crosslinked polymer has increased chloride binding capacity and decreased phosphate binding capacity in SIB compared to the preformed amine polymer; (ii) the crosslinked polymer has increased chloride binding capacity and decreased citrate binding capacity in SIB compared to the preformed amine polymer; (iii) the crosslinked polymer has an increased chloride binding capacity and a decreased citrate binding capacity in SOB compared to the preformed amine polymer; or (iv) A process wherein the crosslinked polymer has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in SOB compared to the preformed amine polymer.
[0260] Embodiment 35. The process of embodiment 34, wherein the crosslinked polymer has a reduced binding capacity for chloride in SGF compared to the preformed amine polymer.
[0261] Embodiment 36. The process of embodiment 34, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride and a decreased binding capacity for phosphate in SIB, and (ii) a decreased binding capacity in SGF, compared to the preformed amine polymer.
[0262] Embodiment 37. The process of embodiment 34, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride in SOB and a decreased binding capacity for phosphate, citrate and / or taurocholate in combination, compared to the preformed amine polymer, and (ii) a decreased binding capacity in SGF.
[0263] Embodiment 38. A pharmaceutical composition comprising a crosslinked amine polymer, characterized by a binding capacity and / or selectivity for chloride relative to citrate, phosphate and / or taurocholate in SGF, SIB and / or SOB as described in any of paragraphs
[0042] to
[0066] .
[0264] Embodiment 39. A method of treating an acid / base disorder in an animal, including a human, by removing HCl through oral administration of the pharmaceutical composition of embodiment 38.
[0265] Embodiment 40. A method of treating an acid / base disorder in an animal, including a human, by scavenging HCl through oral administration of a pharmaceutical composition comprising a crosslinked amine polymer prepared by the process of any of embodiments 1-37.
[0266] Embodiment 41. A process for the preparation of a crosslinked amine polymer comprising: (i) swelling a preformed amine polymer with a swelling agent; (ii) dispersing the preformed amine polymer in a reaction mixture comprising a dispersing solvent, a crosslinking agent, and the swelling agent; and (iii) crosslinking the preformed amine polymer in the reaction mixture to form a crosslinked amine polymer, wherein the preformed amine polymer is crosslinked and has an absorption capacity for the swelling agent, and the amount of swelling agent in the reaction mixture is less than the absorption capacity of the preformed amine polymer for the swelling agent.
[0267] Embodiment 42. The process of embodiment 41, further comprising deprotonating the preformed amine polymer with a base prior to swelling with the swelling agent.
[0268] Embodiment 43. The process of embodiment 41 or 42, wherein the crosslinks in the preformed amine polymer are predominantly carbon-carbon crosslinks, and nitrogen-nitrogen crosslinks are predominantly formed in the crosslinking step.
[0269] Embodiment 44. The process of any of embodiments 41-43, wherein the preformed amine polymer has a chloride binding capacity of at least 10 mmol / g in simulated gastric fluid ("SGF") and a swelling ratio in the range of 2 to 10, and the crosslinked amine polymer has a binding capacity for phosphate, citrate and / or taurocholate in SIB or SOB that is less than the binding capacity of the preformed amine polymer for phosphate, citrate and / or taurocholate in the same assays.
[0270] Embodiment 45. The process of any one of embodiments 41 to 44, wherein the dispersion solvent comprises a non-polar solvent.
[0271] Embodiment 46. The process of any one of embodiments 41-45, wherein the dispersing solvent comprises a solvent that is chemically inert to the preformed amine polymer.
[0272] Embodiment 47. The process of any one of embodiments 41 to 46, wherein the dispersion solvent comprises a cross-linking solvent.
[0273] Embodiment 48. The process of any one of claims 41 to 44, wherein the crosslinker is a dispersion solvent.
[0274] Embodiment 49. The process of any one of embodiments 41 to 48, wherein the swelling agent and the dispersion solvent are immiscible.
[0275] Embodiment 50. The process of any of embodiments 41-49, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 4:1.
[0276] Embodiment 51. The process of any of embodiments 41-50, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 3:1.
[0277] Embodiment 52. The process of any of embodiments 41-51, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 2:1.
[0278] Embodiment 53. The process of any of embodiments 41-52, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 1:1.
[0279] Embodiment 54. A process for the preparation of a crosslinked amine polymer comprising: (i) swelling a preformed amine polymer with a swelling agent; and (ii) crosslinking the preformed amine polymer to form a crosslinked amine polymer in a reaction mixture comprising the crosslinker and the swelling agent, wherein the preformed amine polymer is crosslinked and has an absorption capacity for the swelling agent, the amount of swelling agent in the reaction mixture is lower than the absorption capacity of the preformed amine polymer for the swelling agent, and the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 1:1.
[0280] Embodiment 55. The process of any one of embodiments 41 to 54, wherein the swelling agent is a polar solvent.
[0281] Embodiment 56. The process of any of embodiments 41-55, wherein the swelling agent is water, methanol, ethanol, n-propanol, isopropanol, n-butanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, propylene carbonate, or a combination thereof.
[0282] Embodiment 57. The process of any one of embodiments 41 to 56, wherein the swelling agent is water.
[0283] Embodiment 58. The process of any of embodiments 41-57, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.5:1.
[0284] Embodiment 59. The process of any of embodiments 41-58, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.4:1.
[0285] Embodiment 60. The process of any of embodiments 41-59, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.3:1.
[0286] Embodiment 61. The process of any of embodiments 41-60, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is at least 0.15:1.
[0287] Embodiment 62. The process of any one of embodiments 41 to 61, wherein the crosslinker contains at least two amine-reactive functional groups.
[0288] Embodiment 63. The process of any one of embodiments 41-62, wherein the crosslinker is a compound containing at least two amine-reactive groups selected from the group consisting of alkyl halides, epoxides, phosgene, anhydrides, carbamates, carbonates, isocyanates, thioisocyanates, esters, activated esters, carboxylic acids and their derivatives, sulfonates and their derivatives, acyl halides, aziridines, α,β-unsaturated carbonyls, ketones, aldehydes, and pentafluoroaryl groups.
[0289] Embodiment 64 The process of any one of embodiments 41 to 63, wherein the crosslinking agent is a crosslinking agent selected from Table B.
[0290] Embodiment 65 The process of any one of embodiments 41 to 64, wherein the crosslinking agent is a dichloroalkane.
[0291] Embodiment 66 The process of any one of embodiments 41 to 65, wherein the crosslinking agent is dichloroethane or dichloropropane.
[0292] Embodiment 67. The process of any one of embodiments 41 to 66, wherein the swelling agent and the cross-linking agent are immiscible.
[0293] Embodiment 68. The process of any of embodiments 41-67, wherein the preformed polymer is combined with the crosslinker and the dispersion solvent before the polymer is swelled with the swelling agent.
[0294] Embodiment 69. The process of any of embodiments 41-68, further comprising forming a preformed amine polymer in a solvent system, wherein the crosslinked amine polymer is formed without isolating the preformed amine polymer from the solvent system.
[0295] Embodiment 70. A preformed amine polymer comprises a residue of an amine corresponding to Formula 1: [ka] 70. The process according to any one of embodiments 41 to 69.
[0296] Embodiment 71. A preformed amine polymer comprises a residue of an amine corresponding to formula 1a: [ka] wherein R4 and R5 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; the process of any of embodiments 41 to 69.
[0297] Embodiment 72. The process of claim 71, wherein R4 and R5 are independently hydrogen, aliphatic or heteroaliphatic.
[0298] Embodiment 73. The process of claim 71, wherein R4 and R5 are independently hydrogen, allyl, or aminoalkyl.
[0299] Embodiment 74 The process of any of embodiments 41-73, wherein the preformed amine polymer comprises a residue of an amine of Table C.
[0300] Embodiment 75 The process of any of embodiments 41-74, wherein the preformed amine polymer comprises residues of allylamine.
[0301] Embodiment 76 The process of any of embodiments 41-75, wherein the preformed amine polymer comprises residues of diallylpropyldiamine.
[0302] Embodiment 77. The process of any of embodiments 41-76, wherein the preformed amine polymer is a copolymer comprising residues of allylamine and diallylpropyldiamine.
[0303] Embodiment 78. The preformed amine polymer is characterized by a first selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIB and / or SOB, and the crosslinked polymer is characterized by a second selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIB and / or SOB: (i) the crosslinked polymer has increased chloride binding capacity and decreased phosphate binding capacity in SIB compared to the preformed amine polymer; (ii) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in SOB compared to the preformed amine polymer; (iii) the crosslinked polymer has an increased chloride binding capacity and a decreased citrate binding capacity in SOB compared to the preformed amine polymer; or (iv) The process of any one of embodiments 41-77, wherein the crosslinked polymer has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in SOB compared to the preformed amine polymer.
[0304] Embodiment 79. The process of embodiment 78, wherein the crosslinked polymer has a reduced binding capacity for chloride in SGF compared to the preformed amine polymer.
[0305] Embodiment 80. The process of embodiment 78, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride and a decreased binding capacity for phosphate in SIB, and (ii) a decreased binding capacity in SGF, compared to the preformed amine polymer.
[0306] Embodiment 81. The process of embodiment 78, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride in SOB and a decreased binding capacity for phosphate, citrate and / or taurocholate in combination, compared to the preformed amine polymer, and (ii) a decreased binding capacity in SGF.
[0307] Embodiment 82. A process for preparing a crosslinked amine polymer, comprising crosslinking a preformed amine polymer in a reaction mixture to form a crosslinked amine polymer, the reaction mixture comprising a preformed amine polymer, a swelling agent for swelling the preformed amine polymer, and dichloroethane.
[0308] Embodiment 83 The process of embodiment 82, wherein the reaction mixture comprises a dispersion solvent.
[0309] Embodiment 84. The process of embodiment 82 or 83, wherein the reaction mixture comprises a dispersing solvent that is chemically inert to the preformed amine polymer.
[0310] Embodiment 85. The process of embodiment 82 or 83, wherein the reaction mixture comprises a dispersion solvent, and the dispersion solvent is dichloroethane.
[0311] Embodiment 86 The process of any one of embodiments 82 to 85, wherein the swelling agent and dichloroethane are immiscible.
[0312] Embodiment 87. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 4:1.
[0313] Embodiment 88. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 3:1.
[0314] Embodiment 89. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 2:1.
[0315] Embodiment 90. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 1:1.
[0316] Embodiment 91. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.5:1.
[0317] Embodiment 92. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.4:1.
[0318] Embodiment 93. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is less than 0.3:1.
[0319] Embodiment 94. The process of any of embodiments 82-86, wherein the weight ratio of swelling agent to preformed amine polymer in the reaction mixture is at least 0.15:1.
[0320] Embodiment 95. The process of any of embodiments 82-94, wherein the preformed amine polymer is deprotonated with a base before being crosslinked in the reaction mixture.
[0321] Embodiment 96 The process of any of embodiments 82-95, wherein the preformed amine polymer is crosslinked, and the crosslinks are predominantly carbon-carbon crosslinks.
[0322] Embodiment 97. The process of any one of embodiments 82 to 96, wherein the swelling agent is a polar solvent.
[0323] Embodiment 98. The process of any of embodiments 82-96, wherein the swelling agent is water, methanol, ethanol, n-propanol, isopropanol, n-butanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, propylene carbonate, or a combination thereof.
[0324] Embodiment 99. The process of any one of embodiments 82 to 96, wherein the swelling agent is water.
[0325] Embodiment 100. A preformed amine polymer comprises a residue of an amine corresponding to Formula 1: [ka] A process according to any one of embodiments 82 to 99.
[0326] Embodiment 101. A preformed amine polymer comprises a residue of an amine corresponding to formula 1a: [ka] wherein R4 and R5 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; the process of any of embodiments 82 to 99.
[0327] Embodiment 102. The process of embodiment 101, wherein R4 and R5 are independently hydrogen, aliphatic or heteroaliphatic.
[0328] Embodiment 103. The process of embodiment 101, wherein R4 and R5 are independently hydrogen, allyl, or aminoalkyl.
[0329] Embodiment 104 The process of any of embodiments 82-99, wherein the preformed amine polymer comprises a residue of an amine of Table C.
[0330] Embodiment 105. The process of any of embodiments 82-99, wherein the preformed amine polymer comprises residues of allylamine.
[0331] Embodiment 106 The process of any of embodiments 82-99, wherein the preformed amine polymer comprises residues of diallylpropyldiamine.
[0332] Embodiment 107. The process of any of embodiments 82-99, wherein the preformed amine polymer is a copolymer comprising residues of allylamine and diallylpropyldiamine.
[0333] Embodiment 108. The preformed amine polymer is characterized by a first selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIB and / or SOB, and the crosslinked polymer is characterized by a second selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIB and / or SOB: (i) the crosslinked polymer has increased chloride binding capacity and decreased phosphate binding capacity in SIB compared to the preformed amine polymer; (ii) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in SOB compared to the preformed amine polymer; (iii) the crosslinked polymer has an increased chloride binding capacity and a decreased citrate binding capacity in SOB compared to the preformed amine polymer; or (iv) The process of any one of embodiments 82-107, wherein the crosslinked polymer has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in SOB compared to the preformed amine polymer.
[0334] Embodiment 109. The process of embodiment 108, wherein the crosslinked polymer has a reduced binding capacity for chloride in SGF compared to the preformed amine polymer.
[0335] Embodiment 110. The process of embodiment 108, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride and a decreased binding capacity for phosphate in SIB, and (ii) a decreased binding capacity in SGF, compared to the preformed amine polymer.
[0336] Embodiment 111. The process of embodiment 108, wherein the crosslinked polymer after polymerization has (i) an increased binding capacity for chloride in SOB and a decreased binding capacity for phosphate, citrate and / or taurocholate in combination, compared to the preformed amine polymer, and (ii) a decreased binding capacity in SGF.
[0337] Embodiment 112. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 4 mmol / g.
[0338] Embodiment 113. A pharmaceutical composition comprising a crosslinked amine polymer having a ratio of chloride ion binding capacity to phosphate ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2.3:1, respectively.
[0339] Embodiment 114. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 1 mmol / g, a phosphate ion binding capacity in the SIB of less than 0.4 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively.
[0340] Embodiment 115. A pharmaceutical composition comprising a crosslinked amine polymer having a ratio of chloride ion binding capacity to phosphate ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2.3:1, respectively, and a swelling ratio of less than 5.
[0341] Embodiment 116. A pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content of at least 30% of the chloride initially bound in a GI Compartment Transit Assay ("GICTA").
[0342] Embodiment 117. A pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content in a GI Compartment Transit Assay ("GICTA") of at least 0.5 mmol of chloride / polymer (g).
[0343] Embodiment 118. A pharmaceutical composition comprising a crosslinked amine polymer, having a retained chloride content in a GI compartment transit assay ("GICTA") of at least 0.5 mmol of chloride / polymer (g) and a chloride retention at the end of the GICTA of at least 30% of the chloride initially bound in the GICTA.
[0344] Embodiment 119. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity of at least 5 mmol / g in a 1 hour simulated gastric fluid ("SGF") assay and a chloride ion binding capacity of at least 8 mmol / g in a 24 hour simulated gastric fluid ("SGF") assay.
[0345] Embodiment 120. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay that is at least 50% of its chloride ion binding capacity in a 24 hour simulated gastric fluid ("SGF") assay.
[0346] Embodiment 121. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay of at least 5 mmol / g, a chloride ion binding capacity in a 24 hour simulated gastric fluid ("SGF") assay of at least 8 mmol / g, and a chloride ion binding capacity in a 1 hour simulated gastric fluid ("SGF") assay that is at least 50% of the chloride ion binding capacity in the 24 hour simulated gastric fluid ("SGF") assay.
[0347] Embodiment 122. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 2.5 mmol of chloride / polymer (g).
[0348] Embodiment 123. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 2-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 0.5 mmol of chloride / polymer (g) and a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 2.5 mmol of chloride / polymer (g).
[0349] Embodiment 124. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2 mmol chloride / polymer (g) in 4 hours.
[0350] Embodiment 125. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2 mmol chloride / g of polymer (g) over 4 hours, and a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2 mmol chloride / g of polymer (g) over 24 hours.
[0351] Embodiment 126. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 24-hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 5.5 mmol of chloride / polymer (g).
[0352] Embodiment 127. A pharmaceutical composition comprising a crosslinked amine polymer described in any one of paragraphs
[0038] to
[0056] , wherein the crosslinked amine polymer has a pKa of at least 6 (measured at 100 mM NaCl, at equilibrium).
[0353] Embodiment 128. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 4 mmol / g in 1 hour.
[0354] Embodiment 129. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g.
[0355] Embodiment 130. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestinal inorganic buffer ("SIB") of at least 2 mmol / g in 1 hour.
[0356] Embodiment 131. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride to phosphate ion binding ratio in simulated small intestinal inorganic buffer ("SIB") of at least 2.3:1, respectively.
[0357] Embodiment 132. A pharmaceutical composition comprising a crosslinked amine polymer having (i) a proton binding capacity and chloride binding capacity of at least 5 mmol / g in artificial gastric fluid in 1 hour, and (ii) a proton binding capacity and chloride binding capacity of at least 8 mmol / g in artificial gastric fluid.
[0358] Embodiment 133. A pharmaceutical composition comprising a crosslinked amine polymer having a proton binding capacity and chloride binding capacity at 1 hour in artificial gastric fluid that is at least X% of the proton binding capacity and chloride binding capacity, respectively, of the crosslinked amine polymer at 24 hours in artificial gastric fluid, wherein X% is at least 50%.
[0359] Embodiment 134. A pharmaceutical composition comprising a crosslinked amine polymer having (i) selectivity for chloride over citrate, phosphate and taurocholate in simulated small intestinal organic and inorganic buffers ("SOB"), and (ii) a chloride binding capacity in SOB of at least 4 mmol / g at 24 hours.
[0360] Embodiment 135. A pharmaceutical composition comprising a crosslinked amine polymer having selectivity for chloride over citrate, phosphate and taurocholate in simulated small intestinal organic and inorganic buffers ("SOB") at (i) 1 hour, (ii) 4 hours, (iii) 12 hours, (iv) 18 hours, (v) 24 hours, (vi) 30 hours, (vii) 36 hours, or even (viii) 48 hours.
[0361] Embodiment 136. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g in simulated small intestinal inorganic buffer ("SIB") for (i) 1 hour, (ii) 2 hours, (iii) 3 hours, (iv) 4 hours, and / or (v) more than 4 hours.
[0362] Embodiment 137. A method for treating an acid / base disorder in an animal, including a human, by removing HCl through oral administration of a pharmaceutical composition according to any one of embodiments 122-136.
[0363] Embodiment 138. A method for treating an acid / base disorder in an animal, including a human, by scavenging HCl through oral administration of a pharmaceutical composition comprising a crosslinked amine polymer prepared by the process of any of embodiments 41-111.
[0364] Embodiment 139. A structure corresponding to formula 4: [ka] wherein each R is independently hydrogen or an ethylene bridge between two nitrogen atoms of the crosslinked amine polymer. [ka] and a, b, c, and m are integers.
[0365] Embodiment 140. The polymer of embodiment 139, wherein m is a large integer indicating an extended polymer network.
[0366] Embodiment 141. The polymer of embodiment 139 or 140, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1:1 to 5:1.
[0367] Embodiment 142. The polymer of embodiment 139 or 140, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1.5:1 to 4:1.
[0368] Embodiment 143. The polymer of embodiment 139 or 140, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1.75:1 to 3:1.
[0369] Embodiment 144. The polymer of embodiment 139 or 140, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 2:1 to 2.5:1.
[0370] Embodiment 145. The polymer of embodiment 139 or 140, wherein the sum of a and b is 57 and c is 24.
[0371] Embodiment 146. A polymer according to any of embodiments 139-145, wherein 50-95% of the R substituents are hydrogen and 5-50% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0372] Embodiment 147. A polymer according to any of embodiments 139-145, wherein 55-90% of the R substituents are hydrogen and 10-45% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0373] Embodiment 148. A polymer according to any of embodiments 139-145, wherein 60-90% of the R substituents are hydrogen and 10-40% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0374] Embodiment 149. A polymer according to any of embodiments 139-145, wherein 65-90% of the R substituents are hydrogen and 10-35% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0375] Embodiment 150. A polymer according to any of embodiments 139-145, wherein 70-90% of the R substituents are hydrogen and 10-30% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0376] Embodiment 151. A polymer according to any of embodiments 139-145, wherein 75-85% of the R substituents are hydrogen and 15-25% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0377] Embodiment 152. A polymer according to any of embodiments 139-145, wherein 80-85% of the R substituents are hydrogen and 15-205% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
[0378] Embodiment 153. A polymer according to any of embodiments 139-145, wherein about 81% of the R substituents are hydrogen and about 19% are ethylene bridges.
[0379] Embodiment 154. A pharmaceutical composition comprising a pharma- ceutically acceptable excipient and a crosslinked amine polymer according to any one of embodiments 139-153.
[0380] Embodiment 155. A method for treating an acid / base disorder in an animal, including a human, by removing HCl through oral administration of the pharmaceutical composition of embodiment 154.
[0381] Although the present invention has been described in detail, it will be apparent that modifications and variations are possible without departing from the scope of the invention as defined in the appended claims. Moreover, it should be understood that all embodiments in the present disclosure are provided as non-limiting examples. Working Example
[0382] The following non-limiting examples are provided to further illustrate the present invention. It should be understood by those skilled in the art that the techniques disclosed in the examples that follow represent approaches that the inventors have found to work well in the practice of the present invention, and therefore may be considered to constitute examples of forms for practical use. However, those skilled in the art should understand in light of this disclosure that many changes may be made without departing from the spirit and scope of the present invention in the specific embodiments disclosed and still obtain similar or similar results.
[0383] General procedure for DCE dispersive crosslinking The dried preformed amine polymer beads were added to a reaction vessel equipped with a stirring paddle and nitrogen gas inlet. 1,2-dichloroethane (DCE) was added to the beads. The beads were dispersed in the DCE using mechanical stirring. Water was added directly to the dispersion and stirring was continued for 30 minutes. After 30 minutes, the flask was immersed in an oil bath held at a selected temperature. The reaction was kept in the oil bath and stirred using mechanical stirring under a nitrogen atmosphere for a selected time. Methanol was added to the reaction and the solvent was removed by decanting. The beads were then filtered and purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0384] Example procedure for DCE distributed crosslinking Unless otherwise stated, the following exemplary procedure is the standard procedure for all of the examples in this section. Specifically, it shows a bead to DCE (g / mL) ratio of 1:6, a water to bead mass ratio of 0.25:1, a jacket (oil bath) temperature of 70° C., and a reaction time of 16 hours.
[0385] Dry preformed amine polymer beads (15.00 g) were added to a 250 mL round bottom flask equipped with a stirring paddle and nitrogen gas inlet. 1,2-dichloroethane (DCE) was added to the beads (90 mL, resulting in a 1:6 bead to DCE (g / mL) ratio). The beads were dispersed in the DCE using mechanical stirring (agitation at approximately 150 rpm). Water (3.75 mL, resulting in a 0.25:1 water to bead mass ratio) was added directly to the dispersion and stirring was continued for 30 minutes. After 30 minutes, the flask was immersed in an oil bath held at 70° C. The reaction was kept in the oil bath and stirred under a nitrogen atmosphere for 16 hours using mechanical stirring. Methanol (100 mL) was added to the reaction and the solvent was removed by decantation. The beads were then filtered and then purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0386] Effect of water on the DCE dispersion crosslinking reaction The effect of the amount of water added to the example reaction mixture was investigated (Table 1). Under these conditions, chloride binding in SIB and SOB increased, while phosphate, citrate and taurocholate binding decreased from that of the preformed amine polymer (sample 019069-A1). The particle size decreased after the second step crosslinking. The water content that gave the greatest selectivity and the greatest total chloride binding as measured in SIB was found to be in the water-to-bead ratio range of 0.25-0.35.
[0387] Preformed amine polymer beads, dry beads as a source for the DCE distributed crosslinking reaction, were prepared as follows: Two aqueous stock solutions (50% w / w) of monomers were prepared by independently dissolving 43.83 g of allylamine hydrochloride and 45.60 g of DAPDA in water. A three-necked 2 L round bottom flask equipped with an overhead stirrer (stirring at 180 rpm), four side baffles equipped with a Dean-Stark apparatus and condenser, and a nitrogen inlet was charged with 12 g of surfactant (Stepan Sulfonic 100) dissolved in 1,200 g of heptane / chlorobenzene solution (26 / 74 v / v), followed by the aqueous stock solutions, and an additional portion of water (59.14 g). In a separate vessel, a 15 wt % aqueous solution of initiator V-50 (9.08 g) was prepared. The two mixtures were independently sparged with nitrogen while the reaction vessel was brought to 67° C. in an oil bath (approximately 30 min). The initiator solution was added to the reaction mixture under an inert atmosphere, followed by heating at 67° C. for 16 hours. A second aliquot of the initiator solution (equal to the first) and the reaction mixture were sparged with nitrogen for 30 minutes, combined, and the temperature was then increased to 115° C. for a final dehydration step (Dean-Stark). The reaction was cooled to room temperature until water was removed from the Dean-Stark trap (6 hours, 235 mL removed, >90% of total water, T 内部 The reaction was held at 115°C until collection was stopped at 100°C (>99°C). The reaction was cooled to room temperature, stirring was stopped and the beads were allowed to settle. The organic phase was decanted off the bead cake. The beads were purified by washing (2xMeOH, 1xH2O, 2x1N HCl, 1xH2O, 3x1N NaOH, then H2O until the pH of the solution after washing was 7) and dried by lyophilization. [Table 5]
[0388] Time and temperature effects The effect of temperature on the reaction and subsequently the progress of the reaction as a function of time was investigated. In these experiments, the desired performance could be achieved at all temperatures investigated between 55° C. and 70° C., but the progress of the reaction was found to be slower at lower temperatures (Tables 2, 3, 4 and 5). [Table 6]
[0389] [Table 7]
[0390] [Table 8]
[0391] [Table 9]
[0392] Effect of DCE to preformed amine polymer ratio on second step crosslinking The effect of the amount of DCE added to the reaction mixture to disperse the beads was investigated (Table 6). Under these conditions, it was found that the ratio of DCE to beads (preformed amine polymer) did not substantially change the chloride binding or selectivity in the SIB or SOB. Note that a ratio of 3:1 is approximately the minimum to have enough DCE to disperse the beads.
[0393] [Table 10]
[0394] Effect of HCl in preformed amine polymers on second step crosslinking The effect of residual hydrochloric acid in the preformed amine polymer (e.g., due to insufficient washing) on second step crosslinking was investigated (Table 7). In these experiments, it was found that chloride selectivity and binding capacity were unaffected when less than 3% of the amines in the preformed amine polymer were protonated.
[0395] [Table 11]
[0396] -2) General Procedure for Solvent-Dispersed Cross-Linked DCE The dried preformed amine polymer beads were added to a reaction vessel equipped with a stirring paddle and nitrogen gas inlet. An inert (i.e., not a crosslinker) dispersing solvent was added to the beads. The beads were dispersed in the solvent using mechanical stirring. Water was added directly to the dispersion and stirring was continued for 30 minutes. Neat dichloroethane was added to the flask, which was then immersed in an oil bath heated to the selected temperature. The reaction was heated under a nitrogen atmosphere using mechanical stirring for 16 hours. Methanol was added to the reaction and the solvent was removed by decanting. The beads were then filtered and purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0397] - Example procedure for solvent-dispersed crosslinking-DCE crosslinker Unless otherwise stated, the following exemplary procedure is the standard procedure for all of the examples in this section. Specifically, it shows a bead to dispersion solvent (g / mL) ratio of 1:6, a water to bead mass ratio of 1:1, a jacket temperature of 70° C., and a reaction time of 16 hours.
[0398] Dry beads (3.00 g) were added to a 250 mL round bottom flask equipped with a stirring paddle and nitrogen gas inlet. Heptane was added to the beads (18 mL, resulting in a 1:6 bead to DCE (g / mL) ratio). The beads were dispersed in the heptane using mechanical stirring (agitation at approximately 100 rpm). Water (3 mL, resulting in a 1:1 water to bead ratio) was added directly to the dispersion and stirring was continued for 20 minutes. Neat dichloroethane (3.57 g, 35.9 mmol) was added to the flask, which was then heated to 70° C. The reaction was heated under a nitrogen atmosphere using mechanical stirring for 16 hours. Methanol (100 mL) was added to the reaction and the solvent was removed by decantation. The beads were then filtered and then purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0399] Effect of the amount of DCE crosslinker on heptane-dispersed reactions The effect of the amount of DCE added to the inert solvent-dispersed second step crosslinking was investigated (Table 8). In these experiments, 2 equivalents of DCE (relative to the nitrogen in the preformed amine polymer) produced a material with the best combination of high selectivity and high chloride binding as measured in SIB and SOB.
[0400] [Table 12]
[0401] Dispersion solvent - Effect of DCE crosslinker The effect of using different inert dispersing solvents was investigated (Table 9). Dimethylformamide (DMF, water miscible) was found to give materials with high chloride binding in SOB, but relatively low chloride selectivity and chloride binding in SIB. The addition of water to the DMF reaction mixture did not affect SIB performance, but greatly reduced chloride selectivity and binding in SOB.
[0402] [Table 13]
[0403] 3) Solvent-dispersed crosslinking: General procedure for DCE / DCP mixed crosslinker system The dried preformed amine polymer beads were added to a reaction vessel equipped with a stirring paddle and nitrogen gas inlet. 1,3-dichloropropane (DCP) and 1,2-dichloroethane (DCE) were added sequentially to the beads. The beads were dispersed in the DCE / DCP solution using mechanical stirring. Water was added directly to the dispersion and stirring was continued for 30 minutes. After 30 minutes, the flask was immersed in an oil bath held at a selected temperature. The reaction was kept in the oil bath and stirred using mechanical stirring under a nitrogen atmosphere for a selected time. Methanol was added to the reaction and the solvent was removed by decanting. The beads were then filtered and purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0404] Solvent-dispersed crosslinking: A specific example procedure for a DCE / DCP mixed crosslinker system Unless otherwise stated, the following exemplary procedure is the standard procedure for all of the examples in this section. Specifically, it shows a bead to crosslinker (g / mL) ratio of 1:6, a water to bead mass ratio of 1:1, a jacket (oil bath) temperature of 70° C., and a reaction time of 16 hours.
[0405] Dry preformed amine polymer beads (3.00 g) were added to a 100 mL round bottom flask equipped with a stirring paddle and nitrogen gas inlet. DCP (4.30 mL) and DCE (13.70 mL) were added to the beads, resulting in a mass / volume ratio of beads to DCE of 1:6. The beads were dispersed in the DCE using mechanical stirring (agitation at approximately 150 rpm). Water (3.00 mL, resulting in a water to beads mass ratio of 1:1) was added directly to the dispersion and stirring was continued for 30 minutes. After 30 minutes, the flask was immersed in an oil bath held at 70° C. The reaction was kept in the oil bath and stirred under a nitrogen atmosphere for 16 hours using mechanical stirring. Methanol (60 mL) was added to the reaction and the solvent was removed by decantation. The beads were then filtered and then purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization.
[0406] DCE / DCP Dispersive Crosslinking - Effect of DCE Amount The effect of using different ratios in a mixed crosslinker system where the crosslinker(s) is also the dispersing solvent was investigated (Table 10). It was found that increasing the amount of DCP resulted in a decrease in selectivity for chloride over phosphate in the SIB.
[0407] [Table 14]
[0408] DCE / DCP Dispersion Crosslinking - Effect of Water Content The effect of water content added to the mixed crosslinker in the second step crosslinking was tested (Table 11). Under these conditions, the ideal water content was found to be 0.5-1.0 g water / g preformed amine polymer.
[0409] [Table 15]
[0410] Effect of the amount of heptane on the mixed crosslinker system DCE / DCP The effect of diluting the mixed DCE / DCP crosslinker system with heptane was investigated (Table 12). As the amount of heptane was increased (e.g., 80% heptane), the reaction mixture more closely resembled a crosslinking reaction in which the dispersing solvent was an inert solvent (i.e., not a crosslinker). Under these conditions, both the chloride selectivity and total chloride binding in the SIB decreased as more heptane was added. Alternatively, both the selectivity and total chloride binding as measured by SOB were substantially unaffected up to 40% heptane by volume.
[0411] [Table 16]
[0412] -4) "Non-dispersive" reactive crosslinking - General procedure for DCP crosslinkers Dry preformed amine polymer beads were added to the reaction vessel. Water was added to the beads. The beads were then gently stirred with a spatula to ensure uniform wetting of the beads with the water. The beads were equilibrated for 20 minutes. Neat dichloropropane was added to the vial and the beads were stirred again with a spatula. The vial was heated to 70° C. for 16 hours. Methanol was added to the reaction. The beads were filtered and then purified by washing (2×MeOH, 1×H2O, 2×1N HCl, 1×H2O, 3×1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0413] - "Non-dispersive" reactive crosslinking - specific example procedure for DCP crosslinker Unless otherwise stated, the following exemplary procedure is the standard recipe for all of the examples in this section. Specifically, it shows a DCP (molar ratio of DCP to total nitrogen in the preformed amine polymer) ratio of 0.68 mol equivalents, a water to bead mass ratio of 0.25:1, a jacket (heating mantle) temperature of 70° C., and a reaction time of 16 hours.
[0414] Dry preformed amine polymer beads (0.40 g) were added to a 20 mL scintillation vial. Water was added to the beads (0.10 g, resulting in a water to bead mass ratio of 0.25:1). The beads were then gently stirred with a spatula to ensure uniform wetting of the beads with the water. The beads were equilibrated for 20 minutes. Neat 1,3-dichloropropane (0.46 g, 4.1 mmol, 0.68 molar equivalents of DCP / 1 mol of nitrogen in preformed amine polymer) was added to the vial and the beads were stirred again with a spatula. The vial was heated to 70° C. for 16 hours. Methanol (10 mL) was added to the reaction. The beads were filtered and then purified by washing (2×MeOH, 1×H2O, 2×1N HCl, 1×H2O, 3×1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0415] Effect of water content on non-dispersive crosslinking reactions The effect of added water on the non-dispersive crosslinking reaction was investigated (Table 13). In these experiments, it was found that the water content that gave the highest selectivity and highest chloride binding measured in the SIB was a water to bead ratio of less than 0.5:1.
[0416] [Table 17]
[0417] Effect of DCP crosslinker molar equivalent on "non-dispersive" reactive crosslinking The effect of the amount of DCP added to the non-dispersive crosslinking reaction was investigated (Table 14). Under these conditions, it was found that the molar equivalents of DCP that gave the highest selectivity and highest total chloride binding measured in SIB was less than 0.5:1 water to bead ratio.
[0418] [Table 18]
[0419] 5) Solvent-dispersed crosslinking--General procedure for DCP crosslinkers The dried preformed amine polymer beads were added to a reaction vessel equipped with a stirring paddle and nitrogen gas inlet. An inert (i.e., not a crosslinker) dispersing solvent was added to the beads. The beads were dispersed in the solvent using mechanical stirring. Water was added directly to the dispersion and stirring was continued for 30 minutes. Neat 1,3-dichloropropane (DCP) was added to the flask, which was then immersed in an oil bath heated to 70°C. The reaction was heated under nitrogen atmosphere using mechanical stirring for 16 hours. Methanol was added to the reaction and the solvent was removed by decanting. The beads were then filtered and purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0420] -Solvent-dispersed crosslinking --Specific procedures for DCP crosslinkers Unless otherwise stated, the following exemplary procedure is the standard recipe for all of the examples in this section. Specifically, it shows a bead to dispersion solvent (g / mL) ratio of 1:6, a water to bead mass ratio of 1:1, 1 molar equivalent of DCP relative to nitrogen in the preformed amine polymer, a jacket (heating mantle) temperature of 70° C., and a reaction time of 16 hours.
[0421] Dry preformed amine polymer beads (3.00 g) were added to a 100 mL round bottom flask with a stirring paddle and nitrogen gas inlet. An inert (i.e., not a crosslinker) dispersing solvent was added to the beads (18 mL, resulting in a 1:6 bead to solvent (g / mL) ratio). The beads were dispersed in the solvent using mechanical stirring. Water (3 mL, resulting in a 1:1 water to bead mass ratio) was added directly to the dispersion and stirring was continued for 30 minutes. Neat 1,3-dichloropropane (DCP) (5.22 g, 46.2 mmol) was added to the flask, which was then immersed in an oil bath heated to 70° C. The reaction was heated under a nitrogen atmosphere for 16 hours using mechanical stirring. Methanol (100 mL) was added to the reaction and the solvent was removed by decanting. The beads were then filtered and then purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0422] - Heptane dispersion reaction - Effect of molar equivalent of crosslinker on DCP crosslinker The effect of the equivalent amount of DCP added to the inert solvent-dispersed second step crosslinking was investigated (Table 15). In these experiments, 1.0-1.2 molar equivalents of DCP relative to the nitrogen in the preformed amine polymer produced materials with the best combination of high selectivity and high total chloride binding measured in SIB and SOB (Table 15). Effect of water content in DCP-heptane reaction on chloride selectivity. (100 mL vessel, 1 g beads, 1:3 bead to heptane (g / mL) ratio, 1:1 water to bead mass ratio, 70° C., 16 hours, no Dean-Stark). The exemplary procedure above was used, but with a 1:3 bead to heptane (g / mL) ratio.
[0423] [Table 19]
[0424] Heptane dispersion reaction - Effect of water on DCP crosslinker The effect of the amount of water added to the inert solvent-dispersed second step crosslinking was investigated (Table 16). Under these conditions, a water content of less than 0.5:1 water to bead ratio produced materials with the best combination of high selectivity and high total chloride binding measured in SIB and SOB.
[0425] [Table 20]
[0426] Dispersion solvent - Effect of DCP crosslinker Examples of second step crosslinking of preformed amine polymer using various non-polar dispersion solvents are summarized in Table 17. Reactions with 1-octanol and 2-MeTHF were carried out on 0.4 g of preformed amine polymer in a 20 mL scintillation vial using a 1:10 bead to solvent (g / mL) ratio and 0.68 molar equivalents of DCP per mole of nitrogen in the preformed amine polymer. Cyclohexane was used in the exemplary procedure on a 1 g scale using a 1:3 bead to solvent (g / mL) ratio. Chlorobenzene reactions used the exemplary procedure.
[0427] [Table 21]
[0428] Water-miscible Dispersing Solvent-DCP Crosslinker Examples of second-step crosslinking of preformed amine polymer using various water-miscible dispersing solvents were compiled, using the exemplary procedure above, but on 0.5 g of preformed amine polymer in a scintillation vial, and no water was added to any of the reactions.
[0429] [Table 22]
[0430] Alternative Swelling Agents In most of the examples in Table 17 (except DMF), water is added to swell the beads and is immiscible with the dispersing solvent used. The effect of alternative immiscible non-aqueous swelling agents is summarized in Table 19. Reactions using methanol were carried out on 0.5 g of preformed amine polymer in a 20 mL scintillation vial. The exemplary procedure above was followed by reactions using DMF. All of the conditions tested produced materials with lower selectivity and total chloride binding than similar reactions where water was the swelling agent of choice.
[0431] [Table 23]
[0432] 6) General Procedure for Ammonium Hydroxide Treatment After Post-Curing The general procedure can be performed with beads purified by washing and dried by lyophilization, or with beads partially purified by washing. In the latter case, treatment with ammonium hydroxide is typically performed after three methanol washes, and normal purification by washing is resumed with a wash with 1N HCl.
[0433] To the post-crosslinked beads (either dried or in the process of being washed), an aqueous NH4OH solution preheated to the desired reaction temperature was added. The beads were dispersed in the solution using mechanical stirring and heated in the ammonium hydroxide solution for the selected time. After the treatment was completed, the beads were filtered and then purified by washing (2 times 1N HCl, 1 time H2O, 3 times 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0434] Example Procedure for Ammonium Hydroxide Treatment After Post-Curing Secondary crosslinking was performed by reacting the preformed amine polymer (100 g of dried beads) with DCE in the presence of water as a swelling agent. After reaction, the beads were filtered and washed three times with methanol. The wet beads were transferred to a 2000 mL round bottom flask equipped with a nitrogen inlet and an overhead stirrer. The beads were added to a 1000 mL (10:1::1N NH4OH:1N NH4OH solution of dried beads (mL / g) preheated to 70°C. The round bottom flask was immersed in an oil bath heated to 75°C and the beads were stirred under nitrogen atmosphere for 4 hours. The beads were filtered and then purified by washing (2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7). The purified beads were then dried by lyophilization for 48 hours.
[0435] Ammonia treatment as part of the cleaning protocol Ammonia treatment of the post-crosslinked polymer was carried out according to the exemplary procedure above, except that 10 g of beads were used, 0.5 g samples were taken, and the jacket temperature was 75° C. Ammonia treatment was carried out as part of the wash after the methanol wash and before the 1N HCl wash. Treatment time was varied between 0 and 24 hours. The data is summarized in Table 20.
[0436] [Table 24]
[0437] Ammonia treatment of post-crosslinked, purified and dried beads Ammonia treatment of the post-crosslinked polymer was carried out according to the exemplary procedure above, except that the treatment was carried out after the post-crosslinked polymer had been purified and dried (Table 21).
[0438] [Table 25]
[0439] 7) Example of the effect of heating the post-crosslinked polymer during the drying process on chloride selectivity in SOB Preformed amine polymer beads were prepared as follows: Two aqueous stock solutions (50% w / w) of monomers were prepared by independently dissolving allylamine hydrochloride (93.9 g) and DAPDA (97.7) in water. A 3 L Ace glass jacketed reactor equipped with an overhead stirrer (stirring at 180 rpm), addition funnel, temperature probe, and nitrogen inlet was charged with Stepan Sulf-100 (25.7 g) dissolved in a heptane / chlorobenzene solution (26 / 74 v / v, 2571.4 g), followed by the aqueous stock solutions, and additional water (126.7 g). In a separate vessel, a 15 wt % aqueous solution of V-50 (19.4 g) was prepared and added to the addition funnel. The two mixtures were heated to 67° C. (T 内部 The reaction mixture was sparged independently with nitrogen while at >60°C. Under an inert atmosphere, the initiator solution was added to the reaction mixture, followed by heating at 67°C for 16 hours. A second aliquot of initiator solution (equal to the first) and the reaction mixture were sparged with nitrogen for 30 minutes and combined before the temperature was increased to 115°C for a final dehydration step (Dean-Stark). The reaction was cooled to 100°C until water was removed from the Dean-Stark trap (6 hours, >90% of total water removed, T 内部 The reaction was held at 115°C until collection was stopped at 100°C (>99°C). The reaction was cooled to room temperature and stirring was stopped to allow the beads to settle. The organic phase was siphoned off the bead cake and methanol was added (1 L) to resuspend the beads (with stirring at 150 rpm). The organic solvent removal step was repeated twice. The beads were drained into a 2 L media bottle and the reactor was rinsed with methanol (500 mL). The beads were purified by washing (2x MeOH, 1x H2O, 2x 1N HCl, 1x H2O, 3x 1N NaOH, then H2O until the pH of the solution after washing was 7) and dried by lyophilization.
[0440] The preformed amine polymer beads were subjected to a second step of crosslinking according to the general procedure for solvent dispersion crosslinking:DCE using the specific exemplary procedure above to scale to 10 g of preformed amine polymer beads. At the end of the washing step, the resulting polymer was dried again in either a freeze dryer or a conventional oven at 60° C. for 40 hours. The oven dried polymer had similar binding in SIB but improved chloride binding in SOB compared to the freeze dried polymer (Table 22).
[0441] [Table 26]
[0442] 8) Example of binding reaction rate Selected polymers were evaluated in SGF, SIB and SOB assays (as described elsewhere) for samples taken at multiple time points (1, 2, 4 and 24 hours incubation) to assess anion binding kinetics under these assay conditions. Results are shown below in Tables 23, 24 and 25, which represent three sets of experiments. These polymers were synthesized by subjecting preformed amine polymers, prepared using the general method for preparing preformed amine polymers described above, to a second step of crosslinking according to the "General Procedure for Solvent Dispersed Crosslinking-DCE" described above.
[0443] [Table 27]
[0444] [Table 28]
[0445] [Table 29] [Table 30] [Table 31]
[0446] Equilibrium chloride binding measurements on amine polymers The pH-dependent equilibrium chloride binding of selected polymers was measured using an autotitrator. The polymers were incubated at room temperature for 16 hours in a solution containing 100 mM sodium chloride at a starting concentration of 4 mg / mL. The samples were continuously stirred and maintained at a set pH throughout the incubation via slow addition of 0.1 N HCl solution by the autotitrator. After incubation, 400 microliters of sample was removed, filtered, diluted as necessary, and then assayed for chloride content using ion chromatography. For each polymer tested, chloride binding was calculated using the following formula: ({[Cl] 開始 +[Cl] HCl}-[Cl] 最終 ) / concentration (mg / mL) x dilution factor
[0447] In the formula, [Cl] 開始 is the starting chloride concentration in the incubation solution (mM), [Cl] HCl is the chloride added via autotitration with 0.1 N HCl (mM), and Conc (mg / mL) is the final concentration of polymer in solution (after accounting for the volume of 0.1 N HCl added).
[0448] Equilibrium chloride binding was measured using the above method at pH ranging from 1.5 to 12. A plot of chloride binding versus pH allows for the construction of a titration curve and the determination of the average pK for a given polymer (Figure 3). The following example shows the equilibrium chloride binding (Table 26) and a plot of chloride binding versus pH (see Figure 2), for example, of 019067-A2 in the free amine form, measured using the above procedure.
[0449] The average pKa for this example was determined to be 6.15. The data was fitted using a fourth order polynomial fit. The equilibrium chloride binding at various pH values was calculated from the equation obtained by the curve fit, and the pH value where half maximum binding was observed was taken as the average pKa for the polymer.
[0450] [Table 32]
[0451] 9) GICTA data example The polymers listed in the following table were synthesized by subjecting preformed amine polymers prepared using the general method for preparing preformed amine polymers described above to a second step of crosslinking according to the "General Procedure for Solvent Dispersed Crosslinking-DCE" or "General Procedure for Solvent Dispersed Crosslinking-DCE / DCP Mixed Crosslinker System" described above. For 019067-A2, water removal was performed by applying an additional Dean-Stark step after the reaction. The resulting polymers were evaluated using the GICTA assay. The results are listed in Table 27.
[0452] [Table 33]
[0453] 10) Example of preparation of polymer from polyallylamine Examples for the preparation of polyallylamine / DCE preformed amine polymers To a 500 mL round bottom flask was added polyallylamine (14 g, 15 kDa) and water (28 mL). The solution was purged with nitrogen and overhead stirred at 220 rpm for 1 hour to completely dissolve the polymer. 30 wt% aqueous NaOH (7 mL) was then added and stirred for 5 minutes. To the aqueous solution was added a pre-made solution of DCE (175 mL), n-heptane (105 mL), and Span 80 (2.8 g). The solution was heated to 70° C. and stirred for 16 hours. The Dean-Stark step was initiated by adding cyclohexane (100 mL) and heating the reaction to 95° C. to remove water (>90%) from the beads (Table 28).
[0454] Specific examples of polyarylamine / DCP preformed amine polymers To a 100 mL round bottom flask were added DCP (31 mL), n-heptane (19 mL), and Span80 (0.5 g). A separate aqueous stock solution of polyallylamine (2.3 g, 900 kDa), aqueous NaOH (1 mL, 30 wt%), and water (4 mL) was prepared. The aqueous stock solution was added to the organic solution in the round bottom flask. The solution was purged with nitrogen for 15 minutes, heated to 70° C., and stirred for 16 hours. Methanol (30 mL) was added to the reaction mixture, and the organic solvent was removed by decantation. The resulting beads were purified and isolated by washing the beads using MeOH, HCl, sodium hydroxide solution, and water. The beads were dried using freeze drying technique (Table 28).
[0455] Specific Example for Polyallylamine / Dichloro-2-propanol Preformed Amine Polymer Polyallylamine 15 kDa (3.0 g) and water (9.05 g) were dissolved in a conical flask. Sodium hydroxide (0.71 g) was added to the solution and the mixture was stirred for 30 minutes. 0.38 g of sorbitan sesquioleate and 37.9 g of toluene were added to a 100 mL round bottom flask equipped with a side arm and an overhead stirrer. The overhead stirrer was turned on to provide agitation to the reaction solution. Dichloropropanol (0.41 g) was added directly to the polyallylamine solution with stirring. The resulting aqueous polyallylamine solution was added to the toluene solution in the 100 mL flask. The reaction was heated to 50° C. for 16 hours. After this time, the reaction was heated to 80° C. for 1 hour and then cooled to room temperature. The resulting beads were purified and isolated by washing the beads using MeOH, HCl, aqueous sodium hydroxide, and water. The beads were dried using a freeze drying technique (Table 28).
[0456] Specific examples of polyallylamine / epichlorohydrin preformed amine polymers Polyallylamine 15 kDa (3.1 g) and water (9.35 g) were dissolved in a conical flask. Sodium hydroxide (0.73 g) was added to the solution and the mixture was stirred for 30 minutes. To a 100 mL round bottom flask equipped with a side arm and an overhead stirrer, 0.31 g of sorbitan trioleate and 39.25 g of toluene were added. The overhead stirrer was turned on to provide agitation to the reaction solution. The aqueous polyallylamine solution was added to the toluene solution in the 100 mL flask. Epichlorohydrin (0.30 g) was added directly to the reaction mixture using a syringe. The reaction was heated to 50° C. for 16 hours. After this time, the reaction was heated to 80° C. for 1 hour and then cooled to room temperature. The resulting beads were purified and isolated by washing the beads using MeOH, HCl, aqueous sodium hydroxide, and water. The beads were dried using a freeze drying technique.
[0457] Preformed amine polymer beads can be formed by reaction of a soluble (uncrosslinked) polymer with a crosslinker. In this experiment, the soluble polymer was linear polyallylamine and was crosslinked with a bifunctional crosslinker. When the crosslinking reaction occurs in the aqueous phase, an aqueous-soluble crosslinker may be chosen for these polymerizations. However, there are aqueous-immiscible crosslinkers (e.g., DCE and DCP) that can result in higher capacity polyamine beads due to their small molecular weight. In order to fully crosslink the linear polyallylamine, an aqueous-immiscible crosslinker was used as a crosslinking cosolvent during bead formation. Polyamine beads formed with an aqueous-immiscible crosslinker produced a higher total chloride binding capacity (as described by SGF) than those made with an aqueous-miscible crosslinker (Table 28).
[0458] [Table 34]
[0459] Specific examples of post-crosslinking of PAH / DCE preformed amine polymers To a 100 mL round bottom flask was added preformed polyamine beads (0.5 g) and DCE (3 mL). The solution was purged with nitrogen and overhead stirred for 5 minutes. Water was added (0.5 g) and the solution was stirred for 20 minutes. The reaction mixture was then heated to 70° C. and stirred for 16 hours. Methanol (5 mL) was added to the reaction mixture, stirring was stopped, and the solvent was decanted off (Table 29).
[0460] Specific example of polyallylamine / dichloro-2-propanol preformed amine polymer post-crosslinking To a 20 mL vial was added preformed polyamine beads (0.4 g) and methanol (2.8 g). DCP was added (0.5 g for 002064-B4 FA, 0.7 g for 002064-B5 FA). The reaction mixture was then heated to 70° C. and stirred for 16 hours. The temperature was increased to 80° C. over 1 hour. Methanol (5 mL) was added to the reaction mixture and the solvent was removed by decantation.
[0461] Polyamine beads formed with linear polyallylamine and aqueous-immiscible crossl...
Claims
1. 1. A process for the preparation of a crosslinked amine polymer, comprising: (i) swelling a preformed amine polymer with a swelling agent; (ii) dispersing the preformed amine polymer in a reaction mixture comprising a dispersing solvent, a crosslinking agent, and the swelling agent; and (iii) crosslinking the preformed amine polymer in the reaction mixture to form the crosslinked amine polymer, wherein the preformed amine polymer is crosslinked and has an absorption capacity for the swelling agent, and the amount of the swelling agent in the reaction mixture is less than the absorption capacity of the preformed amine polymer for the swelling agent.
2. 10. The process of claim 1 further comprising deprotonating the preformed amine polymer with a base prior to swelling with the swelling agent.
3. 3. The process of claim 1 or 2, wherein the crosslinks in the preformed amine polymer are predominantly carbon-carbon crosslinks and nitrogen-nitrogen crosslinks are predominantly formed in the crosslinking step.
4. 2. The process of any preceding claim, wherein the preformed amine polymer has a chloride binding capacity in simulated gastric fluid ("SGF") of at least 10 mmol / g and a swelling ratio in the range of 2 to 10, and the crosslinked amine polymer has a binding capacity for phosphate, citrate and / or taurocholate in SIBs or SOBs that is less than the binding capacity of the preformed amine polymer for phosphate, citrate and / or taurocholate in the same assays.
5. 13. The process of any preceding claim, wherein the dispersion solvent comprises a non-polar solvent.
6. 2. The process of any preceding claim, wherein the dispersing solvent comprises a solvent that is chemically inert to the preformed amine polymer.
7. 10. The process of any preceding claim, wherein the dispersing solvent comprises a cross-linking solvent.
8. The process of any of claims 1 to 4, wherein the crosslinking agent is the dispersion solvent.
9. 10. The process of any preceding claim, wherein the swelling agent and the dispersion solvent are immiscible.
10. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 4:
1.
11. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 3:
1.
12. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 2:
1.
13. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 1:
1.
14. 1. A process for the preparation of a crosslinked amine polymer, comprising: (i) swelling a preformed amine polymer with a swelling agent; and (ii) crosslinking the preformed amine polymer to form the crosslinked amine polymer in a reaction mixture comprising a crosslinking agent and the swelling agent, wherein the preformed amine polymer is crosslinked and has an absorption capacity for the swelling agent, the amount of the swelling agent in the reaction mixture is less than the absorption capacity of the preformed amine polymer for the swelling agent, and the weight ratio of swelling agent to the preformed amine polymer in the reaction mixture is less than 1:
1.
15. 10. The process of any preceding claim, wherein the swelling agent is a polar solvent.
16. 10. The process of any preceding claim, wherein the swelling agent is water, methanol, ethanol, n-propanol, isopropanol, n-butanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, propylene carbonate, or a combination thereof.
17. 10. The process of any preceding claim, wherein the swelling agent is water.
18. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 0.5:
1.
19. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 0.4:
1.
20. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 0.3:
1.
21. 2. The process of any preceding claim, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is at least 0.15:
1.
22. 2. The process of any preceding claim, wherein the crosslinker comprises at least two amine-reactive functional groups.
23. The process of any preceding claim, wherein the crosslinker is a compound containing at least two amine reactive groups selected from the group consisting of alkyl halides, epoxides, phosgene, anhydrides, carbamates, carbonates, isocyanates, thioisocyanates, esters, activated esters, carboxylic acids and their derivatives, sulfonates and their derivatives, acyl halides, aziridines, α,β-unsaturated carbonyls, ketones, aldehydes, and pentafluoroaryl groups.
24. 2. The process of any preceding claim, wherein the crosslinking agent is a crosslinking agent selected from Table B.
25. 10. The process of any preceding claim, wherein the cross-linking agent is a dichloroalkane.
26. 10. The process of any preceding claim, wherein the crosslinking agent is dichloroethane or dichloropropane.
27. 10. The process of any preceding claim, wherein the swelling agent and the crosslinking agent are immiscible.
28. 10. The process of any preceding claim, wherein the preformed polymer is combined with the crosslinker and the dispersing solvent before the polymer is swelled with the swelling agent.
29. 2. The process of any preceding claim, further comprising forming the preformed amine polymer in a solvent system, wherein the crosslinked amine polymer is formed without isolating the preformed amine polymer from the solvent system.
30. The preformed amine polymer comprises a residue of an amine corresponding to Formula 1: 【Chemistry 1】 A process as claimed in any preceding claim.
31. The preformed amine polymer comprises the residue of an amine corresponding to formula 1a: 【Chemistry 2】 In the formula, R 4 and R 5 is independently hydrogen, hydrocarbyl, or substituted hydrocarbyl.
32. R 4 and R 5 32. The process of claim 31 , wherein is independently hydrogen, aliphatic or heteroaliphatic.
33. R 4 and R 5 32. The process of claim 31 , wherein is independently hydrogen, allyl, or aminoalkyl.
34. The process of any preceding claim, wherein the preformed amine polymer comprises a residue of an amine of Table C.
35. 2. The process of any preceding claim, wherein the preformed amine polymer comprises residues of allylamine.
36. 2. The process of any preceding claim, wherein the preformed amine polymer comprises residues of diallylpropyldiamine.
37. 2. The process of any preceding claim, wherein the preformed amine polymer is a copolymer comprising residues of allylamine and diallylpropyldiamine.
38. the preformed amine polymer is characterized by a first selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIBs and / or SOBs, and the crosslinked polymer is characterized by a second selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIBs and / or SOBs: (i) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in a SIB compared to the preformed amine polymer; (ii) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in SOB compared to the preformed amine polymer; (iii) the crosslinked polymer has an increased chloride binding capacity and a decreased citrate binding capacity in SOB compared to the preformed amine polymer; or (iv) The process of any preceding claim, wherein the crosslinked polymer has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in SOB compared to the preformed amine polymer.
39. 40. The process of claim 38, wherein the crosslinked polymer has a reduced binding capacity for chloride in SGF compared to the preformed amine polymer.
40. 39. The process of claim 38, wherein, compared to the preformed amine polymer, the polymerized crosslinked polymer has (i) an increased binding capacity for chloride and a decreased binding capacity for phosphate in SIB, and (ii) a decreased binding capacity for SGF.
41. 39. The process of claim 38, wherein, compared to the preformed amine polymer, the polymerized crosslinked polymer has (i) an increased binding capacity for chloride in SOB and a decreased binding capacity for phosphate, citrate and / or taurocholate in combination, and (ii) a decreased binding capacity for SGF.
42. 1. A process for the preparation of a crosslinked amine polymer, comprising crosslinking a preformed amine polymer in a reaction mixture to form said crosslinked amine polymer, said reaction mixture comprising said preformed amine polymer, a swelling agent for swelling said preformed amine polymer, and dichloroethane.
43. 43. The process of claim 42, wherein the reaction mixture comprises a dispersion solvent.
44. 44. The process of claims 42 or 43, wherein the reaction mixture comprises a dispersing solvent that is chemically inert to the preformed amine polymer.
45. 44. The process of claim 42 or 43, wherein the reaction mixture comprises a dispersion solvent, and the dispersion solvent is dichloroethane.
46. The process of any of claims 42 to 45, wherein the swelling agent and dichloroethane are immiscible.
47. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 4:
1.
48. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 3:
1.
49. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 2:
1.
50. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 1:
1.
51. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 0.5:
1.
52. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 0.4:
1.
53. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is less than 0.3:
1.
54. The process of any of claims 42-46, wherein the weight ratio of the swelling agent to preformed amine polymer in the reaction mixture is at least 0.15:
1.
55. The process of any of claims 42 to 54, wherein the preformed amine polymer is deprotonated with a base prior to being crosslinked in the reaction mixture.
56. The process of any of claims 42-55, wherein the preformed amine polymer is crosslinked, the crosslinks being predominantly carbon-carbon crosslinks.
57. The process of any of claims 42 to 56, wherein the swelling agent is a polar solvent.
58. 57. The process of any of claims 42-56, wherein the swelling agent is water, methanol, ethanol, n-propanol, isopropanol, n-butanol, formic acid, acetic acid, acetonitrile, dimethylformamide, dimethylsulfoxide, nitromethane, propylene carbonate, or a combination thereof.
59. The process of any of claims 42 to 56, wherein the swelling agent is water.
60. The preformed amine polymer comprises a residue of an amine corresponding to Formula 1: 【Chemistry 3】 60. The process of any one of claims 42 to 59.
61. The preformed amine polymer comprises a residue of an amine corresponding to formula 1a 【Chemistry 4】 In the formula, R 4 and R 5 is independently hydrogen, hydrocarbyl, or substituted hydrocarbyl.
62. R 4 and R 5 is independently hydrogen, aliphatic or heteroaliphatic.
63. R 4 and R 5 62. The process of claim 61, wherein is independently hydrogen, allyl, or aminoalkyl.
64. The process of any of claims 42-59, wherein the preformed amine polymer comprises a residue of an amine of Table C.
65. The process of any of claims 42-59, wherein the preformed amine polymer comprises residues of allylamine.
66. The process of any of claims 42-59, wherein the preformed amine polymer comprises residues of diallylpropyldiamine.
67. The process of any of claims 42-59, wherein the preformed amine polymer is a copolymer comprising residues of allylamine and diallylpropyldiamine.
68. the preformed amine polymer is characterized by a first selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIBs and / or SOBs, and the crosslinked polymer is characterized by a second selectivity for chloride relative to citrate, phosphate and / or taurocholate in the SIBs and / or SOBs: (i) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in a SIB compared to the preformed amine polymer; (ii) the crosslinked polymer has an increased chloride binding capacity and a decreased phosphate binding capacity in SOB compared to the preformed amine polymer; (iii) the crosslinked polymer has an increased chloride binding capacity and a decreased citrate binding capacity in SOB compared to the preformed amine polymer; or (iv) the process of any of claims 42-67, wherein the crosslinked polymer has an increased binding capacity for chloride and a decreased binding capacity for taurocholate in SOB compared to the preformed amine polymer.
69. 70. The process of claim 68, wherein the crosslinked polymer has a reduced binding capacity for chloride in SGF compared to the preformed amine polymer.
70. 69. The process of claim 68, wherein, compared to the preformed amine polymer, the polymerized crosslinked polymer has (i) an increased binding capacity for chloride and a decreased binding capacity for phosphate in SIB, and (ii) a decreased binding capacity for SGF.
71. 69. The process of claim 68, wherein, compared to the preformed amine polymer, the polymerized crosslinked polymer has (i) an increased binding capacity for chloride in SOB and a decreased binding capacity for phosphate, citrate and / or taurocholate in combination, and (ii) a decreased binding capacity for SGF.
72. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 4 mmol / g.
73. A pharmaceutical composition comprising crosslinked amine polymers having a ratio of chloride ion binding capacity to phosphate ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2.3:1, respectively.
74. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a simulated small intestinal buffer ("SIB") of at least 1 mmol / g, a phosphate ion binding capacity in the SIB of less than 0.4 mmol / g, and a chloride ion to phosphate ion binding ratio in the SIB of at least 2.3:1, respectively.
75. A pharmaceutical composition comprising a crosslinked amine polymer having a ratio of chloride ion binding capacity to phosphate ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2.3:1, respectively, and a swelling ratio of less than 5.
76. A pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content of at least 30% of the chloride initially bound in a GI Compartment Transit Assay ("GICTA").
77. A pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content of at least 0.5 mmol chloride / g of polymer in a GI Compartment Transit Assay ("GICTA").
78. A pharmaceutical composition comprising a crosslinked amine polymer having a retained chloride content in a GI compartment transit assay ("GICTA") of at least 0.5 mmol of chloride / g of polymer, and a chloride retention at the end of the GICTA of at least 30% of the chloride initially bound in the GICTA.
79. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2 mmol of chloride / g of polymer in 4 hours.
80. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2 mmol of chloride / g of polymer at 4 hours, and a crosslinked amine polymer having a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 2 mmol of chloride / g of polymer at 24 hours.
81. A pharmaceutical composition comprising a crosslinked amine polymer having a chloride ion binding capacity in a 24 hour simulated small intestine organic and inorganic buffers ("SOB") assay of at least 5.5 mmol of chloride / g of polymer.
82. 1. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 4 mmol / g in 1 hour.
83. 1. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride ion binding capacity in simulated small intestinal buffer ("SIB") of at least 4 mmol / g and a phosphate ion binding capacity of less than 2 mmol / g.
84. 1. A pharmaceutical composition comprising a crosslinked amine polymer having: (i) a proton binding capacity and a chloride binding capacity in simulated gastric fluid of at least 5 mmol / g; and (ii) a chloride to phosphate ion binding ratio in simulated small intestinal buffer ("SIB") of at least 2.3:1, respectively.
85. A pharmaceutical composition comprising a crosslinked amine polymer having selectivity for chloride over citrate, phosphate and taurocholate in simulated small intestinal organic and inorganic buffers ("SOB") at (i) 1 hour, (ii) 4 hours, (iii) 12 hours, (iv) 18 hours, (v) 24 hours, (vi) 30 hours, (vii) 36 hours, or even (viii) 48 hours.
86. A method for treating acid / base disorders in animals, including humans, by scavenging HCl through oral administration of a pharmaceutical composition according to any one of claims 72-96.
87. 72. A method of treating acid / base disorders in animals, including humans, by scavenging HCl through oral administration of a pharmaceutical composition comprising a crosslinked amine polymer prepared by the process of any of claims 1-71.
88. The structure corresponding to formula 4: 【Chemistry 5】 wherein each R is independently hydrogen or an ethylene bridge between two nitrogen atoms of the crosslinked amine polymer. 【Chemistry 6】 and a, b, c, and m are integers.
89. 90. The polymer of claim 88, wherein m is a large integer indicating an extended polymer network.
90. 90. The polymer of claim 88 or 89, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1:1 to 5:
1.
91. 90. The polymer of claim 88 or 89, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1.5:1 to 4:
1.
92. 90. The polymer of claim 88 or 89, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 1.75:1 to 3:
1.
93. 90. The polymer of claim 88 or 89, wherein the ratio of the sum of a and b to c (i.e., a+b:c) is in the range of about 2:1 to 2.5:
1.
94. 90. The polymer of claim 88 or 89, wherein the sum of a and b is 57 and c is 24.
95. 95. The polymer of any of claims 88-94, wherein 50-95% of the R substituents are hydrogen and 5-50% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
96. 95. The polymer of any of claims 88-94, wherein 55-90% of the R substituents are hydrogen and 10-45% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
97. 95. The polymer of any of claims 88-94, wherein 60-90% of the R substituents are hydrogen and 10-40% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
98. 95. The polymer of any of claims 88-94, wherein 65-90% of the R substituents are hydrogen and 10-35% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
99. 95. The polymer of any of claims 88-94, wherein 70-90% of the R substituents are hydrogen and 10-30% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
100. 95. The polymer of any of claims 88-94, wherein 75-85% of the R substituents are hydrogen and 15-25% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
101. 95. The polymer of any of claims 88-94, wherein 80-85% of the R substituents are hydrogen and 15-20% are ethylene bridges between two nitrogens of the crosslinked amine polymer.
102. 95. The polymer of any of claims 88-94, wherein about 81% of the R substituents are hydrogen and about 19% are ethylene bridges.
103. A pharmaceutical composition comprising a pharma- ceutically acceptable excipient and the crosslinked amine polymer of any of claims 88-102.
104. A method of treating an acid / base disorder in an animal, including a human, by removing HCl through oral administration of the pharmaceutical composition of embodiment 103.
Citation Information
Patent Citations
Anion-binding polymer and its application
JP2007510783A
Crosslinked polyvinyl amine or its acid addition salt, and its medical use
JP2009179724A
Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
WO2009008480A1
